0001428336-23-000033.txt : 20230905 0001428336-23-000033.hdr.sgml : 20230905 20230905160931 ACCESSION NUMBER: 0001428336-23-000033 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20230731 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 231235820 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 10-Q 1 hqy-20230731.htm 10-Q hqy-20230731
00014283361/312024Q2FALSE00014283362023-02-012023-07-3100014283362023-08-31xbrli:shares00014283362023-07-31iso4217:USD00014283362023-01-31iso4217:USDxbrli:shares0001428336us-gaap:ServiceMember2023-05-012023-07-310001428336us-gaap:ServiceMember2022-05-012022-07-310001428336us-gaap:ServiceMember2023-02-012023-07-310001428336us-gaap:ServiceMember2022-02-012022-07-310001428336us-gaap:FinancialServiceOtherMember2023-05-012023-07-310001428336us-gaap:FinancialServiceOtherMember2022-05-012022-07-310001428336us-gaap:FinancialServiceOtherMember2023-02-012023-07-310001428336us-gaap:FinancialServiceOtherMember2022-02-012022-07-310001428336us-gaap:CreditAndDebitCardMember2023-05-012023-07-310001428336us-gaap:CreditAndDebitCardMember2022-05-012022-07-310001428336us-gaap:CreditAndDebitCardMember2023-02-012023-07-310001428336us-gaap:CreditAndDebitCardMember2022-02-012022-07-3100014283362023-05-012023-07-3100014283362022-05-012022-07-3100014283362022-02-012022-07-3100014283362023-04-3000014283362022-04-3000014283362022-01-310001428336us-gaap:CommonStockMember2023-04-300001428336us-gaap:CommonStockMember2022-04-300001428336us-gaap:CommonStockMember2023-01-310001428336us-gaap:CommonStockMember2022-01-310001428336us-gaap:CommonStockMember2023-02-012023-07-310001428336us-gaap:CommonStockMember2023-07-310001428336us-gaap:CommonStockMember2022-07-310001428336us-gaap:AdditionalPaidInCapitalMember2023-04-300001428336us-gaap:AdditionalPaidInCapitalMember2022-04-300001428336us-gaap:AdditionalPaidInCapitalMember2023-01-310001428336us-gaap:AdditionalPaidInCapitalMember2022-01-310001428336us-gaap:AdditionalPaidInCapitalMember2023-05-012023-07-310001428336us-gaap:AdditionalPaidInCapitalMember2022-05-012022-07-310001428336us-gaap:AdditionalPaidInCapitalMember2023-02-012023-07-310001428336us-gaap:AdditionalPaidInCapitalMember2022-02-012022-07-310001428336us-gaap:AdditionalPaidInCapitalMember2023-07-310001428336us-gaap:AdditionalPaidInCapitalMember2022-07-310001428336us-gaap:RetainedEarningsMember2023-04-300001428336us-gaap:RetainedEarningsMember2022-04-300001428336us-gaap:RetainedEarningsMember2023-01-310001428336us-gaap:RetainedEarningsMember2022-01-310001428336us-gaap:RetainedEarningsMember2023-05-012023-07-310001428336us-gaap:RetainedEarningsMember2022-05-012022-07-310001428336us-gaap:RetainedEarningsMember2023-02-012023-07-310001428336us-gaap:RetainedEarningsMember2022-02-012022-07-310001428336us-gaap:RetainedEarningsMember2023-07-310001428336us-gaap:RetainedEarningsMember2022-07-3100014283362022-07-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2023-02-012023-07-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2022-02-012022-07-310001428336hqy:AcquiredHSAIntangibleAssetsMember2023-02-012023-07-310001428336hqy:AcquiredHSAIntangibleAssetsMember2022-02-012022-07-310001428336us-gaap:LeaseholdImprovementsMember2023-07-310001428336us-gaap:LeaseholdImprovementsMember2023-01-310001428336us-gaap:FurnitureAndFixturesMember2023-07-310001428336us-gaap:FurnitureAndFixturesMember2023-01-310001428336us-gaap:ComputerEquipmentMember2023-07-310001428336us-gaap:ComputerEquipmentMember2023-01-3100014283362023-08-012023-07-31xbrli:pure00014283362023-04-012023-04-3000014283362024-08-012023-07-310001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-07-310001428336hqy:AcquiredHSAIntangibleAssetsMember2023-07-310001428336us-gaap:CustomerRelationshipsMember2023-07-310001428336us-gaap:DevelopedTechnologyRightsMember2023-07-310001428336us-gaap:TradeNamesMember2023-07-310001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2023-01-310001428336us-gaap:CustomerRelationshipsMember2023-01-310001428336us-gaap:DevelopedTechnologyRightsMember2023-01-310001428336us-gaap:TradeNamesMember2023-01-310001428336hqy:TermLoanFacilityMember2023-04-300001428336hqy:WageWorksInc.Member2021-04-300001428336hqy:WageWorksInc.Memberhqy:UnionMesaMember2021-11-240001428336hqy:A4500SeniorNotesDue2029Member2023-07-310001428336hqy:A4500SeniorNotesDue2029Member2023-01-310001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMember2023-07-310001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMember2023-01-310001428336us-gaap:RevolvingCreditFacilityMember2023-07-310001428336us-gaap:RevolvingCreditFacilityMember2023-01-310001428336us-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-080001428336us-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2023-07-310001428336us-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2023-01-310001428336us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:DebtInstrumentRedemptionPeriodFourMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:DebtInstrumentRedemptionPeriodFiveMemberus-gaap:SeniorNotesMemberhqy:A4500SeniorNotesDue2029Member2021-10-082021-10-080001428336us-gaap:SecuredDebtMemberhqy:CreditAgreementMemberhqy:TermLoanFacilityMember2021-10-082021-10-080001428336us-gaap:SecuredDebtMemberhqy:CreditAgreementMemberhqy:TermLoanFacilityMember2021-10-080001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-10-082021-10-080001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-10-080001428336hqy:CreditAgreementMemberus-gaap:LetterOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-10-080001428336hqy:CreditAgreementMember2021-10-080001428336srt:MinimumMemberhqy:CreditAgreementMemberhqy:LondonInterbankOfferedRateMember2023-05-312023-05-310001428336hqy:CreditAgreementMembersrt:MaximumMemberhqy:LondonInterbankOfferedRateMember2023-05-312023-05-310001428336us-gaap:BaseRateMembersrt:MinimumMemberhqy:CreditAgreementMember2023-05-312023-05-310001428336us-gaap:BaseRateMemberhqy:CreditAgreementMembersrt:MaximumMember2023-05-312023-05-310001428336hqy:CreditAgreementMemberhqy:SecuredOvernightFinancingRateSOFRMember2023-06-012023-06-010001428336srt:MinimumMemberhqy:CreditAgreementMemberhqy:SecuredOvernightFinancingRateSOFRMember2023-06-012023-06-010001428336hqy:CreditAgreementMembersrt:MaximumMemberhqy:SecuredOvernightFinancingRateSOFRMember2023-06-012023-06-010001428336us-gaap:BaseRateMembersrt:MinimumMemberhqy:CreditAgreementMember2023-06-012023-06-010001428336us-gaap:BaseRateMemberhqy:CreditAgreementMembersrt:MaximumMember2023-06-012023-06-010001428336hqy:CreditAgreementMember2023-07-310001428336srt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-02-012023-07-310001428336srt:MaximumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-02-012023-07-310001428336hqy:CreditAgreementMemberhqy:DebtInstrumentAmortizationPeriodOneMemberhqy:TermLoanFacilityMemberus-gaap:LineOfCreditMember2023-07-310001428336hqy:CreditAgreementMemberhqy:DebtInstrumentAmortizationPeriodTwoAndThreePeriodMemberhqy:TermLoanFacilityMemberus-gaap:LineOfCreditMember2023-07-310001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMemberus-gaap:LineOfCreditMemberhqy:DebtInstrumentAmortizationPeriodFourMember2023-07-310001428336hqy:CreditAgreementMemberhqy:DebtInstrumentAmortizationPeriodFiveMemberhqy:TermLoanFacilityMemberus-gaap:LineOfCreditMember2023-07-310001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMemberus-gaap:LineOfCreditMember2023-07-310001428336hqy:CreditAgreementMemberhqy:TermLoanFacilityMemberus-gaap:LineOfCreditMember2023-02-012023-07-310001428336us-gaap:CostOfSalesMember2023-05-012023-07-310001428336us-gaap:CostOfSalesMember2022-05-012022-07-310001428336us-gaap:CostOfSalesMember2023-02-012023-07-310001428336us-gaap:CostOfSalesMember2022-02-012022-07-310001428336hqy:SalesandMarketingMember2023-05-012023-07-310001428336hqy:SalesandMarketingMember2022-05-012022-07-310001428336hqy:SalesandMarketingMember2023-02-012023-07-310001428336hqy:SalesandMarketingMember2022-02-012022-07-310001428336hqy:TechnologyandDevelopmentMember2023-05-012023-07-310001428336hqy:TechnologyandDevelopmentMember2022-05-012022-07-310001428336hqy:TechnologyandDevelopmentMember2023-02-012023-07-310001428336hqy:TechnologyandDevelopmentMember2022-02-012022-07-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2023-05-012023-07-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2022-05-012022-07-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2023-02-012023-07-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2022-02-012022-07-310001428336hqy:IncentivePlanMember2023-07-3100014283362022-02-012023-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2023-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2023-02-012023-07-310001428336us-gaap:RestrictedStockUnitsRSUMember2023-07-310001428336hqy:PerformanceRestrictedStockUnitsMember2023-02-012023-04-300001428336hqy:PerformanceRestrictedStockUnitsMember2023-07-310001428336srt:MinimumMemberhqy:PerformanceRestrictedStockUnitsMember2023-02-012023-07-310001428336srt:MaximumMemberhqy:PerformanceRestrictedStockUnitsMember2023-02-012023-07-310001428336us-gaap:FairValueInputsLevel2Memberhqy:A4500SeniorNotesDue2029Member2023-07-31



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Form 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-36568
HEALTHEQUITY, INC.
(Exact name of registrant as specified in its charter)
Delaware52-2383166
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(Address of principal executive offices) (Zip code)

(801) 727-1000
(Registrant's telephone Number, including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
 Emerging growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 31, 2023, there were 85,627,521 shares of the registrant's common stock outstanding.



HealthEquity, Inc. and subsidiaries
Form 10-Q quarterly report

Table of contents
Page
Part I. FINANCIAL INFORMATION
Item 1.
Item 2.
Item 3.
Item 4.
Part II. OTHER INFORMATION
Item 1.
Item 1A.
Item 5.
Item 6.


-2-


Part I. Financial information
Item 1. Financial statements

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
(in thousands, except par value)July 31, 2023January 31, 2023
(unaudited)
Assets
Current assets
Cash and cash equivalents$290,345 $254,266 
Accounts receivable, net of allowance for doubtful accounts of $4,639 and $4,989 as of July 31, 2023 and January 31, 2023, respectively
92,581 96,835 
Other current assets39,631 31,792 
Total current assets422,557 382,893 
Property and equipment, net9,145 12,862 
Operating lease right-of-use assets51,976 56,461 
Intangible assets, net881,937 936,359 
Goodwill1,648,145 1,648,145 
Other assets52,696 52,180 
Total assets$3,066,456 $3,088,900 
Liabilities and stockholders’ equity
Current liabilities
Accounts payable$12,543 $13,899 
Accrued compensation31,421 45,835 
Accrued liabilities49,281 43,668 
Current portion of long-term debt 17,500 
Operating lease liabilities10,026 10,159 
Total current liabilities103,271 131,061 
Long-term liabilities
Long-term debt, net of issuance costs873,581 907,838 
Operating lease liabilities, non-current52,371 58,988 
Other long-term liabilities13,092 12,708 
Deferred tax liability74,527 82,665 
Total long-term liabilities1,013,571 1,062,199 
Total liabilities1,116,842 1,193,260 
Commitments and contingencies (see Note 5)
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively
  
Common stock, $0.0001 par value, 900,000 shares authorized, 85,612 and 84,758 shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively
9 8 
Additional paid-in capital1,785,014 1,745,716 
Accumulated earnings164,591 149,916 
Total stockholders’ equity1,949,614 1,895,640 
Total liabilities and stockholders’ equity$3,066,456 $3,088,900 
See accompanying notes to condensed consolidated financial statements.

-3-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and
comprehensive income (loss) (unaudited)
Three months ended July 31,Six months ended July 31,
(in thousands, except per share data)2023202220232022
Revenue
Service revenue$105,719 $103,034 $210,831 $207,382 
Custodial revenue98,917 65,599 193,358 124,964 
Interchange revenue38,913 37,509 83,792 79,475 
Total revenue243,549 206,142 487,981 411,821 
Cost of revenue
Service costs76,543 74,914 157,098 155,788 
Custodial costs9,133 7,090 18,133 13,731 
Interchange costs6,943 6,326 13,994 13,317 
Total cost of revenue92,619 88,330 189,225 182,836 
Gross profit150,930 117,812 298,756 228,985 
Operating expenses
Sales and marketing19,123 15,843 39,058 32,403 
Technology and development54,767 46,580 107,959 91,763 
General and administrative27,090 25,937 51,984 49,664 
Amortization of acquired intangible assets23,166 24,181 46,332 47,879 
Merger integration2,044 7,683 5,502 16,977 
Total operating expenses126,190 120,224 250,835 238,686 
Income (loss) from operations24,740 (2,412)47,921 (9,701)
Other expense
Interest expense(13,272)(11,493)(28,269)(21,954)
Other income (expense), net2,756 32 4,584 (269)
Total other expense(10,516)(11,461)(23,685)(22,223)
Income (loss) before income taxes14,224 (13,873)24,236 (31,924)
Income tax provision (benefit)3,643 (3,219)9,561 (7,631)
Net income (loss) and comprehensive income (loss)$10,581 $(10,654)$14,675 $(24,293)
Net income (loss) per share:
Basic$0.12 $(0.13)$0.17 $(0.29)
Diluted$0.12 $(0.13)$0.17 $(0.29)
Weighted-average number of shares used in computing net income (loss) per share:
Basic85,533 84,443 85,286 84,236 
Diluted86,341 84,443 86,356 84,236 
See accompanying notes to condensed consolidated financial statements.
-4-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of stockholders’ equity (unaudited)
Three months ended July 31,Six months ended July 31,
(in thousands)2023202220232022
Total stockholders' equity, beginning balance$1,918,592 $1,855,263 $1,895,640 $1,852,575 
Common stock:
Beginning balance9 8 8 8 
Issuance of common stock upon exercise of stock options, and for restricted stock— — 1 — 
Ending balance9 8 9 8 
Additional paid-in capital:
Beginning balance1,764,573 1,692,834 1,745,716 1,676,508 
Issuance of common stock upon exercise of stock options, and for restricted stock368 2,134 1,021 4,474 
Stock-based compensation20,073 18,154 38,277 32,140 
Ending balance1,785,014 1,713,122 1,785,014 1,713,122 
Accumulated earnings
Beginning balance154,010 162,420 149,916 176,059 
Net income (loss)10,581 (10,654)14,675 (24,293)
Ending balance164,591 151,766 164,591 151,766 
Total stockholders' equity, ending balance$1,949,614 $1,864,896 $1,949,614 $1,864,896 
See accompanying notes to condensed consolidated financial statements.

-5-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)
Six months ended July 31,
(in thousands)20232022
Cash flows from operating activities:
Net income (loss)$14,675 $(24,293)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization77,387 80,226 
Stock-based compensation38,277 32,140 
Amortization of debt discount and issuance costs1,461 1,639 
Loss on extinguishment of debt1,157  
Other non-cash items 269 
Deferred taxes(8,138)(7,558)
Changes in operating assets and liabilities:
Accounts receivable, net4,254 (3,161)
Other assets(8,526)(1,546)
Operating lease right-of-use assets6,594 4,117 
Accrued compensation(14,675)(4,973)
Accounts payable, accrued liabilities, and other current liabilities3,970 (25,586)
Operating lease liabilities, non-current(8,175)(3,594)
Other long-term liabilities384 (454)
Net cash provided by operating activities108,645 47,226 
Cash flows from investing activities:
Purchases of software and capitalized software development costs(18,794)(24,215)
Purchases of property and equipment(590)(2,384)
Acquisitions of HSA portfolios (68,725)
Net cash used in investing activities(19,384)(95,324)
Cash flows from financing activities:
Principal payments on long-term debt(54,375)(4,375)
Settlement of client-held funds obligation, net(161)(991)
Proceeds from exercise of common stock options1,354 4,936 
Net cash used in financing activities(53,182)(430)
Increase (decrease) in cash and cash equivalents36,079 (48,528)
Beginning cash and cash equivalents254,266 225,414 
Ending cash and cash equivalents$290,345 $176,886 
See accompanying notes to condensed consolidated financial statements.
-6-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)
Six months ended July 31,
(in thousands)20232022
Supplemental cash flow data:
Interest expense paid in cash$23,504 $19,450 
Income tax payments, net15,113 573 
Supplemental disclosures of non-cash investing and financing activities:
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation3,228 5,040 
Purchases of property and equipment included in accounts payable or accrued liabilities300 356 
Acquisitions of HSA portfolios included in accounts payable or accrued liabilities 1,849 
Exercise of common stock options receivable50 8 
Increase in goodwill due to measurement period adjustments, net 163 
See accompanying notes to condensed consolidated financial statements.
-7-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements
Note 1. Summary of business and significant accounting policies
Business
HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Principles of consolidation
The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation
The accompanying condensed consolidated financial statements as of July 31, 2023 and for the three and six months ended July 31, 2023 and 2022 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2023. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2023.
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
-8-

Note 2. Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended July 31,Six months ended July 31,
(in thousands, except per share data)2023202220232022
Numerator (basic and diluted):
Net income (loss)$10,581 $(10,654)$14,675 $(24,293)
Denominator (basic):
Weighted-average common shares outstanding85,533 84,443 85,286 84,236 
Denominator (diluted):
Weighted-average common shares outstanding85,533 84,443 85,286 84,236 
Weighted-average dilutive effect of stock options and restricted stock units808  1,070  
Diluted weighted-average common shares outstanding86,341 84,443 86,356 84,236 
Net income (loss) per share:
Basic $0.12 $(0.13)$0.17 $(0.29)
Diluted$0.12 $(0.13)$0.17 $(0.29)
For the three months ended July 31, 2023 and 2022, approximately 1.6 million and 3.3 million shares, respectively, attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted net income (loss) per share as their inclusion would have been anti-dilutive.
For the six months ended July 31, 2023 and 2022, approximately 0.9 million and 2.6 million shares, respectively, attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted net income (loss) per share as their inclusion would have been anti-dilutive.
Note 3. Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:
Property and equipment
Property and equipment consisted of the following:
(in thousands)July 31, 2023January 31, 2023
Leasehold improvements$18,199 $18,269 
Furniture and fixtures8,392 8,392 
Computer equipment27,696 28,021 
Property and equipment, gross54,287 54,682 
Accumulated depreciation(45,142)(41,820)
Property and equipment, net$9,145 $12,862 
Depreciation expense for the three months ended July 31, 2023 and 2022 was $2.0 million and $3.2 million, respectively, and $4.5 million and $6.4 million for the six months ended July 31, 2023 and 2022, respectively.
Contract balances
The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of July 31, 2023 and January 31, 2023, the balance of deferred revenue was $6.7 million and $8.3 million, respectively. The balances are related to cash received in advance for interchange and custodial revenue arrangements, other up-front fees and other commuter deferred revenue. The Company expects to recognize approximately 63% of its balance of deferred revenue as revenue over the next 12 months and the remainder thereafter. During the three and six months ended July 31, 2023, approximately $1.4 million and $2.9 million, respectively, of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2023. The Company expects to satisfy its remaining obligations for these arrangements.
-9-

Leases
The components of operating lease costs were as follows:
Three months ended July 31,Six months ended July 31,
(in thousands)
2023202220232022
Operating lease expense$2,365 $2,854 $4,966 $5,713 
Sublease income(619)(551)(981)(1,046)
Net operating lease expense$1,746 $2,303 $3,985 $4,667 
Other income (expense), net
Other income (expense), net, consisted of the following:
Three months ended July 31,Six months ended July 31,
(in thousands)2023202220232022
Interest income$2,484 $89 $4,082 $141 
Acquisition costs (47) (53)
Other income (expense), net272 (10)502 (357)
Total other income (expense), net$2,756 $32 $4,584 $(269)
Interest expense
Based on the application of Accounting Standards Codification ("ASC") 470-50, Debt - Modifications and Extinguishments, the Company recorded a $1.2 million loss on extinguishment of debt due to the prepayment of $50.0 million under the Company's Term Loan Facility (as defined in Note 6—Indebtedness) in April 2023, which is included within interest expense in the condensed consolidated statement of operations and comprehensive income for the six months ended July 31, 2023.
Supplemental cash flow information
Supplemental cash flow information related to the Company's operating leases was as follows:
Six months ended July 31,
(in thousands)20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$5,451 $6,232 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$2,109 $1,092 
Note 4. Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows:
July 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$246,789 $(173,865)$72,924 
Acquired HSA portfolios261,188 (72,253)188,935 
Acquired customer relationships759,782 (179,280)580,502 
Acquired developed technology132,825 (93,370)39,455 
Acquired trade names12,900 (12,779)121 
Total amortizable intangible assets$1,413,484 $(531,547)$881,937 
-10-

January 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$233,194 $(152,178)$81,016 
Acquired HSA portfolios261,188 (63,547)197,641 
Acquired customer relationships759,782 (153,434)606,348 
Acquired developed technology132,825 (81,692)51,133 
Acquired trade names12,900 (12,679)221 
Total amortizable intangible assets$1,399,889 $(463,530)$936,359 
Amortization expense for the three months ended July 31, 2023 and 2022 was $36.3 million and $37.6 million, respectively, and $72.8 million and $73.8 million for the six months ended July 31, 2023 and 2022, respectively.
Goodwill
There were no changes to the carrying value of goodwill during the six months ended July 31, 2023.
Note 5. Commitments and contingencies
Commitments
The Company’s principal commitments consist of long-term debt, operating lease obligations for office space and data storage facilities, processing services agreements, software subscriptions, telephony services, and other contractual commitments. In April 2023, the Company used $50.0 million of cash to prepay, in direct order of maturity, principal due under its Term Loan Facility. There were no other material changes during the six months ended July 31, 2023, outside of the ordinary course of business, in the Company's commitments from those disclosed in its Annual Report on Form 10-K for the fiscal year ended January 31, 2023.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
In April 2021, WageWorks, Inc. ("WageWorks"), a wholly owned subsidiary of the Company, exercised its right to terminate a lease for office space in Mesa, Arizona that had not yet commenced, with aggregate lease payments of $63.1 million and a term of approximately 11 years, following the landlord's failure to fulfill its obligations under the lease agreement. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease. WageWorks' right to terminate the lease agreement was disputed by the landlord, Union Mesa 1, LLC (“Union Mesa”). On November 5, 2021, Union Mesa notified WageWorks that it was in default of the lease for failure to pay rent, which Union Mesa claimed was due beginning in November 2021, and on November 24, 2021 drew $2.8 million, the full amount under the letter of credit that WageWorks had posted to secure its obligations under the lease. On December 1, 2021, WageWorks filed a lawsuit against Union Mesa in the Superior Court of the State of Arizona in and for the County of Maricopa. On January 4, 2022, WageWorks filed an amended complaint in the Superior Court. Pursuant to the lawsuit, WageWorks seeks declaratory judgment that the lease was properly terminated and recourse against Union Mesa for breach of contract, breach of the duty of good faith and fair dealing, and conversion, including return of the funds drawn under the letter of credit. On January 31, 2022, Union Mesa filed a motion to dismiss for the conversion cause of action, which the Superior Court denied on April 13, 2022. On May 18, 2022, Union Mesa filed an answer and counterclaim with the Superior Court, wherein Union Mesa denied WageWorks' claims, and separately seeks recourse against WageWorks for breach of contract and breach of the implied covenant of good faith and fair dealing. On May 19, 2022, Union Mesa filed an amended complaint and counterclaim seeking the same recourse. On June 29, 2022, Union Mesa filed a second amended answer and counterclaim, which names the Company as a counter-defendant. On July 21, 2022, WageWorks and the Company filed an answer to the counterclaims. On April 26, 2023, Union Mesa filed a motion for partial summary judgment, and the Company expects to file its response in due course. Through its claims, Union Mesa is seeking direct and consequential damages in an amount to be
-11-

proven at trial and an award of its reasonable attorney fees, plus interest until any damages or fees that are awarded are paid. The parties are currently engaged in discovery.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
Note 6. Indebtedness
Long-term debt consisted of the following:
(in thousands)July 31, 2023January 31, 2023
4.50% Senior Notes due 2029
$600,000 $600,000 
Term Loan Facility286,875 341,250 
Principal amount886,875 941,250 
Less: unamortized discount and issuance costs (1)13,294 15,912 
Total debt, net873,581 925,338 
Less: current portion of long-term debt17,500
Long-term debt, net$873,581 $907,838 
(1)In addition to the $13.3 million and $15.9 million of unamortized discount and issuance costs related to long-term debt as of July 31, 2023 and January 31, 2023, respectively, $3.0 million and $3.4 million of unamortized issuance costs related to the Company's Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of July 31, 2023 and January 31, 2023, respectively.
4.50% Senior Notes due 2029
On October 8, 2021, the Company completed its offering of $600 million aggregate principal amount of its 4.50% Senior Notes due 2029 (the “Notes”). The Notes were issued under an indenture (the “Indenture”), dated October 8, 2021, among the Company, the guarantors party thereto, and Wells Fargo Bank, National Association, as trustee.
The Notes are guaranteed by each of the Company’s existing, wholly owned domestic subsidiaries that guarantees its obligations under the Credit Agreement (as defined below) and are required to be guaranteed by any of the Company’s future subsidiaries that guarantee its obligations under the Credit Agreement or certain of its other indebtedness. The Notes will mature on October 1, 2029. Interest on the Notes is payable on April 1 and October 1 of each year. Accrued interest on the Notes was $9.0 million at each of July 31, 2023 and January 31, 2023, and is included within accrued liabilities on the Company's condensed consolidated balance sheets. The effective interest rate on the Notes is 4.72%.
The Notes are unsecured senior obligations of the Company and rank equally in right of payment to all of its existing and future senior unsecured debt and senior in right of payment to all of its future subordinated debt.
The Notes are redeemable at the Company’s option, in whole or in part, at any time on or after October 1, 2024, at a redemption price if redeemed during the 12 months beginning (i) October 1, 2024 of 102.250%, (ii) October 1, 2025 of 101.125%, and (iii) October 1, 2026 and thereafter of 100.000%, in each case of the principal amount of the Notes being redeemed, and together with accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may also redeem some or all of the Notes before October 1, 2024 at a redemption price equal to 100% of the principal amount of the Notes, plus the applicable “make-whole” premium as of, and accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, at any time prior to October 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the Notes issued under the Indenture on one or more occasions in an aggregate amount equal to the net cash proceeds of one or more equity offerings at a redemption price equal to 104.500% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control.
-12-

The Indenture contains covenants that impose significant operational and financial restrictions on the Company; however, these covenants generally align with the covenants contained in the Credit Agreement. See "Credit Agreement" below for a description of these covenants.
Credit Agreement
On October 8, 2021, the Company entered into a credit agreement (the “Credit Agreement”) among the Company, as borrower, each lender from time to time party thereto (the “Lenders”), JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Agent”) and the Swing Line Lender (as defined in the Credit Agreement), and each L/C Issuer (as defined therein) party thereto, pursuant to which the Company established:
(i)a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $350 million; and
(ii)a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1.0 billion (with a $25 million sub-limit for the issuance of letters of credit), the proceeds of which may be used for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments.
Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company’s pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.
Prior to June 1, 2023, borrowings under the Credit Facilities bore interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement.
On June 1, 2023, the Company entered into an amendment to the Credit Agreement (“Amendment No. 1”) which replaced interest rate provisions based on LIBOR with the forward-looking term rate based on the secured overnight financing rate published by the CME Group Benchmark Administration Limited (“Term SOFR”). As a result, borrowings under the Credit Agreement as so amended by Amendment No. 1 bear interest, as of July 31, 2023, at an annual rate equal to, at the option of the Company, either (i) Term SOFR, plus a 0.10% credit spread adjustment, plus a margin ranging from 1.25% to 2.25%, or (ii) an alternate base rate, plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement (as amended by Amendment No. 1). As of July 31, 2023, the stated interest rate was 6.92% and the effective interest rate was 7.68%.
The Company is also required to pay certain fees to the Lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of July 31, 2023, no amounts have been drawn under the Revolving Credit Facility.
The loans made under the Term Loan Facility amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the Term Loan Facility: (i) 2.5% for the first year after October 8, 2021; (ii) 5.0% for each of the second and third years after October 8, 2021; (iii) 7.5% for the fourth year after October 8, 2021; and (iv) 10.0% for the fifth year after October 8, 2021. In addition, the Term Loan Facility is required to be mandatorily prepaid with 100% of the net cash proceeds of all asset sales, insurance and condemnation recoveries, subject to customary exceptions and thresholds, including to the extent such proceeds are reinvested in assets useful in the business of the Company and its subsidiaries within 450 days following receipt (or committed to be reinvested within such 450-day period and reinvested within 180 days after the end of such 450-day period). The loans under the Credit Facilities may be prepaid, and the commitments thereunder may be reduced, by the Company without penalty or premium, subject to the reimbursement of customary “breakage costs.” In April 2023, the Company used $50.0 million of cash to prepay, in direct order of maturity, principal due under its Term Loan Facility.
The Credit Agreement contains significant customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its
-13-

organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.00 to 1.00 and (ii) a minimum consolidated interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of July 31, 2023, and for the period then ended.
The repayment obligation under the Credit Agreement may be accelerated upon the occurrence of an event of default thereunder, including, among other things, failure to pay principal, interest or fees on a timely basis, material inaccuracy of any representation or warranty, failure to comply with covenants, cross-default to other material debt, material judgments, change of control and certain insolvency or bankruptcy-related events, in each case, subject to any certain grace and/or cure periods.
The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by each of the Company’s existing or subsequently acquired or organized domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.
Note 7. Income taxes
The Company follows ASC 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to pre-tax income through the end of the latest fiscal quarter to determine the interim income tax provision. For the three and six months ended July 31, 2023, the Company recorded an income tax provision of $3.6 million and $9.6 million, respectively. This resulted in an effective income tax provision rate of 25.6% and 39.4% for the three and six months ended July 31, 2023, respectively, compared with an effective income tax benefit rate of 23.2% and 23.9% for the three and six months ended July 31, 2022, respectively. For the three and six months ended July 31, 2023 and 2022, discrete tax items impacting the effective tax rate were primarily due to differences in tax deductible stock-based compensation compared to GAAP stock-based compensation expense.
As of July 31, 2023 and January 31, 2023, the Company’s total gross unrecognized tax benefit was $8.9 million and $8.7 million, respectively. If recognized, $5.6 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of July 31, 2023.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to the Company's taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2003.
Note 8. Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended July 31,Six months ended July 31,
(in thousands)2023202220232022
Cost of revenue$4,714 $3,998 $8,549 $7,005 
Sales and marketing3,478 2,553 6,257 4,567 
Technology and development4,283 2,963 9,175 6,343 
General and administrative7,598 8,640 14,296 14,225 
Total stock-based compensation expense$20,073 $18,154 $38,277 $32,140 
Stock award plans
Incentive Plan. The Company grants stock options and restricted stock units ("RSUs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing
-14-

through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of July 31, 2023, 11.5 million shares were available for grant under the Incentive Plan.
Stock options
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20231,021 
$14.00 - 82.39
$36.06 3.2$27,293 
Exercised(34)
$14.00 - 44.53
$29.71 
Forfeited(4)
$24.36 - 44.53
$38.41 
Outstanding as of July 31, 2023983 
$14.00 - 82.39
$36.27 2.6$32,047 
Vested and expected to vest as of July 31, 2023983 $36.27 2.6$32,047 
Exercisable as of July 31, 2023983 $36.27 2.6$32,047 
Restricted stock units
A summary of RSU activity is as follows:
RSUs and PRSUs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair value
Outstanding as of January 31, 20233,011 $70.40 
Granted1,767 64.46 
Vested(801)67.53 
Forfeited(250)71.53 
Outstanding as of July 31, 20233,727 $68.13 
Performance restricted stock units. During the three months ended April 30, 2023, the Company awarded 270,966 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2026. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $23.9 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors.
Note 9. Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Cash and cash equivalents are considered Level 1 instruments and are valued based on publicly available daily net asset values. The carrying values of cash and cash equivalents approximate fair values due to the short-term nature of these instruments.
-15-

The Notes are valued based upon quoted market prices and are considered Level 2 instruments because the markets in which the Notes trade are not considered active markets. As of July 31, 2023, the fair value of the Notes was $536.7 million.
The Term Loan Facility is considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Term Loan Facility reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, the fair value of the Term Loan Facility approximates carrying value.

-16-

Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Statements that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. Such statements include, but are not limited to, statements concerning our ability to integrate acquired businesses, the impact on the Company of societal and economic changes arising out of the COVID-19 pandemic, the anticipated synergies and other benefits of acquired businesses and any future acquisitions, health savings accounts and other tax-advantaged consumer-directed benefits, tax and other regulatory changes, market opportunity, our future financial and operating results, our investment and acquisition strategy, our sales and marketing strategy, management’s plans, beliefs and objectives for future operations, technology and development, economic and industry trends or trend analysis, expectations about seasonality, opportunity for portfolio purchases and other acquisitions, operating expenses, anticipated income tax rates, capital expenditures, cash flows and liquidity. These statements are based on the beliefs and assumptions of our management based on information currently available to us. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk factors” included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023 and our other reports filed with the SEC. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such events.

Overview
We are a leader and an innovator in providing technology-enabled services that empower consumers to make healthcare saving and spending decisions. We use our innovative technology to manage consumers' tax-advantaged health savings accounts ("HSAs") and other consumer-directed benefits ("CDBs") offered by employers, including flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”), and to administer Consolidated Omnibus Budget Reconciliation Act (“COBRA”), commuter and other benefits. As part of our services, we provide consumers with healthcare bill evaluation and payment processing services, personalized benefit information, including information on treatment options and comparative pricing, access to remote and telemedicine benefits, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings.
The core of our offerings is the HSA, a financial account through which consumers spend and save long-term for healthcare expenses on a tax-advantaged basis. As of July 31, 2023, we administered 8.2 million HSAs, with balances totaling $23.2 billion, which we call HSA Assets, as well as 6.8 million complementary CDBs. We refer to the aggregate number of HSAs and other CDBs that we administer as Total Accounts, of which we had 15.0 million as of July 31, 2023.
We reach consumers primarily through relationships with their employers, which we call Clients. We reach Clients primarily through relationships with benefits brokers and advisors, integrated partnerships with a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan recordkeepers, which we call Network Partners, and a sales force that calls on Clients directly.
We have increased our share of the growing HSA market from 4% in December 2010 to 20% as of December 2022, measured by HSA Assets. According to Devenir, as of December 2022, we are the largest HSA provider by both accounts and HSA Assets. In addition, we believe we are the largest provider of other CDBs. We seek to differentiate ourselves through our service-driven culture, product breadth, ecosystem connectivity, and proprietary
-17-

technology. Our proprietary technology allows us to help consumers optimize the value of their HSAs and other CDBs and gain confidence and skills in managing their healthcare costs as part of their financial security.
Our ability to assist consumers is enhanced by our capacity to securely share data in both directions with others in the health, benefits, and retirement ecosystems. Our commuter benefits offering also leverages connectivity to an ecosystem of mass transit, ride hailing, and parking providers.
We earn revenue primarily from three sources: service, custodial, and interchange. We earn service revenue mainly from fees paid by our Network Partners, Clients, and members for the administration services we provide in connection with the HSAs and other CDBs we offer. We earn custodial revenue primarily from HSA Assets held by our federally insured bank and credit union partners, which we collectively call our Depository Partners, or our insurance company partners, recordkeeping fees we earn in respect of mutual funds in which our members invest, and Client-held funds deposited with our Depository Partners. We earn interchange revenue mainly from fees paid by merchants on payments that our members make using our physical payment cards and on our virtual payment system. See “Key components of our results of operations” for additional information on our sources of revenue, including the adverse impacts caused by the societal and economic changes arising out of the COVID-19 pandemic.
Key factors affecting our performance
We believe that our future performance will be driven by a number of factors, including those identified below. Each of these factors presents both significant opportunities and significant risks to our future performance. See also the section entitled “Risk factors” included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023 and our other reports filed with the SEC.
Our acquisition and integration strategy
We have historically acquired HSA portfolios and businesses that strengthen our service offerings. We plan to continue this growth strategy and are regularly engaged in evaluating different opportunities. We have developed an internal capability to source, evaluate, and integrate acquired HSA portfolios. Our success depends in part on our ability to successfully integrate acquired businesses and HSA portfolios with our business in an efficient and effective manner and to realize anticipated synergies.
Structural change in U.S. health insurance
We derive revenue primarily from healthcare-related saving and spending by consumers in the U.S., which are driven by changes in the broader healthcare industry, including the structure of health insurance. The average premium for employer-sponsored health insurance has risen by 20% since 2017 and 43% since 2012, resulting in increased participation in HSA-qualified health plans and HSAs and increased consumer cost-sharing in health insurance more generally. We believe that continued growth in healthcare costs and related factors will spur continued growth in HSA-qualified health plans and HSAs and may encourage policy changes making HSAs or similar vehicles available to new populations such as individuals in Medicare. However, the timing and impact of these and other developments in U.S. healthcare are uncertain. Moreover, changes in healthcare policy, such as "Medicare for all" plans, could materially and adversely affect our business in ways that are difficult to predict.
Trends in U.S. tax law
Tax law has a profound impact on our business. Our offerings to members, Clients, and Network Partners consist primarily of services enabled, mandated, or advantaged by provisions of U.S. tax law and regulations. Changes in tax policy are speculative and may affect our business in ways that are difficult to predict.
Our client base
Our business model is based on a B2B2C distribution strategy, whereby we work with Network Partners and Clients to reach consumers to increase the number of our members with HSA accounts and complementary CDBs. We believe that there are significant opportunities to expand the scope of services that we provide to our current Clients.
Broad distribution footprint
We believe we have a diverse distribution footprint to attract new Clients and Network Partners. Our sales force calls on enterprise and regional employers in industries across the U.S., as well as potential Network Partners from among health plans, benefits administrators, and retirement plan record keepers.

-18-

Product breadth
We are the largest custodian and administrator of HSAs, as well as a market-share leader in each of the major categories of complementary CDBs, including FSAs and HRAs, COBRA and commuter benefits administration. Our Clients and their benefits advisors increasingly seek HSA providers that can deliver an integrated offering of HSAs and complementary CDBs. With our CDB capabilities, we can provide employers with a single partner for both HSAs and complementary CDBs, which is preferred by the vast majority of employers, according to research conducted for us by Aite Group. We believe that the combination of HSA and complementary CDB offerings significantly strengthens our value proposition to employers, health benefits brokers and consultants, and Network Partners as a leading single-source provider.
Interest rates
As a non-bank custodian, our members’ custodial HSA cash assets are held by either our federally insured Depository Partners (our “Basic Rates” offering), pursuant to contractual arrangements we have with these Depository Partners, or by our insurance company partners through group annuity contracts or other similar arrangements (our “Enhanced Rates” offering).
The lengths of our agreements with Depository Partners typically range from three to five years and may have fixed or variable interest rate terms. The terms of new and renewing agreements with our Depository Partners are impacted by the then-prevailing interest rate environment, which in turn is driven by macroeconomic factors and government policies over which we have no control. Such factors, and the response of our competitors to them, also determine the amount of interest retained by our members.
HSA members who place their HSA cash into our Enhanced Rates offering retain a higher yield compared to our Basic Rates offering. An increase in the percentage of HSA cash held in our Enhanced Rates offering also positively impacts our custodial revenue, as we generally receive a higher yield on HSA cash held by our insurance company partners compared to cash held by our Depository Partners. As with our Depository Partners, yields paid by our insurance company partners are impacted by the prevailing interest rate environment, which in turn is driven by macroeconomic factors and government policies over which we have no control. Such factors, and the response of our competitors to them, also determine the amount of interest retained by our members.
We believe that diversification of Depository Partners and insurance company partners, varied contract terms, and other factors reduce our exposure to short-term fluctuations in prevailing interest rates and mitigate the short-term impact of sustained increases or declines in prevailing interest rates on our custodial revenue. Over longer periods, sustained shifts in prevailing interest rates affect the amount of custodial revenue we can realize on custodial assets and the interest retained by our members.
Although interest rates have increased, we expect our custodial revenue to continue to be adversely affected by the interest rate cuts by the Federal Reserve at the beginning of the COVID-19 pandemic due to the impact of contracts signed with our Depository Partners in that environment and other market conditions that have caused our average annualized yield on HSA cash to decline from historical levels.
Interest on our term loan facility changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates. Recent interest rate increases have caused interest expense related to our term loan facility to increase substantially.
Our proprietary technology
We believe that innovations incorporated in our technology, which enable us to better assist consumers to make healthcare saving and spending decisions and maximize the value of their tax-advantaged benefits, differentiate us from our competitors and drive our growth. Our full suite of CDB offerings complements our HSA solution and enhances our leadership position within the HSA sector. We intend to continue to invest in our technology development to enhance our capabilities and infrastructure, while maintaining a focus on data security and the privacy of our customers' data. For example, we are making significant investments in the architecture and infrastructure of the technology that we use to provide our services to improve our transaction processing capabilities and support continued account and transaction growth, as well as in data-driven personalized engagement to help our members spend less, save more, and build wealth for retirement.
Our Purple culture
A successful healthcare consumer needs education and guidance delivered by people as well as by technology. The education and customer service we provide is driven by our Purple culture, which we believe is a significant factor in our ability to attract and retain customers and to address opportunities in the rapidly changing healthcare
-19-

sector. We invest in and intend to continue to invest in human capital through technology-enabled training, career development, and advancement opportunities.
Our competition and industry
Our direct competitors are HSA custodians and other CDB providers. Many of these are state or federally chartered banks and other financial institutions for which we believe benefits administration services are not a core business. Some of our direct competitors (including healthcare service companies such as UnitedHealth Group's Optum, Webster Bank, and well-known retail investment companies, such as Fidelity Investments) are in a position to devote more resources to the development, sale, and support of their products and services than we have at our disposal. Our other CDB administration competitors include health insurance carriers, human resources consultants and outsourcers, payroll providers, national CDB specialists, regional third-party administrators, and commercial banks. In addition, numerous indirect competitors, including benefits administration service providers, partner with banks and other HSA custodians to compete with us. Our Network Partners may also choose to offer competitive services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
As a result of the COVID-19 pandemic, we have seen a significant decline in the use of commuter benefits due to many of our members working from home, which has negatively impacted both our interchange revenue and service revenue, and this "work from home" trend, or hybrid work environments, may continue indefinitely.
Regulatory environment
Federal law and regulations, including the Affordable Care Act, the Internal Revenue Code, the Employee Retirement Income Security Act and Department of Labor regulations, and public health regulations that govern the provision of health insurance and provide the tax advantages associated with our services, play a pivotal role in determining our market opportunity. Privacy and data security-related laws such as the Health Insurance Portability and Accountability Act, or HIPAA, and the Gramm-Leach-Bliley Act, laws governing the provision of investment advice to consumers, such as the Investment Advisers Act of 1940, or the Advisers Act, the USA PATRIOT Act, anti-money laundering laws, and the Federal Deposit Insurance Act, all play a similar role in determining our competitive landscape. In addition, state-level regulations also have significant implications for our business in some cases. For example, our subsidiary HealthEquity Trust Company is regulated by the Wyoming Division of Banking, and several states are considering, or have already passed, new privacy regulations that can affect our business. Various states also have laws and regulations that impose additional restrictions on our collection, storage, and use of personally identifiable information. Privacy regulation in particular has become a priority issue in many states, including, for example, the California Privacy Rights Act, which became effective on January 1, 2023. Our ability to predict and react quickly to relevant legal and regulatory trends and to correctly interpret their market and competitive implications is important to our success.
-20-

Key financial and operating metrics
Our management regularly reviews a number of key operating and financial metrics to evaluate our business, determine the allocation of our resources, make decisions regarding corporate strategies and evaluate forward-looking projections and trends affecting our business. We discuss certain of these key financial metrics, including revenue, below in the section entitled “Key components of our results of operations.” In addition, we utilize other key metrics as described below.
Total Accounts
The following table sets forth our HSAs, CDBs, and Total Accounts as of and for the periods indicated:
(in thousands, except percentages)July 31, 2023July 31, 2022% ChangeJanuary 31, 2023
HSAs8,164 7,523 %7,984 
New HSAs from sales - Quarter-to-date156 196 (20)%445 
New HSAs from sales - Year-to-date290 355 (18)%971 
New HSAs from acquisitions - Year-to-date— 90 (100)%90 
HSAs with investments574 516 11 %541 
CDBs6,831 7,023 (3)%6,933 
Total Accounts14,995 14,546 %14,917 
Average Total Accounts - Quarter-to-date14,954 14,497 %14,677 
Average Total Accounts - Year-to-date14,967 14,462 %14,531 
The number of our HSAs and CDBs are key metrics because our revenue is driven by the amount we earn from them. The number of our HSAs increased by 0.6 million, or 9%, from July 31, 2022 to July 31, 2023, primarily driven by new HSAs from sales. The number of our CDBs decreased by 0.2 million, or 3%, from July 31, 2022 to July 31, 2023, primarily driven by a decrease in COBRA accounts due to a change in the manner in which COBRA accounts are counted following migration to our current COBRA platform.
HSA Assets
The following table sets forth HSA Assets as of and for the periods indicated:
(in millions, except percentages)July 31, 2023July 31, 2022% ChangeJanuary 31, 2023
HSA cash$14,021 $13,097 %$14,199 
HSA investments9,181 7,441 23 %7,947 
Total HSA Assets23,202 20,538 13 %22,146 
Average daily HSA cash - Year-to-date14,048 12,924 %13,049 
Average daily HSA cash - Quarter-to-date14,001 12,941 %13,375 
HSA Assets includes our HSA members’ custodial assets, which consists of the following components: (i) HSA cash, which includes cash deposits held by our Depository Partners and our insurance company partners, and (ii) HSA investments in mutual funds through our custodial investment fund partners. Measuring HSA Assets is important because our custodial revenue is directly affected by average daily custodial balances for HSA Assets that are revenue generating.
HSA cash increased by $0.9 billion, or 7%, from July 31, 2022 to July 31, 2023, primarily due to net HSA contributions from new and existing HSA members, partially offset by transfers to HSA investments.
HSA investments increased by $1.7 billion, or 23%, from July 31, 2022 to July 31, 2023, primarily due to transfers from HSA cash and the increased value of invested balances.
Total HSA Assets increased by $2.7 billion, or 13%, from July 31, 2022 to July 31, 2023, primarily due to net HSA contributions from new and existing HSA members and the increased value of invested balances.
Client-held funds
(in millions, except percentages)July 31, 2023July 31, 2022% ChangeJanuary 31, 2023
Client-held funds$811 $801 %$901 
Average daily Client-held funds - Year-to-date896 852 %827 
Average daily Client-held funds - Quarter-to-date891 839 %809 
-21-

Client-held funds are interest-earning deposits from which we generate custodial revenue. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of CDBs. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. Client-held funds fluctuate depending on the timing of funding and spending of CDB balances and the number of CDBs we administer.
Adjusted EBITDA
We define Adjusted EBITDA, which is a non-GAAP financial metric, as adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items. We believe that Adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because it reflects operating profitability before consideration of non-operating expenses and non-cash expenses and serves as a basis for comparison against other companies in our industry.
The following table presents a reconciliation of net income (loss), the most comparable GAAP financial measure, to Adjusted EBITDA for the periods indicated:
Three months ended July 31,Six months ended July 31,
(in thousands)2023202220232022
Net income (loss)$10,581 $(10,654)$14,675 $(24,293)
Interest income(2,484)(89)(4,082)(141)
Interest expense13,272 11,493 28,269 21,954 
Income tax provision (benefit)3,643 (3,219)9,561 (7,631)
Depreciation and amortization15,180 16,559 31,055 32,347 
Amortization of acquired intangible assets23,166 24,181 46,332 47,879 
Stock-based compensation expense20,073 18,154 38,277 32,140 
Merger integration expenses2,044 7,683 5,502 16,977 
Acquisition costs— 47 — 53 
Amortization of incremental costs to obtain a contract1,350 1,074 2,654 2,142 
Costs associated with unused office space1,286 1,313 2,302 2,607 
Other— 501 153 1,345 
Adjusted EBITDA$88,111 $67,043 $174,698 $125,379 
The following table sets forth our net income (loss) as a percentage of revenue:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20232022$ Change% Change20232022$ Change% Change
Net income (loss)$10,581 $(10,654)$21,235 (199)%$14,675 $(24,293)$38,968 (160)%
As a percentage of revenue%(5)%%(6)%
Our net income increased by $21.2 million, from net loss of $10.7 million for the three months ended July 31, 2022 to net income of $10.6 million for the three months ended July 31, 2023, due to an increase in gross profit and other income, net, partially offset by net increases in operating expenses and income tax provision, as described more fully in the section entitled "Comparison of the three and six months ended July 31, 2023 and 2022."
Our net income increased by $39.0 million, from net loss of $24.3 million for the six months ended July 31, 2022 to net income of $14.7 million for the six months ended July 31, 2023, due to an increase in gross profit and other income, net, partially offset by net increases in operating expenses and income tax provision, as described more fully in the section entitled "Comparison of the three and six months ended July 31, 2023 and 2022."
-22-

The following table sets forth our Adjusted EBITDA as a percentage of revenue:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20232022$ Change% Change20232022$ Change% Change
Adjusted EBITDA$88,111 $67,043 $21,068 31 %$174,698 $125,379 $49,319 39 %
As a percentage of revenue36 %33 %36 %30 %
Our Adjusted EBITDA increased by $21.1 million, or 31%, from $67.0 million for the three months ended July 31, 2022 to $88.1 million for the three months ended July 31, 2023, primarily due to an increase in total revenue, partially offset by increases in personnel and related costs.
Our Adjusted EBITDA increased by $49.3 million, or 39%, from $125.4 million for the six months ended July 31, 2022 to $174.7 million for the six months ended July 31, 2023, primarily due to an increase in total revenue, partially offset by increases in personnel and related costs.
Our use of Adjusted EBITDA, including as a percentage of revenue, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.
Key components of our results of operations
Revenue
We generate revenue from three primary sources: service revenue, custodial revenue, and interchange revenue.
Service revenue.    We earn service revenue from the fees we charge our Network Partners, Clients, and members for the administration services we provide in connection with the HSAs and other CDBs we offer. With respect to our Network Partners and Clients, our fees are generally based on a fixed tiered structure for the duration of the relevant service agreement and are paid to us on a monthly basis. We recognize revenue on a monthly basis as services are rendered to our members and Clients.
Custodial revenue.    We earn custodial revenue primarily from HSA Assets held by our Depository Partners or our insurance company partners, recordkeeping fees we earn in respect of mutual funds in which our members invest, and Client-held funds deposited with our Depository Partners. HSA cash is held by our Depository Partners pursuant to contracts that (i) typically have terms ranging from three to five years, (ii) provide for a fixed or variable interest rate payable on the average daily cash balances held by the relevant Depository Partner, and (iii) have minimum and maximum required balances. HSA cash held by our insurance company partners is held in group annuity contracts or similar arrangements. Client-held funds held by our Depository Partners are held in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. We earn custodial revenue on HSA Assets and Client-held funds that is based on the interest rates offered to us by these Depository Partners and insurance company partners. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA Assets in mutual funds through our custodial investment partner from which we earn a recordkeeping fee, calculated as a percentage of custodial investments.
Interchange revenue.    We earn interchange revenue each time one of our members uses one of our physical payment cards or virtual platforms to make a purchase. This revenue is collected each time a member “swipes” our payment card to pay expenses. We recognize interchange revenue monthly based on reports received from third parties, namely, the card-issuing banks and card processors.
Cost of revenue
Cost of revenue includes costs related to servicing accounts, managing Client and Network Partner relationships and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations (such as office rent, supplies, and other overhead expenses), new member and participant supplies, and other operating costs related to servicing our members. Other components of cost of revenue include interest retained by members on HSA cash and interchange costs incurred in connection with processing card transactions for our members.
Service costs.    Service costs include the servicing costs described in the paragraph above. Additionally, for new accounts, we incur on-boarding costs associated with the new accounts, such as new member welcome kits, the cost associated with issuance of new payment cards, and costs of marketing materials that we produce for our Network Partners.
-23-

Custodial costs.    Custodial costs are comprised of interest retained by our HSA members, in respect of HSA cash, personnel-related costs, and fees we pay to banking consultants whom we use to help secure agreements with our Depository Partners. Interest retained by HSA members is calculated on a tiered basis. The interest rates retained by HSA members can change based on a formula or upon required notice.
Interchange costs.    Interchange costs are comprised of costs we incur in connection with processing payment transactions initiated by our members. Due to the substantiation requirement on FSA/HRA-linked payment card transactions, payment card costs are higher for FSA/HRA card transactions. In addition to fixed per card fees, we are assessed additional transaction costs determined by the amount of the transaction.
Gross profit and gross margin
Our gross profit is our total revenue minus our total cost of revenue, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including interest rates, the amount we charge our Network Partners, Clients, and members, the mix of our sources of revenue, how many services we deliver per account, and payment processing costs per account.
Operating expenses
Sales and marketing.    Sales and marketing expenses consist primarily of personnel and related expenses for our sales and marketing staff, including sales commissions for our direct sales force, external agent/broker commission expenses, marketing expenses, depreciation, amortization, stock-based compensation, and common expense allocations.
Technology and development.    Technology and development expenses include personnel and related expenses for software development and delivery, licensed software, information technology, data management, product, and security. Technology and development expenses also include software engineering services, the costs of operating our technology infrastructure, depreciation, amortization of capitalized software development costs, stock-based compensation, and common expense allocations.
General and administrative.    General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, legal, internal audit, corporate development, compliance, and people departments. They also include depreciation, amortization, stock-based compensation, and common expense allocations.
Amortization of acquired intangible assets.    Amortization of acquired intangible assets results primarily from intangible assets acquired in connection with business combinations. The assets include acquired customer relationships, acquired developed technology, and acquired trade names and trademarks, which we amortize over the assets' estimated useful lives, estimated to be 7-15 years, 2-5 years, and 3 years, respectively. We also acquired intangible HSA portfolios from third-party custodians. We amortize these assets over the assets’ estimated useful life of 15 years. We evaluate our acquired intangible assets for impairment annually, or at a triggering event.
Merger integration.    Merger integration expenses include personnel and related expenses, including severance, professional fees, legal expenses, and facilities and technology expenses directly related to integration activities to merge operations as a result of acquisitions.
Interest expense
Interest expense primarily consists of accrued interest expense and amortization of deferred financing costs associated with our long-term debt. Interest on our term loan facility changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates.
Other income (expense), net
Other income (expense), net, consists primarily of interest income earned on corporate cash and other miscellaneous income and expense.
Income tax provision (benefit)
We are subject to federal and state income taxes in the United States based on a January 31 fiscal year end. We use the asset and liability method to account for income taxes, under which current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, net operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory
-24-

tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. As of July 31, 2023, we have not recorded a valuation allowance on federal deferred tax assets, but we have recorded a valuation allowance on certain state deferred tax assets. We maintain an overall net federal and state deferred tax liability on our condensed consolidated balance sheet.
Comparison of the three and six months ended July 31, 2023 and 2022
Revenue
The following table sets forth our revenue for the periods indicated:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20232022$ Change% Change20232022$ Change% Change
Service revenue$105,719 $103,034 $2,685 %$210,831 $207,382 $3,449 %
Custodial revenue98,917 65,599 33,318 51 %193,358 124,964 68,394 55 %
Interchange revenue38,913 37,509 1,404 %83,792 79,475 4,317 %
Total revenue$243,549 $206,142 $37,407 18 %$487,981 $411,821 $76,160 18 %
Service revenue. The $2.7 million, or 3%, increase in service revenue from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to service revenue earned with respect to new HSAs.
The $3.4 million, or 2%, increase in service revenue from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to service revenue earned with respect to new HSAs.
Custodial revenue. The $33.3 million, or 51%, increase in custodial revenue from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to an increase in average annualized yield on HSA cash from 1.80% for the three months ended July 31, 2022 to 2.37% for the three months ended July 31, 2023, an increase in interest rates on the portion of our Client-held funds held by our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate, and the $1.1 billion, or 8%, increase in the year-over-year average daily balance of HSA cash, as described above.
The $68.4 million, or 55%, increase in custodial revenue from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to an increase in average annualized yield on HSA cash from 1.75% for the six months ended July 31, 2022 to 2.34% for the six months ended July 31, 2023, an increase in interest rates on the portion of our Client-held funds held by our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate, and the $1.1 billion, or 9%, increase in the year-over-year average daily balance of HSA cash, as described above.
Assuming the current interest rate environment continues, we expect our average annualized yield on HSA cash to increase as our existing agreements with our Depository Partners are renewed or replaced, resulting in higher custodial revenue. In addition, we expect an increase in the percentage of HSA cash held in our Enhanced Rates offering to positively impact our average annualized yield and thus our custodial revenue. In addition, on an annual basis, relative to the fiscal year ended January 31, 2023, we expect custodial revenue resulting from the portion of our Client-held funds held by our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate to increase.
Interchange revenue. The $1.4 million, or 4%, increase in interchange revenue from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to an increase in Total Accounts, partially offset by lower average spend per HSA account.
The $4.3 million, or 5%, increase in interchange revenue from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to an increase in Total Accounts, partially offset by lower average spend per HSA account.
Total revenue. Total revenue increased $37.4 million, or 18%, from the three months ended July 31, 2022 to the three months ended July 31, 2023 due to the increases in custodial, service, and interchange revenues, described above.
Total revenue increased $76.2 million, or 18%, from the six months ended July 31, 2022 to the six months ended July 31, 2023 due to the increases in custodial, interchange, and service revenues, described above.

-25-

Impact of COVID-19. Our business was adversely affected by the COVID-19 pandemic, and we expect that it will continue to be adversely affected by the societal and economic changes arising out of the pandemic. Although interest rates have increased from their pandemic lows, a majority of our members' HSA cash is deposited with our Depository Partners pursuant to contracts that have fixed interest rate terms, typically ranging from three to five years, which reduces the short-term impact of an increase or decline in prevailing interest rates on our custodial revenue. As a result, the average annualized yield we currently receive from our Depository Partners remains below the levels seen immediately before the pandemic due to the HSA cash that was deposited with them during the pandemic. Our financial results related to certain of our products were adversely affected, such as commuter benefits, due to "work from home" and hybrid work environments, which have continued and may continue indefinitely. We saw a negative impact on the financial results related to our COBRA product, as the Employee Benefits Security Administration provided disaster relief in the form of an extension to the required timeline for participants to make COBRA elections, which we believe resulted in fewer COBRA elections by our members because they had more time to assess the cost of their out-of-pocket expenses against the cost of COBRA premiums. The national emergency under which the disaster relief was provided ended in April 2023; however, the extent to which COBRA elections will return to their prior levels, if at all, remains uncertain. During the initial stages of the COVID-19 pandemic, and during subsequent increases in COVID-19 cases, we saw a negative impact on our members' spend on healthcare, which negatively impacted both our interchange revenue and service revenue. In the event of further outbreaks, we may be unable to meet our service level commitments to our Clients as a result of disruptions to our workforce and disruptions to third-party contracts that we rely on to provide our services. The extent to which the societal and economic changes arising out of the COVID-19 pandemic, including any longer lasting impacts on the usage of our services, will continue to negatively impact our business remains highly uncertain and as a result may have a material adverse impact on our business and financial results.
Cost of revenue
The following table sets forth our cost of revenue for the periods indicated:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20232022$ Change% Change20232022$ Change% Change
Service costs$76,543 $74,914 $1,629 %$157,098 $155,788 $1,310 %
Custodial costs9,133 7,090 2,043 29 %18,133 13,731 4,402 32 %
Interchange costs6,943 6,326 617 10 %13,994 13,317 677 %
Total cost of revenue$92,619 $88,330 $4,289 %$189,225 $182,836 $6,389 %
Service costs. The $1.6 million, or 2%, increase in service costs from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to the 3% increase in average Total Accounts, partially offset by a decrease in personnel costs.
The $1.3 million, or 1%, increase in service costs from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to the 3% increase in average Total Accounts, partially offset by a decrease in personnel costs.
Custodial costs. The $2.0 million, or 29%, increase in custodial costs from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to an increase in the average annualized rate of interest retained by HSA members on HSA cash from 0.18% during the three months ended July 31, 2022 to 0.22% during the three months ended July 31, 2023, and the $1.1 billion, or 8%, increase in the year-over-year average daily balance of HSA cash, as described above.
The $4.4 million, or 32%, increase in custodial costs from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to an increase in the average annualized rate of interest retained by HSA members on HSA cash from 0.17% during the six months ended July 31, 2022 to 0.22% during the six months ended July 31, 2023, and the $1.1 billion, or 9%, increase in the year-over-year average daily balance of HSA cash, as described above.
Interchange costs. The $0.6 million, or 10%, increase in interchange costs from the three months ended July 31, 2022 to the three months ended July 31, 2023 was due to an increase in Total Accounts, partially offset by lower average spend per HSA account.
-26-

The $0.7 million, or 5%, increase in interchange costs from the six months ended July 31, 2022 to the six months ended July 31, 2023 was due to an increase in Total Accounts, partially offset by lower average spend per HSA account.
Total cost of revenue. As we continue to add Total Accounts, we expect that our cost of revenue will increase in dollar amount to support our Network Partners, Clients, and members. However, on an annual basis, relative to the fiscal year ended January 31, 2023, we expect our cost of revenue to decrease as a percentage of our total revenue, primarily due to an increase in custodial revenue, partially offset by increases in stock-based compensation and other personnel costs. Cost of revenue will continue to be affected by a number of different factors, including our ability to scale our service delivery, Network Partner implementation, account management functions, and the impact of societal and economic changes arising out of the COVID-19 pandemic.
Operating expenses
The following table sets forth our operating expenses for the periods indicated:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20232022$ Change% Change20232022$ Change% Change
Sales and marketing$19,123 $15,843 $3,280 21 %$39,058 $32,403 $6,655 21 %
Technology and development54,767 46,580 8,187 18 %107,959 91,763 16,196 18 %
General and administrative27,090 25,937 1,153 %51,984 49,664 2,320 %
Amortization of acquired intangible assets23,166 24,181 (1,015)(4)%46,332 47,879 (1,547)(3)%
Merger integration2,044 7,683 (5,639)(73)%5,502 16,977 (11,475)(68)%
Total operating expenses$126,190 $120,224 $5,966 %$250,835 $238,686 $12,149 %
Sales and marketing. The $3.3 million, or 21%, increase in sales and marketing expenses from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to an increase in marketing expenses from increased personnel-related expenses and travel costs.
The $6.7 million, or 21%, increase in sales and marketing expenses from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to an increase in marketing expenses from increased personnel-related expenses and travel costs.
We expect our sales and marketing expenses to increase for the foreseeable future as we continue to focus on our cross-selling program and marketing campaigns. On an annual basis, relative to the fiscal year ended January 31, 2023, we expect our sales and marketing expenses to remain relatively steady as a percentage of our total revenue. However, our sales and marketing expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our sales and marketing expenses.
Technology and development. The $8.2 million, or 18%, increase in technology and development expenses from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to increases in personnel-related expenses and software costs.
The $16.2 million, or 18%, increase in technology and development expenses from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to increases in personnel-related expenses and software costs.
We expect our technology and development expenses to increase for the foreseeable future as we continue to invest in the development and security of our proprietary technology. On an annual basis, relative to the fiscal year ended January 31, 2023, we expect our technology and development expenses to remain relatively steady as a percentage of our total revenue. However, our technology and development expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our technology and development expenses.
General and administrative. The $1.2 million, or 4%, increase in general and administrative expenses from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to increases in professional services expense and credit losses from trade receivables, partially offset by a decrease in stock-based compensation.
-27-

The $2.3 million, or 5%, increase in general and administrative expenses from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to increases in professional services expense and credit losses from trade receivables.
We expect our general and administrative expenses to increase for the foreseeable future due to the additional demands on our legal, compliance, and finance functions as we continue to grow our business. On an annual basis, relative to the fiscal year ended January 31, 2023, we expect our general and administrative expenses to remain relatively steady as a percentage of our total revenue. However, our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.
Amortization of acquired intangible assets. The $1.0 million, or 4%, decrease in amortization of acquired intangible assets from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to the smaller carrying amount of intangible assets that have not been fully amortized.
The $1.5 million, or 3%, decrease in amortization of acquired intangible assets from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to the smaller amount of intangible assets that have not been fully amortized.
Merger integration. The $5.6 million, or 73%, decrease in merger integration expense from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to a decrease in merger integration activities related to the acquisitions of WageWorks and the Further business.
The $11.5 million, or 68%, decrease in merger integration expense from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to a decrease in merger integration activities related to the acquisitions of the Further business and WageWorks.
The $2.0 million and $5.5 million in merger integration expense for the three and six months ended July 31, 2023 was primarily due to personnel and related expenses, including expenses incurred in conjunction with the migration of accounts, professional fees, and technology-related expenses directly related to the Further acquisition and certain ongoing merger integration expenses related to the WageWorks acquisition, including ongoing lease expense related to WageWorks offices that have been permanently closed, less any related sublease income, and professional fees associated with the remediation of material weaknesses in internal control over financial reporting. We expect merger integration expenses attributable to the Further acquisition totaling approximately $55 million to be incurred over a period of approximately five to six years from the date of the acquisition, which occurred in November 2021.
Interest expense
The $1.8 million, or 15%, increase in interest expense from the three months ended July 31, 2022 to the three months ended July 31, 2023 was primarily due to the impact of higher interest rates on our Term Loan Facility, which had an effective interest rate of 7.68% as of July 31, 2023, up from 4.92% as of July 31, 2022, partially offset by a lower average principal balance under our Term Loan Facility.
The $6.3 million, or 29%, increase in interest expense from the six months ended July 31, 2022 to the six months ended July 31, 2023 was primarily due to the impact of higher interest rates on our Term Loan Facility, which had an effective interest rate of 7.68% as of July 31, 2023, up from 4.92% as of July 31, 2022, and a $1.2 million loss on extinguishment of debt due to the prepayment of $50.0 million under our Term Loan Facility in April 2023, partially offset by a lower average principal balance under our Term Loan Facility.
Our Term Loan Facility had an outstanding principal balance of $286.9 million and $345.6 million as of July 31, 2023 and 2022, respectively. The decrease was due to principal payments, including the $50.0 million prepayment in April 2023.
On an annual basis, relative to the fiscal year ended January 31, 2023, we expect our interest expense to increase, primarily due to the impact of increased interest rates on our Term Loan Facility and the $1.2 million loss on extinguishment of debt in April 2023, partially offset by a lower average principal balance under our Term Loan Facility. The interest rate on our Term Loan Facility and Revolving Credit Facility is variable and, accordingly, we may incur additional expense if interest rates continue to increase in future periods.
Other income (expense), net
The $2.7 million increase in other income, net, from $32 thousand during the three months ended July 31, 2022 to $2.8 million during the three months ended July 31, 2023 was primarily due to a $2.4 million increase in interest income on corporate cash and a $0.3 million increase in other income, net.
-28-

The $4.9 million change in other income (expense), net, from expense of $0.3 million during the six months ended July 31, 2022 to income of $4.6 million during the six months ended July 31, 2023 was primarily due to a $3.9 million increase in interest income on corporate cash and a $0.9 million increase in other income, net.

Income tax provision (benefit)
For the three months ended July 31, 2023 and 2022, we recorded an income tax provision of $3.6 million and an income tax benefit of $3.2 million, respectively. The increase in income tax provision was primarily the result of an increase in pre-tax book income, a decrease in tax deductible stock-based compensation compared to GAAP stock-based compensation expense, an increase in nondeductible executive compensation, and a decrease in research and development tax credits.
For the six months ended July 31, 2023 and 2022, we recorded an income tax provision of $9.6 million and an income tax benefit of $7.6 million, respectively. The increase in income tax provision was primarily the result of an increase in pre-tax book income, a decrease in tax deductible stock-based compensation compared to GAAP stock-based compensation expense, an increase in nondeductible executive compensation, and a decrease in research and development tax credits.
Seasonality
Seasonal concentration of our growth combined with our recurring revenue model create seasonal variation in our results of operations. Revenue results are seasonally impacted due to ancillary service fees, timing of HSA contributions, and timing of card spend. Cost of revenue is seasonally impacted as a significant number of new and existing Network Partners bring us new HSAs and CDBs beginning in January of each year concurrent with the start of many employers’ benefit plan years. Before we realize any revenue from these new accounts, we incur costs related to implementing and supporting our new Network Partners and new accounts. These costs of services relate to activating accounts and hiring additional staff, including seasonal help to support our member support center. These expenses begin to ramp up during our third fiscal quarter, with the majority of seasonal expenses incurred in our fourth fiscal quarter.
Liquidity and capital resources
Cash and cash equivalents overview
Our principal sources of liquidity are our current cash and cash equivalents balances, collections from our service, custodial, and interchange revenue activities, and availability under our Revolving Credit Facility (as defined below). We rely on cash provided by operating activities to meet our short-term liquidity requirements, which primarily relate to the payment of corporate payroll and other operating costs, principal and interest payments on our long-term debt, and capital expenditures.
As of July 31, 2023 and January 31, 2023, cash and cash equivalents were $290.3 million and $254.3 million, respectively.
Capital resources
We maintain a “shelf” registration statement on Form S-3 on file with the SEC. A shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings. Unless otherwise specified in a prospectus supplement accompanying the base prospectus, we would use the net proceeds from the sale of any securities offered pursuant to the shelf registration statement for general corporate purposes, including, but not limited to, working capital, sales and marketing activities, general and administrative matters, capital expenditures, and repayment of indebtedness, and if opportunities arise, for the acquisition of, or investment in, assets, technologies, solutions or businesses that complement our business. Pending such uses, we may invest the net proceeds in interest-bearing securities. In addition, we may conduct concurrent or other financings at any time.
Our credit agreement includes a five-year senior secured revolving credit facility (the “Revolving Credit Facility”), in an aggregate principal amount of up to $1.0 billion, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments. For a description of the terms of the credit agreement, refer to Note 6—Indebtedness. As of July 31, 2023, there were no amounts outstanding under the Revolving Credit Facility. We were in compliance with all covenants under the credit agreement as of July 31, 2023, and for the period then ended.

-29-

Use of cash
In April 2023, we used $50.0 million of cash to prepay, in direct order of maturity, principal due under our Term Loan Facility.
Capital expenditures for the six months ended July 31, 2023 and 2022 were $19.4 million and $26.6 million, respectively. We expect to continue our current level of capital expenditures for the remainder of the fiscal year ending January 31, 2024 as we continue to invest in improving the architecture and functionality of our proprietary systems. Capital expenditures to improve the architecture of our proprietary systems include computer hardware, personnel and related costs for software engineering, and outsourced software engineering services.
We believe our existing cash, cash equivalents, and Revolving Credit Facility will be sufficient to meet our operating and capital expenditure requirements for at least the next 12 months. To the extent these current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may need to raise additional funds through public or private equity or debt financing. In the event that additional financing is required, we may not be able to raise it on favorable terms, if at all.
The following table shows our cash flows from operating activities, investing activities, and financing activities for the stated periods:
Six months ended July 31,
(in thousands)20232022
Net cash provided by operating activities$108,645 $47,226 
Net cash used in investing activities(19,384)(95,324)
Net cash used in financing activities(53,182)(430)
Increase (decrease) in cash and cash equivalents36,079 (48,528)
Beginning cash and cash equivalents254,266 225,414 
Ending cash and cash equivalents$290,345 $176,886 
Cash flows from operating activities. Net cash provided by operating activities increased by $61.4 million from the six months ended July 31, 2022 to the six months ended July 31, 2023 primarily due to increased collections with respect to our custodial and interchange revenues and a decrease in cash payments made to our accounts payable, accrued liabilities, and other current liabilities during the six months ended July 31, 2023.
Cash flows from investing activities. Net cash used in investing activities decreased by $75.9 million from the six months ended July 31, 2022 to the six months ended July 31, 2023 due to a $68.7 million decrease in cash used in HSA portfolio acquisitions, a $5.4 million decrease in cash used for purchases of software and capitalized software development costs, and a $1.8 million decrease in cash used for purchases of property and equipment.
Cash flows from financing activities. Net cash used in financing activities increased by $52.8 million from the six months ended July 31, 2022 to the six months ended July 31, 2023 due to the $50.0 million of cash used to prepay, in direct order of maturity, principal due under our Term Loan Facility and a $3.6 million decrease in proceeds from the exercise of common stock options. These changes were partially offset by a $0.8 million decrease in net payments made in the settlement of client-held funds obligation.
Contractual obligations
See Note 5—Commitments and contingencies for information about our contractual obligations.
Off-balance sheet arrangements
As of July 31, 2023, other than outstanding letters of credit issued under our Revolving Credit Facility, we did not have any off-balance sheet arrangements. The standby letters of credit generally expire within one year. However, in the ordinary course of business, we will continue to renew or modify the terms of the letters of credit to support business requirements. The letters of credit are contingent liabilities, supported by our Revolving Credit Facility, and are not reflected on our condensed consolidated balance sheets.
-30-

Critical accounting policies and significant management estimates
Our management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.
Our significant accounting policies are more fully described in Note 1 of the accompanying unaudited condensed consolidated financial statements and in Note 1 to our audited consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023. There have been no significant or material changes in our critical accounting policies during the six months ended July 31, 2023, as compared to those disclosed in “Management’s discussion and analysis of financial condition and results of operations – Critical accounting policies and significant management estimates” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023.
Recent accounting pronouncements
See Note 1—Summary of business and significant accounting policies within the interim financial statements included in this Form 10-Q for further discussion.
Item 3. Quantitative and qualitative disclosures about market risk
Market risk
Concentration of market risk. We derive a substantial portion of our revenue from providing services to tax-advantaged healthcare account holders. A significant downturn in this market or changes in state and/or federal laws impacting the preferential tax treatment of healthcare accounts such as HSAs could have a material adverse effect on our results of operations. During the six months ended July 31, 2023 and 2022, no one customer accounted for greater than 10% of our total revenue. We monitor market and regulatory changes regularly and make adjustments to our business if necessary.
Inflation. Inflationary factors may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, the current high rate of inflation may have an adverse effect on our ability to maintain current levels of expenses as a percentage of revenue if our revenue does not correspondingly increase with inflation.
Concentration of credit risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents. We maintain our cash and cash equivalents in bank and other depository accounts, which frequently may exceed federally insured limits. Our cash and cash equivalents as of July 31, 2023 and January 31, 2023 were $290.3 million and $254.3 million, respectively, the vast majority of which was not covered by federal depository insurance. We have not experienced any material losses in such accounts. Our accounts receivable balance as of July 31, 2023 and January 31, 2023 was $92.6 million and $96.8 million, respectively. We have not experienced any significant write-offs to our accounts receivable and believe that we are not exposed to significant credit risk with respect to our accounts receivable. We continue to monitor our credit risk and place our cash and cash equivalents with reputable financial institutions.
Interest rate risk
HSA Assets and Client-held funds. HSA Assets consist of custodial HSA funds we hold in custody on behalf of our members. As of July 31, 2023 and January 31, 2023, we held in custody HSA Assets of $23.2 billion and $22.1 billion, respectively. As a non-bank custodian, we contract with our Depository Partners and insurance company partners to hold custodial cash assets on behalf of our members, and we earn a significant portion of our total revenue from interest paid to us by these partners. Custodial cash assets held by our insurance company partners are held in group annuity contracts or similar arrangements. The lengths of our agreements with Depository Partners typically range from three to five years and have either fixed or variable interest rates. As HSA Assets increase and existing contracts with Depository Partners expire, we seek to enter into new contracts with Depository Partners, the terms of which are impacted by the then-prevailing interest rate environment. The diversification of
-31-

HSA Assets held by our Depository Partners and insurance company partners, and varied contract terms, substantially reduces our exposure to short-term fluctuations in prevailing interest rates and mitigates the short-term impact of a sustained increase or decline in prevailing interest rates on our custodial revenue. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the interest rate yield, or yield, available to us and thus the amount of the custodial revenue we can realize. Conversely, a sustained increase in prevailing interest rates can increase our yield. An increase in our yield would increase our custodial revenue as a percentage of total revenue. In addition, if our yield increases, we expect the spread to also increase between the interest offered to us by our Depository Partners and insurance company partners and the interest retained by our members, thus increasing our profitability. However, we may be required to increase the interest retained by our members in a rising prevailing interest rate environment. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Client-held funds are interest earning deposits from which we generate custodial revenue. As of July 31, 2023 and January 31, 2023, we held Client-held funds of $811 million and $901 million, respectively. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of our other CDBs. These deposits are held with Depository Partners. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the yield available to us and thus the amount of the custodial revenue we can realize from Client-held funds. Conversely, a sustained increase in prevailing interest rates may increase our yield. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Cash and cash equivalents. We consider all highly liquid investments purchased with an original maturity of three months or less to be unrestricted cash equivalents. Our unrestricted cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market account that is unrestricted as to withdrawal or use. As of July 31, 2023 and January 31, 2023, we had unrestricted cash and cash equivalents of $290.3 million and $254.3 million, respectively. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our cash and cash equivalents as a result of changes in interest rates.
Long-term debt. As of July 31, 2023 and January 31, 2023, we had $286.9 million and $341.3 million, respectively, outstanding under our term loan facility and no amounts drawn under our Revolving Credit Facility. Our overall interest rate sensitivity under these credit facilities is primarily influenced by any amounts borrowed and the prevailing interest rates on these instruments. The stated interest rate on our term loan credit facility and Revolving Credit Facility is variable and was 6.92% at July 31, 2023. Accordingly, we may incur additional expense if interest rates further increase in future periods. For example, a one percent increase in the interest rate on the amount outstanding under our credit facilities as of July 31, 2023 would result in approximately $2.9 million of additional interest expense over the next 12 months. The interest rate on our $600 million of unsecured Senior Notes due 2029 is fixed at 4.50%.
Item 4. Controls and procedures
Evaluation of disclosure controls and procedures
Management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of the Company’s disclosure controls and procedures as of July 31, 2023, the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation, our CEO and our CFO concluded that as of July 31, 2023, the Company's disclosure controls and procedures were effective at the reasonable assurance level.
-32-

Changes in internal control over financial reporting
There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended July 31, 2023 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
-33-


Part II—Other information
Item 1. Legal proceedings
From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. Except as described in Note 5—Commitments and contingencies, as of the date of this Quarterly Report on Form 10-Q, we were not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations, cash flows or financial position. For a description of these legal proceedings, see Note 5—Commitments and contingencies of the notes to condensed consolidated financial statements.
Item 1A. Risk factors
The risks described in “Risk factors” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023, and subsequent periodic reports could materially and adversely affect our business, financial condition and results of operations. Except as described below, there have been no material changes in such risks. These risk factors do not identify all risks that we face, and our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations.
Item 5. Other information
Rule 10b5-1 plan elections
None of the Company's directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408(c) of Regulation S-K) during the fiscal quarter ended July 31, 2023.
-34-

Item 6. Exhibits
Incorporate by reference
Exhibit
no.
DescriptionFormFile No.ExhibitFiling Date
10.18-K001-3656810.1June 2, 2023
10.2
    
8-K001-3656810.1June 14, 2023
10.3
    
8-K001-3656810.1July 3, 2023
31.1+
31.2+
32.1*#
32.2*#
101.INSXBRL Instance document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy schema linkbase document
101.CALInline XBRL Taxonomy calculation linkbase document
101.DEFInline XBRL Taxonomy definition linkbase document
101.LABInline XBRL Taxonomy labels linkbase document
101.PREInline XBRL Taxonomy presentation linkbase document
104
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2023, formatted in Inline XBRL.
+Filed herewith.
*Furnished herewith.
#These certifications are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference in any filing the registrant makes under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, irrespective of any general incorporation language in any filings.
 

-35-

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HEALTHEQUITY, INC.
Date: September 5, 2023By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:Executive Vice President and Chief Financial Officer

-36-
EX-31.1 2 exhibit311-ceo302xfy24q2.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as Adopted Pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Jon Kessler, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: September 5, 2023
 
By:/s/ Jon Kessler
Name:Jon Kessler
Title:
Chief Executive Officer
(Principal Executive Officer)


EX-31.2 3 exhibit312-cfo302xfy24q2.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Tyson Murdock, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 5, 2023
By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


EX-32.1 4 exhibit321-ceo906xfy24q2.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jon Kessler, the Chief Executive Officer (Principal Executive Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Quarterly Report on Form 10-Q for the quarter ended July 31, 2023 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: September 5, 2023
 
By: /s/ Jon Kessler
Name:Jon Kessler
Title:
Chief Executive Officer
(Principal Executive Officer)


EX-32.2 5 exhibit322-cfo906xfy24q2.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Tyson Murdock, Executive Vice President and Chief Financial Officer (Principal Financial Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Quarterly Report on Form 10-Q for the quarter ended July 31, 2023 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 5, 2023
 
By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 


EX-101.SCH 6 hqy-20230731.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed consolidated balance sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed consolidated balance sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed consolidated statements of cash flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Summary of business and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Net income (loss) per share link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Supplemental financial statement information link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Fair value link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - Summary of business and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Net income (loss) per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Supplemental financial statement information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Indebtedness (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Supplemental financial statement information (Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Supplemental financial statement information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Supplemental financial statement information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Supplemental financial statement information (Lease Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Supplemental financial statement information (Other Income (Expense), Net) (Details) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Intangible assets and goodwill (Schedule of Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Intangible assets and goodwill (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Commitments and contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Indebtedness (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Stock-based compensation (Summary of Share Based Compensation Recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Stock-based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Stock-based compensation (Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Stock-based compensation (Restricted Stock Unit Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - Fair value (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hqy-20230731_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hqy-20230731_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hqy-20230731_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Deferred taxes Deferred Income Taxes and Tax Credits Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Amortization of acquired intangible assets Amortization Of Acquired Intangible Amortization of Acquired Intangible Pay vs Performance Disclosure [Line Items] Accrued liabilities Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Credit facility, amount Line of Credit Facility, Maximum Borrowing Capacity Technology and development Research and Development Expense Other income (expense), net Other Nonoperating Income (Expense), Miscellaneous Other Nonoperating Income (Expense), Miscellaneous Increase in goodwill due to measurement period adjustments, net Noncash Changes In Goodwill, Measurement Period Adjustments Noncash Changes In Goodwill, Measurement Period Adjustments Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Indebtedness Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Deferred tax liability Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Exercisable, weighted-average contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Computer equipment Computer Equipment [Member] Beginning balance, maximum (in usd per share) Ending balance, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Restatement Determination Date: Restatement Determination Date [Axis] Total other expense Nonoperating Income (Expense) Commitments and contingencies (see Note 5) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Second and third years after the Effective Date Debt Instrument, Amortization Period Two and Three Period [Member] Debt Instrument, Amortization Period Two and Three Period Income taxes Income Tax Disclosure [Text Block] Current liabilities Liabilities, Current [Abstract] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively Preferred Stock, Value, Issued Weighted-average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Diluted (in usd per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable, net of allowance for doubtful accounts of $4,639 and $4,989 as of July 31, 2023 and January 31, 2023, respectively Accounts Receivable, after Allowance for Credit Loss, Current Percentage of capital stock Share-Based Compensation Arrangement By Share-Based Payment Award, Additional Shares Available For Grants, Percentage Of Capital Stock Outstanding, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Additional Shares Available For Grants, Percentage Of Capital Stock Outstanding, Percentage Operating lease not yet commenced undiscounted amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Vested and expected to vest, weighted average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Line of Credit Line of Credit [Member] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercised, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Other expense Other Nonoperating Income (Expense) [Abstract] Trading Symbol Trading Symbol Letters of credit outstanding Letters of Credit Outstanding, Amount Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Fair value of the notes Long-Term Debt, Fair Value Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Beginning balance, minimum (in usd per share) Ending balance, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Accrued interest Interest Payable, Current Cost of revenue Cost of Revenue [Abstract] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Stockholders’ equity Equity, Attributable to Parent [Abstract] First year after the Effective Date Debt Instrument, Amortization Period One [Member] Debt Instrument, Amortization Period One Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Earnings Income (Loss) Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of revenue Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Forfeited, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Name Measure Name Name Forgone Recovery, Individual Name Goodwill Goodwill Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accounts payable, accrued liabilities, and other current liabilities Increase (Decrease) in Accrued Liabilities Shares available for grant under incentive plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant London Interbank Offered Rate (LIBOR) London Interbank Offered Rate [Member] London Interbank Offered Rate Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Denominator (basic): Weighted Average Number of Shares Outstanding, Basic [Abstract] Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of Credit Letter of Credit [Member] Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Summary of business and significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Restricted Stock Units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Facility term (in years) Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation expense Depreciation Exercised, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay (as a percent) Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales Less: unamortized discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Operating lease liabilities, non-current Increase (Decrease) In Operating Lease Liability, Noncurrent Increase (Decrease) In Operating Lease Liability, Noncurrent Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Lease Cost Lease, Cost [Table Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Acquisition costs Business Combination, Acquisition Related Costs Award Type [Axis] Award Type [Axis] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Performance units awards (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Prepayment of debt Payment for Debt Extinguishment or Debt Prepayment Cost Supplemental disclosures of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Interest expense Interest Expense Purchases of property and equipment included in accounts payable or accrued liabilities Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Supplemental financial statement information Additional Financial Information Disclosure [Text Block] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized General and administrative General and Administrative Expense [Member] Property and equipment, gross Property, Plant and Equipment, Gross Outstanding stock options, weighted average contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Operating lease right-of-use assets obtained in exchange for new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Fifth year after the Effective Date Debt Instrument, Amortization Period Five [Member] Debt Instrument, Amortization Period Five [Member] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Operating lease liabilities Operating Lease, Liability, Current Computer software intangible asset Computer Software, Intangible Asset [Member] Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Net carrying amount Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Operating lease not yet commenced term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Credit spread adjustment on variable rate (as a percent) Debt Instrument, Credit Spread Adjustment On Variable Rate Debt Instrument, Credit Spread Adjustment On Variable Rate Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Beginning cash and cash equivalents Ending cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Gross profit Gross Profit Commitment fee (as a percent) Line of Credit Facility, Commitment Fee Percentage Security Exchange Name Security Exchange Name Total debt, net Long-Term Debt Award vesting rights percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Employee Stock Option Employee Stock Option [Member] Maximum Maximum [Member] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Stock-based compensation Share-Based Payment Arrangement [Text Block] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash items Other Noncash Income (Expense) Weighted- average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Remaining performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Schedule of Finite-lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Sublease income Sublease Income Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Issuance of common stock upon exercise of stock options, and for restricted stock Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Net operating lease expense Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Entity Interactive Data Current Entity Interactive Data Current Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Fourth year after the Effective Date Debt Instrument, Amortization Period Four [Member] Debt Instrument, Amortization Period Four [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Other Income (Expense), Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Accumulated earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Forfeited, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Principal amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Operating cash flows from operating leases Operating Lease, Payments Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Net income (loss) per share: Net income (loss) per share: Earnings Per Share, Basic [Abstract] PEO PEO [Member] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Sales and marketing Sales and Marketing [Member] Sales and Marketing [Member] Custodial Financial Service, Other [Member] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Number of options (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Change in goodwill Goodwill, Period Increase (Decrease) Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Exercise of common stock options receivable Exercise Of Stock Options Receivable Exercise Of Stock Options Receivable Vested and expected to vest, aggregate intrinsic value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Service Service [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] All Executive Categories All Executive Categories [Member] Maximum leverage ratio Debt Instrument, Covenant, Net Leverage Ratio Debt Instrument, Covenant, Net Leverage Ratio Long-term liabilities Liabilities, Noncurrent [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Purchases of software and capitalized software development costs Payments for Software Debt Disclosure [Abstract] Debt Disclosure [Abstract] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Sales and marketing Selling and Marketing Expense Common stock, $0.0001 par value, 900,000 shares authorized, 85,612 and 84,758 shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively Common Stock, Value, Issued Redemption price (as a percent) Debt Instrument, Redemption Price, Percentage General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Acquired trade names Trade Names [Member] Other long-term liabilities Increase (Decrease) in Other Deferred Liability Debt Instrument, Amortization Period [Axis] Debt Instrument, Amortization Period [Axis] Debt Instrument, Amortization Period Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period (in days) Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period All Individuals All Individuals [Member] Supplemental cash flow data: Supplemental Cash Flow Information [Abstract] Debt Instrument, Amortization Period [Domain] Debt Instrument, Amortization Period [Domain] Debt Instrument, Amortization Period Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Other income (expense), net Total other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Incentive Plan Incentive Plan [Member] Incentive Plan [Member] Range of exercise prices Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract] Gross unrecognized tax benefits Unrecognized Tax Benefits PEO Name PEO Name Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Customary Base Rate Base Rate [Member] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] October 1, 2026 and thereafter Debt Instrument, Redemption, Period Three [Member] Settlement of client-held funds obligation, net Proceeds From Settlement Of Client Held Funds Proceeds From Settlement Of Client Held Funds Depreciation and amortization Depreciation, Depletion and Amortization Furniture and fixtures Furniture and Fixtures [Member] Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Accrued compensation Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Unrecognized tax benefits that would impact the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Purchases of intangible assets Noncash or Part Noncash Acquisition, Intangible Assets Acquired Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue recognition Contract with Customer, Liability, Revenue Recognized Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Acquisitions of HSA portfolios Payments to Acquire Intangible Assets Fair value Fair Value Measurement, Policy [Policy Text Block] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Debt issuance costs, net Debt Issuance Costs, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Opening balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease expense Operating Lease, Expense Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Prior to October 1, 2024, 40% of Principal Debt Instrument, Redemption, Period Five [Member] Common stock: Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net income (loss) per share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Software and software development costs Software and Software Development Costs [Member] Minimum Minimum [Member] Denominator (diluted): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Income tax payments, net Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Acquired developed technology Developed Technology Rights [Member] Accumulated earnings Retained Earnings [Member] Current portion of long-term debt Less: current portion of long-term debt Long-Term Debt, Current Maturities Schedule of Share Based Compensation Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic (in usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Maximum borrowing capacity of future commitments Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Principles of consolidation Consolidation, Policy [Policy Text Block] Total long-term liabilities Liabilities, Noncurrent Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Common stock, authorized (in shares) Common Stock, Shares Authorized Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Technology and development Technology and Development [Member] Technology and Development [Member] Principal amount Long-Term Debt, Gross Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Debt instrument, amortization of loans, percentage of principal amount (as a percent) Debt Instrument, Periodic Repayments, Percentage Of Principal Amount Debt Instrument, Periodic Repayments, Percentage Of Principal Amount Additional paid-in capital Additional Paid in Capital Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Insider Trading Arrangements [Line Items] Union Mesa Union Mesa [Member] Union Mesa Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Acquired HSA portfolios Acquired HSA Intangible Assets [Member] Acquired HSA Intangible Assets [Member] October 1, 2024 Debt Instrument, Redemption, Period One [Member] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Weighted-average dilutive effect of stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Other assets Increase (Decrease) in Other Operating Assets Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of revenue Cost of Sales [Member] Debt instrument, number of days to reinvest proceeds from sales of assets (in days) Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales Grant date fair value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Exercisable, weighted-average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Principal payments on long-term debt Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Total stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross carrying amount Finite-Lived Intangible Assets, Gross Numerator (basic and diluted): Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Income tax provision (benefit) Income Tax Expense (Benefit) Accrued compensation Employee-related Liabilities, Current Fair value Fair Value Disclosures [Text Block] Merger integration Business Combination, Integration Related Costs Name Trading Arrangement, Individual Name 4.50% Senior Notes due 2029 4.500% Senior Notes due 2029 [Member] 4.500% Senior Notes due 2029 WageWorks, Inc WageWorks Inc. [Member] WageWorks Inc. [Member] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Interchange Credit and Debit Card [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] Prior to October 1, 2024 Debt Instrument, Redemption, Period Four [Member] Credit Facility [Domain] Credit Facility [Domain] Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units [Member] Minimum interest coverage ratio Debt Instrument, Covenant, Minimum Interest Coverage Ratio Debt Instrument, Covenant, Minimum Interest Coverage Ratio Variable rate borrowing spread (as a percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt, net of issuance costs Long-term debt, net Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Operating lease right-of-use assets Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Operating expenses Operating Expenses [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital: Additional Paid-in Capital [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover page. Cover [Abstract] Interest income Investment Income, Nonoperating Vested and expected to vest, weighted average contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Weighted-average number of shares used in computing net income (loss) per share: Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Other long-term liabilities Other Liabilities, Noncurrent Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Total operating expenses Operating Expenses Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Secured Debt Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted-average common shares outstanding (in shares) Weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Income (loss) from operations Operating Income (Loss) October 1, 2025 Debt Instrument, Redemption, Period Two [Member] Revenue Revenues [Abstract] Percentage of principal amount redeemed (as a percent) Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Acquired customer relationships Customer Relationships [Member] EX-101.PRE 10 hqy-20230731_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page - shares
6 Months Ended
Jul. 31, 2023
Aug. 31, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jul. 31, 2023  
Document Transition Report false  
Entity File Number 001-36568  
Entity Registrant Name HEALTHEQUITY, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 52-2383166  
Entity Address, Address Line One 15 West Scenic Pointe Drive  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Draper,  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84020  
City Area Code 801  
Local Phone Number 727-1000  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol HQY  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   85,627,521
Entity Central Index Key 0001428336  
Current Fiscal Year End Date --01-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed consolidated balance sheets - USD ($)
$ in Thousands
Jul. 31, 2023
Jan. 31, 2023
Current assets    
Cash and cash equivalents $ 290,345 $ 254,266
Accounts receivable, net of allowance for doubtful accounts of $4,639 and $4,989 as of July 31, 2023 and January 31, 2023, respectively 92,581 96,835
Other current assets 39,631 31,792
Total current assets 422,557 382,893
Property and equipment, net 9,145 12,862
Operating lease right-of-use assets 51,976 56,461
Intangible assets, net 881,937 936,359
Goodwill 1,648,145 1,648,145
Other assets 52,696 52,180
Total assets 3,066,456 3,088,900
Current liabilities    
Accounts payable 12,543 13,899
Accrued compensation 31,421 45,835
Accrued liabilities 49,281 43,668
Current portion of long-term debt 0 17,500
Operating lease liabilities 10,026 10,159
Total current liabilities 103,271 131,061
Long-term liabilities    
Long-term debt, net of issuance costs 873,581 907,838
Operating lease liabilities, non-current 52,371 58,988
Other long-term liabilities 13,092 12,708
Deferred tax liability 74,527 82,665
Total long-term liabilities 1,013,571 1,062,199
Total liabilities 1,116,842 1,193,260
Commitments and contingencies (see Note 5)
Stockholders’ equity    
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively 0 0
Common stock, $0.0001 par value, 900,000 shares authorized, 85,612 and 84,758 shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively 9 8
Additional paid-in capital 1,785,014 1,745,716
Accumulated earnings 164,591 149,916
Total stockholders’ equity 1,949,614 1,895,640
Total liabilities and stockholders’ equity $ 3,066,456 $ 3,088,900
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed consolidated balance sheets (Parenthetical) - USD ($)
$ in Thousands
Jul. 31, 2023
Jan. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 4,639 $ 4,989
Preferred stock, par value (in usd per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 100,000,000 100,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in usd per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 900,000,000 900,000,000
Common stock, issued (in shares) 85,612,000 84,758,000
Common stock, outstanding (in shares) 85,612,000 84,758,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Revenue        
Revenue $ 243,549 $ 206,142 $ 487,981 $ 411,821
Cost of revenue        
Cost of revenue 92,619 88,330 189,225 182,836
Gross profit 150,930 117,812 298,756 228,985
Operating expenses        
Sales and marketing 19,123 15,843 39,058 32,403
Technology and development 54,767 46,580 107,959 91,763
General and administrative 27,090 25,937 51,984 49,664
Amortization of acquired intangible assets 23,166 24,181 46,332 47,879
Merger integration 2,044 7,683 5,502 16,977
Total operating expenses 126,190 120,224 250,835 238,686
Income (loss) from operations 24,740 (2,412) 47,921 (9,701)
Other expense        
Interest expense (13,272) (11,493) (28,269) (21,954)
Other income (expense), net 2,756 32 4,584 (269)
Total other expense (10,516) (11,461) (23,685) (22,223)
Income (loss) before income taxes 14,224 (13,873) 24,236 (31,924)
Income tax provision (benefit) 3,643 (3,219) 9,561 (7,631)
Net income (loss) 10,581 (10,654) 14,675 (24,293)
Comprehensive income (loss) $ 10,581 $ (10,654) $ 14,675 $ (24,293)
Net income (loss) per share:        
Basic (in usd per share) $ 0.12 $ (0.13) $ 0.17 $ (0.29)
Diluted (in usd per share) $ 0.12 $ (0.13) $ 0.17 $ (0.29)
Weighted-average number of shares used in computing net income (loss) per share:        
Basic (in shares) 85,533 84,443 85,286 84,236
Diluted (in shares) 86,341 84,443 86,356 84,236
Service        
Revenue        
Revenue $ 105,719 $ 103,034 $ 210,831 $ 207,382
Cost of revenue        
Cost of revenue 76,543 74,914 157,098 155,788
Custodial        
Revenue        
Revenue 98,917 65,599 193,358 124,964
Cost of revenue        
Cost of revenue 9,133 7,090 18,133 13,731
Interchange        
Revenue        
Revenue 38,913 37,509 83,792 79,475
Cost of revenue        
Cost of revenue $ 6,943 $ 6,326 $ 13,994 $ 13,317
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed consolidated statements of stockholders' equity (unaudited) - USD ($)
$ in Thousands
Total
Common stock:
Additional paid-in capital:
Accumulated earnings
Beginning balance at Jan. 31, 2022 $ 1,852,575 $ 8 $ 1,676,508 $ 176,059
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     4,474  
Stock-based compensation     32,140  
Net income (loss) (24,293)     (24,293)
Ending balance at Jul. 31, 2022 1,864,896 8 1,713,122 151,766
Beginning balance at Apr. 30, 2022 1,855,263 8 1,692,834 162,420
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     2,134  
Stock-based compensation     18,154  
Net income (loss) (10,654)     (10,654)
Ending balance at Jul. 31, 2022 1,864,896 8 1,713,122 151,766
Beginning balance at Jan. 31, 2023 1,895,640 8 1,745,716 149,916
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock   1 1,021  
Stock-based compensation     38,277  
Net income (loss) 14,675     14,675
Ending balance at Jul. 31, 2023 1,949,614 9 1,785,014 164,591
Beginning balance at Apr. 30, 2023 1,918,592 9 1,764,573 154,010
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     368  
Stock-based compensation     20,073  
Net income (loss) 10,581     10,581
Ending balance at Jul. 31, 2023 $ 1,949,614 $ 9 $ 1,785,014 $ 164,591
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed consolidated statements of cash flows (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Cash flows from operating activities:    
Net income (loss) $ 14,675 $ (24,293)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 77,387 80,226
Stock-based compensation 38,277 32,140
Amortization of debt discount and issuance costs 1,461 1,639
Loss on extinguishment of debt 1,157 0
Other non-cash items 0 269
Deferred taxes (8,138) (7,558)
Changes in operating assets and liabilities:    
Accounts receivable, net 4,254 (3,161)
Other assets (8,526) (1,546)
Operating lease right-of-use assets 6,594 4,117
Accrued compensation (14,675) (4,973)
Accounts payable, accrued liabilities, and other current liabilities 3,970 (25,586)
Operating lease liabilities, non-current (8,175) (3,594)
Other long-term liabilities 384 (454)
Net cash provided by operating activities 108,645 47,226
Cash flows from investing activities:    
Purchases of software and capitalized software development costs (18,794) (24,215)
Purchases of property and equipment (590) (2,384)
Acquisitions of HSA portfolios 0 (68,725)
Net cash used in investing activities (19,384) (95,324)
Cash flows from financing activities:    
Principal payments on long-term debt (54,375) (4,375)
Settlement of client-held funds obligation, net (161) (991)
Proceeds from exercise of common stock options 1,354 4,936
Net cash used in financing activities (53,182) (430)
Increase (decrease) in cash and cash equivalents 36,079 (48,528)
Beginning cash and cash equivalents 254,266 225,414
Ending cash and cash equivalents 290,345 176,886
Supplemental cash flow data:    
Interest expense paid in cash 23,504 19,450
Income tax payments, net 15,113 573
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of property and equipment included in accounts payable or accrued liabilities 300 356
Exercise of common stock options receivable 50 8
Increase in goodwill due to measurement period adjustments, net 0 163
Computer software intangible asset    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of intangible assets 3,228 5,040
Acquired HSA portfolios    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of intangible assets $ 0 $ 1,849
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of business and significant accounting policies
6 Months Ended
Jul. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of business and significant accounting policies Summary of business and significant accounting policies
Business
HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Principles of consolidation
The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation
The accompanying condensed consolidated financial statements as of July 31, 2023 and for the three and six months ended July 31, 2023 and 2022 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2023. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2023.
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Net income (loss) per share
6 Months Ended
Jul. 31, 2023
Earnings Per Share [Abstract]  
Net income (loss) per share Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended July 31,Six months ended July 31,
(in thousands, except per share data)2023202220232022
Numerator (basic and diluted):
Net income (loss)$10,581 $(10,654)$14,675 $(24,293)
Denominator (basic):
Weighted-average common shares outstanding85,533 84,443 85,286 84,236 
Denominator (diluted):
Weighted-average common shares outstanding85,533 84,443 85,286 84,236 
Weighted-average dilutive effect of stock options and restricted stock units808 — 1,070 — 
Diluted weighted-average common shares outstanding86,341 84,443 86,356 84,236 
Net income (loss) per share:
Basic $0.12 $(0.13)$0.17 $(0.29)
Diluted$0.12 $(0.13)$0.17 $(0.29)
For the three months ended July 31, 2023 and 2022, approximately 1.6 million and 3.3 million shares, respectively, attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted net income (loss) per share as their inclusion would have been anti-dilutive.
For the six months ended July 31, 2023 and 2022, approximately 0.9 million and 2.6 million shares, respectively, attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted net income (loss) per share as their inclusion would have been anti-dilutive.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental financial statement information
6 Months Ended
Jul. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental financial statement information Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:
Property and equipment
Property and equipment consisted of the following:
(in thousands)July 31, 2023January 31, 2023
Leasehold improvements$18,199 $18,269 
Furniture and fixtures8,392 8,392 
Computer equipment27,696 28,021 
Property and equipment, gross54,287 54,682 
Accumulated depreciation(45,142)(41,820)
Property and equipment, net$9,145 $12,862 
Depreciation expense for the three months ended July 31, 2023 and 2022 was $2.0 million and $3.2 million, respectively, and $4.5 million and $6.4 million for the six months ended July 31, 2023 and 2022, respectively.
Contract balances
The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of July 31, 2023 and January 31, 2023, the balance of deferred revenue was $6.7 million and $8.3 million, respectively. The balances are related to cash received in advance for interchange and custodial revenue arrangements, other up-front fees and other commuter deferred revenue. The Company expects to recognize approximately 63% of its balance of deferred revenue as revenue over the next 12 months and the remainder thereafter. During the three and six months ended July 31, 2023, approximately $1.4 million and $2.9 million, respectively, of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2023. The Company expects to satisfy its remaining obligations for these arrangements.
Leases
The components of operating lease costs were as follows:
Three months ended July 31,Six months ended July 31,
(in thousands)
2023202220232022
Operating lease expense$2,365 $2,854 $4,966 $5,713 
Sublease income(619)(551)(981)(1,046)
Net operating lease expense$1,746 $2,303 $3,985 $4,667 
Other income (expense), net
Other income (expense), net, consisted of the following:
Three months ended July 31,Six months ended July 31,
(in thousands)2023202220232022
Interest income$2,484 $89 $4,082 $141 
Acquisition costs— (47)— (53)
Other income (expense), net272 (10)502 (357)
Total other income (expense), net$2,756 $32 $4,584 $(269)
Interest expense
Based on the application of Accounting Standards Codification ("ASC") 470-50, Debt - Modifications and Extinguishments, the Company recorded a $1.2 million loss on extinguishment of debt due to the prepayment of $50.0 million under the Company's Term Loan Facility (as defined in Note 6—Indebtedness) in April 2023, which is included within interest expense in the condensed consolidated statement of operations and comprehensive income for the six months ended July 31, 2023.
Supplemental cash flow information
Supplemental cash flow information related to the Company's operating leases was as follows:
Six months ended July 31,
(in thousands)20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$5,451 $6,232 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$2,109 $1,092 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Intangible assets and goodwill
6 Months Ended
Jul. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets and goodwill Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows:
July 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$246,789 $(173,865)$72,924 
Acquired HSA portfolios261,188 (72,253)188,935 
Acquired customer relationships759,782 (179,280)580,502 
Acquired developed technology132,825 (93,370)39,455 
Acquired trade names12,900 (12,779)121 
Total amortizable intangible assets$1,413,484 $(531,547)$881,937 
January 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$233,194 $(152,178)$81,016 
Acquired HSA portfolios261,188 (63,547)197,641 
Acquired customer relationships759,782 (153,434)606,348 
Acquired developed technology132,825 (81,692)51,133 
Acquired trade names12,900 (12,679)221 
Total amortizable intangible assets$1,399,889 $(463,530)$936,359 
Amortization expense for the three months ended July 31, 2023 and 2022 was $36.3 million and $37.6 million, respectively, and $72.8 million and $73.8 million for the six months ended July 31, 2023 and 2022, respectively.
Goodwill
There were no changes to the carrying value of goodwill during the six months ended July 31, 2023.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and contingencies
6 Months Ended
Jul. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Commitments
The Company’s principal commitments consist of long-term debt, operating lease obligations for office space and data storage facilities, processing services agreements, software subscriptions, telephony services, and other contractual commitments. In April 2023, the Company used $50.0 million of cash to prepay, in direct order of maturity, principal due under its Term Loan Facility. There were no other material changes during the six months ended July 31, 2023, outside of the ordinary course of business, in the Company's commitments from those disclosed in its Annual Report on Form 10-K for the fiscal year ended January 31, 2023.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
In April 2021, WageWorks, Inc. ("WageWorks"), a wholly owned subsidiary of the Company, exercised its right to terminate a lease for office space in Mesa, Arizona that had not yet commenced, with aggregate lease payments of $63.1 million and a term of approximately 11 years, following the landlord's failure to fulfill its obligations under the lease agreement. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease. WageWorks' right to terminate the lease agreement was disputed by the landlord, Union Mesa 1, LLC (“Union Mesa”). On November 5, 2021, Union Mesa notified WageWorks that it was in default of the lease for failure to pay rent, which Union Mesa claimed was due beginning in November 2021, and on November 24, 2021 drew $2.8 million, the full amount under the letter of credit that WageWorks had posted to secure its obligations under the lease. On December 1, 2021, WageWorks filed a lawsuit against Union Mesa in the Superior Court of the State of Arizona in and for the County of Maricopa. On January 4, 2022, WageWorks filed an amended complaint in the Superior Court. Pursuant to the lawsuit, WageWorks seeks declaratory judgment that the lease was properly terminated and recourse against Union Mesa for breach of contract, breach of the duty of good faith and fair dealing, and conversion, including return of the funds drawn under the letter of credit. On January 31, 2022, Union Mesa filed a motion to dismiss for the conversion cause of action, which the Superior Court denied on April 13, 2022. On May 18, 2022, Union Mesa filed an answer and counterclaim with the Superior Court, wherein Union Mesa denied WageWorks' claims, and separately seeks recourse against WageWorks for breach of contract and breach of the implied covenant of good faith and fair dealing. On May 19, 2022, Union Mesa filed an amended complaint and counterclaim seeking the same recourse. On June 29, 2022, Union Mesa filed a second amended answer and counterclaim, which names the Company as a counter-defendant. On July 21, 2022, WageWorks and the Company filed an answer to the counterclaims. On April 26, 2023, Union Mesa filed a motion for partial summary judgment, and the Company expects to file its response in due course. Through its claims, Union Mesa is seeking direct and consequential damages in an amount to be
proven at trial and an award of its reasonable attorney fees, plus interest until any damages or fees that are awarded are paid. The parties are currently engaged in discovery.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Indebtedness
6 Months Ended
Jul. 31, 2023
Debt Disclosure [Abstract]  
Indebtedness Indebtedness
Long-term debt consisted of the following:
(in thousands)July 31, 2023January 31, 2023
4.50% Senior Notes due 2029
$600,000 $600,000 
Term Loan Facility286,875 341,250 
Principal amount886,875 941,250 
Less: unamortized discount and issuance costs (1)13,294 15,912 
Total debt, net873,581 925,338 
Less: current portion of long-term debt17,500
Long-term debt, net$873,581 $907,838 
(1)In addition to the $13.3 million and $15.9 million of unamortized discount and issuance costs related to long-term debt as of July 31, 2023 and January 31, 2023, respectively, $3.0 million and $3.4 million of unamortized issuance costs related to the Company's Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of July 31, 2023 and January 31, 2023, respectively.
4.50% Senior Notes due 2029
On October 8, 2021, the Company completed its offering of $600 million aggregate principal amount of its 4.50% Senior Notes due 2029 (the “Notes”). The Notes were issued under an indenture (the “Indenture”), dated October 8, 2021, among the Company, the guarantors party thereto, and Wells Fargo Bank, National Association, as trustee.
The Notes are guaranteed by each of the Company’s existing, wholly owned domestic subsidiaries that guarantees its obligations under the Credit Agreement (as defined below) and are required to be guaranteed by any of the Company’s future subsidiaries that guarantee its obligations under the Credit Agreement or certain of its other indebtedness. The Notes will mature on October 1, 2029. Interest on the Notes is payable on April 1 and October 1 of each year. Accrued interest on the Notes was $9.0 million at each of July 31, 2023 and January 31, 2023, and is included within accrued liabilities on the Company's condensed consolidated balance sheets. The effective interest rate on the Notes is 4.72%.
The Notes are unsecured senior obligations of the Company and rank equally in right of payment to all of its existing and future senior unsecured debt and senior in right of payment to all of its future subordinated debt.
The Notes are redeemable at the Company’s option, in whole or in part, at any time on or after October 1, 2024, at a redemption price if redeemed during the 12 months beginning (i) October 1, 2024 of 102.250%, (ii) October 1, 2025 of 101.125%, and (iii) October 1, 2026 and thereafter of 100.000%, in each case of the principal amount of the Notes being redeemed, and together with accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may also redeem some or all of the Notes before October 1, 2024 at a redemption price equal to 100% of the principal amount of the Notes, plus the applicable “make-whole” premium as of, and accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, at any time prior to October 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the Notes issued under the Indenture on one or more occasions in an aggregate amount equal to the net cash proceeds of one or more equity offerings at a redemption price equal to 104.500% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control.
The Indenture contains covenants that impose significant operational and financial restrictions on the Company; however, these covenants generally align with the covenants contained in the Credit Agreement. See "Credit Agreement" below for a description of these covenants.
Credit Agreement
On October 8, 2021, the Company entered into a credit agreement (the “Credit Agreement”) among the Company, as borrower, each lender from time to time party thereto (the “Lenders”), JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Agent”) and the Swing Line Lender (as defined in the Credit Agreement), and each L/C Issuer (as defined therein) party thereto, pursuant to which the Company established:
(i)a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $350 million; and
(ii)a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1.0 billion (with a $25 million sub-limit for the issuance of letters of credit), the proceeds of which may be used for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments.
Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company’s pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.
Prior to June 1, 2023, borrowings under the Credit Facilities bore interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement.
On June 1, 2023, the Company entered into an amendment to the Credit Agreement (“Amendment No. 1”) which replaced interest rate provisions based on LIBOR with the forward-looking term rate based on the secured overnight financing rate published by the CME Group Benchmark Administration Limited (“Term SOFR”). As a result, borrowings under the Credit Agreement as so amended by Amendment No. 1 bear interest, as of July 31, 2023, at an annual rate equal to, at the option of the Company, either (i) Term SOFR, plus a 0.10% credit spread adjustment, plus a margin ranging from 1.25% to 2.25%, or (ii) an alternate base rate, plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement (as amended by Amendment No. 1). As of July 31, 2023, the stated interest rate was 6.92% and the effective interest rate was 7.68%.
The Company is also required to pay certain fees to the Lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of July 31, 2023, no amounts have been drawn under the Revolving Credit Facility.
The loans made under the Term Loan Facility amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the Term Loan Facility: (i) 2.5% for the first year after October 8, 2021; (ii) 5.0% for each of the second and third years after October 8, 2021; (iii) 7.5% for the fourth year after October 8, 2021; and (iv) 10.0% for the fifth year after October 8, 2021. In addition, the Term Loan Facility is required to be mandatorily prepaid with 100% of the net cash proceeds of all asset sales, insurance and condemnation recoveries, subject to customary exceptions and thresholds, including to the extent such proceeds are reinvested in assets useful in the business of the Company and its subsidiaries within 450 days following receipt (or committed to be reinvested within such 450-day period and reinvested within 180 days after the end of such 450-day period). The loans under the Credit Facilities may be prepaid, and the commitments thereunder may be reduced, by the Company without penalty or premium, subject to the reimbursement of customary “breakage costs.” In April 2023, the Company used $50.0 million of cash to prepay, in direct order of maturity, principal due under its Term Loan Facility.
The Credit Agreement contains significant customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its
organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.00 to 1.00 and (ii) a minimum consolidated interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of July 31, 2023, and for the period then ended.
The repayment obligation under the Credit Agreement may be accelerated upon the occurrence of an event of default thereunder, including, among other things, failure to pay principal, interest or fees on a timely basis, material inaccuracy of any representation or warranty, failure to comply with covenants, cross-default to other material debt, material judgments, change of control and certain insolvency or bankruptcy-related events, in each case, subject to any certain grace and/or cure periods.
The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by each of the Company’s existing or subsequently acquired or organized domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Income taxes
6 Months Ended
Jul. 31, 2023
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company follows ASC 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to pre-tax income through the end of the latest fiscal quarter to determine the interim income tax provision. For the three and six months ended July 31, 2023, the Company recorded an income tax provision of $3.6 million and $9.6 million, respectively. This resulted in an effective income tax provision rate of 25.6% and 39.4% for the three and six months ended July 31, 2023, respectively, compared with an effective income tax benefit rate of 23.2% and 23.9% for the three and six months ended July 31, 2022, respectively. For the three and six months ended July 31, 2023 and 2022, discrete tax items impacting the effective tax rate were primarily due to differences in tax deductible stock-based compensation compared to GAAP stock-based compensation expense.
As of July 31, 2023 and January 31, 2023, the Company’s total gross unrecognized tax benefit was $8.9 million and $8.7 million, respectively. If recognized, $5.6 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of July 31, 2023.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to the Company's taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2003.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based compensation
6 Months Ended
Jul. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended July 31,Six months ended July 31,
(in thousands)2023202220232022
Cost of revenue$4,714 $3,998 $8,549 $7,005 
Sales and marketing3,478 2,553 6,257 4,567 
Technology and development4,283 2,963 9,175 6,343 
General and administrative7,598 8,640 14,296 14,225 
Total stock-based compensation expense$20,073 $18,154 $38,277 $32,140 
Stock award plans
Incentive Plan. The Company grants stock options and restricted stock units ("RSUs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing
through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of July 31, 2023, 11.5 million shares were available for grant under the Incentive Plan.
Stock options
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20231,021 
$14.00 - 82.39
$36.06 3.2$27,293 
Exercised(34)
$14.00 - 44.53
$29.71 
Forfeited(4)
$24.36 - 44.53
$38.41 
Outstanding as of July 31, 2023983 
$14.00 - 82.39
$36.27 2.6$32,047 
Vested and expected to vest as of July 31, 2023983 $36.27 2.6$32,047 
Exercisable as of July 31, 2023983 $36.27 2.6$32,047 
Restricted stock units
A summary of RSU activity is as follows:
RSUs and PRSUs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair value
Outstanding as of January 31, 20233,011 $70.40 
Granted1,767 64.46 
Vested(801)67.53 
Forfeited(250)71.53 
Outstanding as of July 31, 20233,727 $68.13 
Performance restricted stock units. During the three months ended April 30, 2023, the Company awarded 270,966 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2026. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $23.9 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Fair value
6 Months Ended
Jul. 31, 2023
Fair Value Disclosures [Abstract]  
Fair value Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Cash and cash equivalents are considered Level 1 instruments and are valued based on publicly available daily net asset values. The carrying values of cash and cash equivalents approximate fair values due to the short-term nature of these instruments.
The Notes are valued based upon quoted market prices and are considered Level 2 instruments because the markets in which the Notes trade are not considered active markets. As of July 31, 2023, the fair value of the Notes was $536.7 million.
The Term Loan Facility is considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Term Loan Facility reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, the fair value of the Term Loan Facility approximates carrying value.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Pay vs Performance Disclosure        
Net income (loss) $ 10,581 $ (10,654) $ 14,675 $ (24,293)
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
3 Months Ended
Jul. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of business and significant accounting policies (Policies)
6 Months Ended
Jul. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of consolidation The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation The accompanying condensed consolidated financial statements as of July 31, 2023 and for the three and six months ended July 31, 2023 and 2022 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2023. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP.
Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Net income (loss) per share (Tables)
6 Months Ended
Jul. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Income (Loss) Per Share, Basic and Diluted The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended July 31,Six months ended July 31,
(in thousands, except per share data)2023202220232022
Numerator (basic and diluted):
Net income (loss)$10,581 $(10,654)$14,675 $(24,293)
Denominator (basic):
Weighted-average common shares outstanding85,533 84,443 85,286 84,236 
Denominator (diluted):
Weighted-average common shares outstanding85,533 84,443 85,286 84,236 
Weighted-average dilutive effect of stock options and restricted stock units808 — 1,070 — 
Diluted weighted-average common shares outstanding86,341 84,443 86,356 84,236 
Net income (loss) per share:
Basic $0.12 $(0.13)$0.17 $(0.29)
Diluted$0.12 $(0.13)$0.17 $(0.29)
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental financial statement information (Tables)
6 Months Ended
Jul. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Property and Equipment Property and equipment consisted of the following:
(in thousands)July 31, 2023January 31, 2023
Leasehold improvements$18,199 $18,269 
Furniture and fixtures8,392 8,392 
Computer equipment27,696 28,021 
Property and equipment, gross54,287 54,682 
Accumulated depreciation(45,142)(41,820)
Property and equipment, net$9,145 $12,862 
Schedule of Lease Cost The components of operating lease costs were as follows:
Three months ended July 31,Six months ended July 31,
(in thousands)
2023202220232022
Operating lease expense$2,365 $2,854 $4,966 $5,713 
Sublease income(619)(551)(981)(1,046)
Net operating lease expense$1,746 $2,303 $3,985 $4,667 
Supplemental cash flow information related to the Company's operating leases was as follows:
Six months ended July 31,
(in thousands)20232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$5,451 $6,232 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$2,109 $1,092 
Schedule of Other Income (Expense), Net Other income (expense), net, consisted of the following:
Three months ended July 31,Six months ended July 31,
(in thousands)2023202220232022
Interest income$2,484 $89 $4,082 $141 
Acquisition costs— (47)— (53)
Other income (expense), net272 (10)502 (357)
Total other income (expense), net$2,756 $32 $4,584 $(269)
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Intangible assets and goodwill (Tables)
6 Months Ended
Jul. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-lived Intangible Assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows:
July 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$246,789 $(173,865)$72,924 
Acquired HSA portfolios261,188 (72,253)188,935 
Acquired customer relationships759,782 (179,280)580,502 
Acquired developed technology132,825 (93,370)39,455 
Acquired trade names12,900 (12,779)121 
Total amortizable intangible assets$1,413,484 $(531,547)$881,937 
January 31, 2023
(in thousands)Gross carrying amountAccumulated amortizationNet carrying amount
Amortizable intangible assets:
Software and software development costs$233,194 $(152,178)$81,016 
Acquired HSA portfolios261,188 (63,547)197,641 
Acquired customer relationships759,782 (153,434)606,348 
Acquired developed technology132,825 (81,692)51,133 
Acquired trade names12,900 (12,679)221 
Total amortizable intangible assets$1,399,889 $(463,530)$936,359 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Indebtedness (Tables)
6 Months Ended
Jul. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Long-term debt consisted of the following:
(in thousands)July 31, 2023January 31, 2023
4.50% Senior Notes due 2029
$600,000 $600,000 
Term Loan Facility286,875 341,250 
Principal amount886,875 941,250 
Less: unamortized discount and issuance costs (1)13,294 15,912 
Total debt, net873,581 925,338 
Less: current portion of long-term debt17,500
Long-term debt, net$873,581 $907,838 
(1)In addition to the $13.3 million and $15.9 million of unamortized discount and issuance costs related to long-term debt as of July 31, 2023 and January 31, 2023, respectively, $3.0 million and $3.4 million of unamortized issuance costs related to the Company's Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of July 31, 2023 and January 31, 2023, respectively.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based compensation (Tables)
6 Months Ended
Jul. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Share Based Compensation Recognized The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended July 31,Six months ended July 31,
(in thousands)2023202220232022
Cost of revenue$4,714 $3,998 $8,549 $7,005 
Sales and marketing3,478 2,553 6,257 4,567 
Technology and development4,283 2,963 9,175 6,343 
General and administrative7,598 8,640 14,296 14,225 
Total stock-based compensation expense$20,073 $18,154 $38,277 $32,140 
Schedule of Stock Option Activity A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20231,021 
$14.00 - 82.39
$36.06 3.2$27,293 
Exercised(34)
$14.00 - 44.53
$29.71 
Forfeited(4)
$24.36 - 44.53
$38.41 
Outstanding as of July 31, 2023983 
$14.00 - 82.39
$36.27 2.6$32,047 
Vested and expected to vest as of July 31, 2023983 $36.27 2.6$32,047 
Exercisable as of July 31, 2023983 $36.27 2.6$32,047 
Schedule of Restricted Stock Unit Activity A summary of RSU activity is as follows:
RSUs and PRSUs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair value
Outstanding as of January 31, 20233,011 $70.40 
Granted1,767 64.46 
Vested(801)67.53 
Forfeited(250)71.53 
Outstanding as of July 31, 20233,727 $68.13 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Net income (loss) per share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Numerator (basic and diluted):        
Net income (loss) $ 10,581 $ (10,654) $ 14,675 $ (24,293)
Denominator (basic):        
Weighted-average common shares outstanding (in shares) 85,533 84,443 85,286 84,236
Denominator (diluted):        
Weighted-average common shares outstanding (in shares) 85,533 84,443 85,286 84,236
Weighted-average dilutive effect of stock options and restricted stock units (in shares) 808 0 1,070 0
Diluted weighted-average common shares outstanding (in shares) 86,341 84,443 86,356 84,236
Net income (loss) per share:        
Basic (in usd per share) $ 0.12 $ (0.13) $ 0.17 $ (0.29)
Diluted (in usd per share) $ 0.12 $ (0.13) $ 0.17 $ (0.29)
Antidilutive securities excluded from computation of earnings per share (in shares) 1,600 3,300 900 2,600
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental financial statement information (Property and Equipment) (Details) - USD ($)
$ in Thousands
Jul. 31, 2023
Jan. 31, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 54,287 $ 54,682
Accumulated depreciation (45,142) (41,820)
Property and equipment, net 9,145 12,862
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 18,199 18,269
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 8,392 8,392
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 27,696 $ 28,021
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental financial statement information (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2023
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Jan. 31, 2023
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]            
Depreciation expense   $ 2,000 $ 3,200 $ 4,500 $ 6,400  
Remaining performance obligation   6,700   6,700   $ 8,300
Revenue recognition   $ 1,400   2,900    
Loss on extinguishment of debt       $ 1,157 $ 0  
Prepayment of debt $ 50,000          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-08-01            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]            
Remaining performance obligation, percentage   63.00%   63.00%    
Revenue, remaining performance obligation, expected timing of satisfaction, period   12 months   12 months    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-08-01            
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]            
Revenue, remaining performance obligation, expected timing of satisfaction, period        
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental financial statement information (Lease Cost) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Operating lease expense $ 2,365 $ 2,854 $ 4,966 $ 5,713
Sublease income (619) (551) (981) (1,046)
Net operating lease expense $ 1,746 $ 2,303 $ 3,985 $ 4,667
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental financial statement information (Other Income (Expense), Net) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Interest income $ 2,484 $ 89 $ 4,082 $ 141
Acquisition costs 0 (47) 0 (53)
Other income (expense), net 272 (10) 502 (357)
Total other income (expense), net $ 2,756 $ 32 $ 4,584 $ (269)
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental financial statement information (Supplemental Cash Flow Information) (Details) - USD ($)
$ in Thousands
6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 5,451 $ 6,232
Operating lease right-of-use assets obtained in exchange for new operating lease obligations $ 2,109 $ 1,092
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Intangible assets and goodwill (Schedule of Intangible Assets) (Details) - USD ($)
$ in Thousands
Jul. 31, 2023
Jan. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount $ 1,413,484 $ 1,399,889
Accumulated amortization (531,547) (463,530)
Net carrying amount 881,937 936,359
Software and software development costs    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 246,789 233,194
Accumulated amortization (173,865) (152,178)
Net carrying amount 72,924 81,016
Acquired HSA portfolios    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 261,188 261,188
Accumulated amortization (72,253) (63,547)
Net carrying amount 188,935 197,641
Acquired customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 759,782 759,782
Accumulated amortization (179,280) (153,434)
Net carrying amount 580,502 606,348
Acquired developed technology    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 132,825 132,825
Accumulated amortization (93,370) (81,692)
Net carrying amount 39,455 51,133
Acquired trade names    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying amount 12,900 12,900
Accumulated amortization (12,779) (12,679)
Net carrying amount $ 121 $ 221
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Intangible assets and goodwill (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization expense $ 36.3 $ 37.6 $ 72.8 $ 73.8
Change in goodwill     $ 0.0  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and contingencies (Details) - USD ($)
$ in Millions
Apr. 30, 2023
Nov. 24, 2021
Apr. 30, 2021
WageWorks, Inc      
Loss Contingencies [Line Items]      
Operating lease not yet commenced undiscounted amount     $ 63.1
Operating lease not yet commenced term of contract     11 years
WageWorks, Inc | Union Mesa      
Loss Contingencies [Line Items]      
Letters of credit outstanding   $ 2.8  
Term Loan Facility      
Loss Contingencies [Line Items]      
Fair value of the notes $ 50.0    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Indebtedness (Schedule of Long-term Debt) (Details) - USD ($)
$ in Thousands
Jul. 31, 2023
Jan. 31, 2023
Debt Instrument [Line Items]    
Principal amount $ 886,875 $ 941,250
Less: unamortized discount and issuance costs 13,294 15,912
Total debt, net 873,581 925,338
Less: current portion of long-term debt 0 17,500
Long-term debt, net 873,581 907,838
4.50% Senior Notes due 2029    
Debt Instrument [Line Items]    
Principal amount $ 600,000 600,000
Stated interest rate (as a percent) 4.50%  
Credit Agreement    
Debt Instrument [Line Items]    
Stated interest rate (as a percent) 6.92%  
Term Loan Facility | Credit Agreement    
Debt Instrument [Line Items]    
Principal amount $ 286,875 341,250
Revolving Credit Facility    
Debt Instrument [Line Items]    
Debt issuance costs, net $ 3,000 $ 3,400
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Indebtedness (Narrative) (Details) - USD ($)
6 Months Ended
Jun. 01, 2023
May 31, 2023
Oct. 08, 2021
Jul. 31, 2023
Apr. 30, 2023
Jan. 31, 2023
Term Loan Facility            
Debt Instrument [Line Items]            
Fair value of the notes         $ 50,000,000  
Line of Credit | Revolving Credit Facility | Minimum            
Debt Instrument [Line Items]            
Commitment fee (as a percent)       0.20%    
Line of Credit | Revolving Credit Facility | Maximum            
Debt Instrument [Line Items]            
Commitment fee (as a percent)       0.40%    
4.50% Senior Notes due 2029            
Debt Instrument [Line Items]            
Stated interest rate (as a percent)       4.50%    
4.50% Senior Notes due 2029 | Senior Notes            
Debt Instrument [Line Items]            
Stated interest rate (as a percent)     4.50%      
Principal amount     $ 600,000,000      
Accrued interest       $ 9,000,000   $ 9,000,000
Effective interest rate (as a percent)       4.72%    
4.50% Senior Notes due 2029 | Senior Notes | October 1, 2024            
Debt Instrument [Line Items]            
Redemption price (as a percent)     102.25%      
4.50% Senior Notes due 2029 | Senior Notes | October 1, 2025            
Debt Instrument [Line Items]            
Redemption price (as a percent)     101.125%      
4.50% Senior Notes due 2029 | Senior Notes | October 1, 2026 and thereafter            
Debt Instrument [Line Items]            
Redemption price (as a percent)     100.00%      
4.50% Senior Notes due 2029 | Senior Notes | Prior to October 1, 2024            
Debt Instrument [Line Items]            
Redemption price (as a percent)     100.00%      
4.50% Senior Notes due 2029 | Senior Notes | Prior to October 1, 2024, 40% of Principal            
Debt Instrument [Line Items]            
Redemption price (as a percent)     104.50%      
Percentage of principal amount redeemed (as a percent)     40.00%      
Credit Agreement            
Debt Instrument [Line Items]            
Stated interest rate (as a percent)       6.92%    
Effective interest rate (as a percent)       7.68%    
Maximum borrowing capacity of future commitments     $ 300,000,000      
Maximum leverage ratio     3.85 5.00    
Minimum interest coverage ratio       3.00    
Credit Agreement | London Interbank Offered Rate (LIBOR) | Minimum            
Debt Instrument [Line Items]            
Variable rate borrowing spread (as a percent)   1.25%        
Credit Agreement | London Interbank Offered Rate (LIBOR) | Maximum            
Debt Instrument [Line Items]            
Variable rate borrowing spread (as a percent)   2.25%        
Credit Agreement | Customary Base Rate | Minimum            
Debt Instrument [Line Items]            
Variable rate borrowing spread (as a percent) 0.25% 0.25%        
Credit Agreement | Customary Base Rate | Maximum            
Debt Instrument [Line Items]            
Variable rate borrowing spread (as a percent) 1.25% 1.25%        
Credit Agreement | Secured Overnight Financing Rate (SOFR)            
Debt Instrument [Line Items]            
Credit spread adjustment on variable rate (as a percent) 0.10%          
Credit Agreement | Secured Overnight Financing Rate (SOFR) | Minimum            
Debt Instrument [Line Items]            
Variable rate borrowing spread (as a percent) 1.25%          
Credit Agreement | Secured Overnight Financing Rate (SOFR) | Maximum            
Debt Instrument [Line Items]            
Variable rate borrowing spread (as a percent) 2.25%          
Credit Agreement | Secured Debt | Term Loan Facility            
Debt Instrument [Line Items]            
Facility term (in years)     5 years      
Credit facility, amount     $ 350,000,000      
Credit Agreement | Line of Credit | Term Loan Facility            
Debt Instrument [Line Items]            
Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay (as a percent)       100.00%    
Debt instrument, number of days to reinvest proceeds from sales of assets (in days)       450 days    
Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period (in days)       180 days    
Credit Agreement | Line of Credit | Term Loan Facility | First year after the Effective Date            
Debt Instrument [Line Items]            
Debt instrument, amortization of loans, percentage of principal amount (as a percent)       2.50%    
Credit Agreement | Line of Credit | Term Loan Facility | Second and third years after the Effective Date            
Debt Instrument [Line Items]            
Debt instrument, amortization of loans, percentage of principal amount (as a percent)       5.00%    
Credit Agreement | Line of Credit | Term Loan Facility | Fourth year after the Effective Date            
Debt Instrument [Line Items]            
Debt instrument, amortization of loans, percentage of principal amount (as a percent)       7.50%    
Credit Agreement | Line of Credit | Term Loan Facility | Fifth year after the Effective Date            
Debt Instrument [Line Items]            
Debt instrument, amortization of loans, percentage of principal amount (as a percent)       10.00%    
Credit Agreement | Line of Credit | Revolving Credit Facility            
Debt Instrument [Line Items]            
Facility term (in years)     5 years      
Credit facility, amount     $ 1,000,000,000      
Credit Agreement | Letter of Credit | Revolving Credit Facility            
Debt Instrument [Line Items]            
Credit facility, amount     $ 25,000,000      
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Income taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Jan. 31, 2023
Income Tax Disclosure [Abstract]          
Income tax provision (benefit) $ 3,643 $ (3,219) $ 9,561 $ (7,631)  
Effective tax rate (as a percent) 25.60% 23.20% 39.40% 23.90%  
Gross unrecognized tax benefits $ 8,900   $ 8,900   $ 8,700
Unrecognized tax benefits that would impact the effective tax rate $ 5,600   $ 5,600    
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based compensation (Summary of Share Based Compensation Recognized) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 20,073 $ 18,154 $ 38,277 $ 32,140
Cost of revenue        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 4,714 3,998 8,549 7,005
Sales and marketing        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 3,478 2,553 6,257 4,567
Technology and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 4,283 2,963 9,175 6,343
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 7,598 $ 8,640 $ 14,296 $ 14,225
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based Compensation (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Apr. 30, 2023
Jul. 31, 2023
Performance restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Performance units awards (in shares) 270,966  
Grant date fair value   $ 23.9
Performance restricted stock units | Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Award vesting rights percentage   0.00%
Performance restricted stock units | Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Award vesting rights percentage   200.00%
Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares)   2,600,000
Percentage of capital stock   3.00%
Shares available for grant under incentive plan (in shares)   11,500,000
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based compensation (Stock Option Activity) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
6 Months Ended 12 Months Ended
Jul. 31, 2023
Jan. 31, 2023
Number of options (shares)    
Outstanding, beginning balance (in shares) 1,021  
Exercised (in shares) (34)  
Forfeited (in shares) (4)  
Outstanding, ending balance (in shares) 983 1,021
Vested and expected to vest (in shares) 983  
Exercisable (in shares) 983  
Range of exercise prices    
Beginning balance, minimum (in usd per share) $ 14.00  
Beginning balance, maximum (in usd per share) 82.39  
Exercised, minimum (in usd per share) 14.00  
Exercised, maximum (in usd per share) 44.53  
Forfeited, minimum (in usd per share) 24.36  
Forfeited, maximum (in usd per share) 44.53  
Ending balance, minimum (in usd per share) 14.00 $ 14.00
Ending balance, maximum (in usd per share) 82.39 82.39
Weighted- average exercise price    
Opening balance (in usd per share) 36.06  
Exercised (in usd per share) 29.71  
Forfeited (in usd per share) 38.41  
Ending balance (in usd per share) 36.27 $ 36.06
Vested and expected to vest, weighted average exercise price (in usd per share) 36.27  
Exercisable, weighted-average exercise price (in usd per share) $ 36.27  
Outstanding stock options, weighted average contractual term (in years) 2 years 7 months 6 days 3 years 2 months 12 days
Vested and expected to vest, weighted average contractual term (in years) 2 years 7 months 6 days  
Exercisable, weighted-average contractual term (in years) 2 years 7 months 6 days  
Aggregate intrinsic value $ 32,047 $ 27,293
Vested and expected to vest, aggregate intrinsic value (in usd per share) 32,047  
Exercisable, aggregate intrinsic value $ 32,047  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based compensation (Restricted Stock Unit Activity) (Details) - Restricted Stock Units
shares in Thousands
6 Months Ended
Jul. 31, 2023
$ / shares
shares
Shares  
Outstanding, beginning balance (in shares) | shares 3,011
Granted (in shares) | shares 1,767
Vested (in shares) | shares (801)
Forfeited (in shares) | shares (250)
Outstanding, ending balance (in shares) | shares 3,727
Weighted-average grant date fair value  
Outstanding, beginning balance (in usd per share) | $ / shares $ 70.40
Granted (in usd per share) | $ / shares 64.46
Vested (in usd per share) | $ / shares 67.53
Forfeited (in usd per share) | $ / shares 71.53
Outstanding, ending balance (in usd per share) | $ / shares $ 68.13
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Fair value (Details)
$ in Millions
Jul. 31, 2023
USD ($)
Level 2 | 4.50% Senior Notes due 2029  
Defined Benefit Plan Disclosure [Line Items]  
Fair value of the notes $ 536.7
XML 51 hqy-20230731_htm.xml IDEA: XBRL DOCUMENT 0001428336 2023-02-01 2023-07-31 0001428336 2023-08-31 0001428336 2023-07-31 0001428336 2023-01-31 0001428336 us-gaap:ServiceMember 2023-05-01 2023-07-31 0001428336 us-gaap:ServiceMember 2022-05-01 2022-07-31 0001428336 us-gaap:ServiceMember 2023-02-01 2023-07-31 0001428336 us-gaap:ServiceMember 2022-02-01 2022-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2023-05-01 2023-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2022-05-01 2022-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2023-02-01 2023-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2022-02-01 2022-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2023-05-01 2023-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2022-05-01 2022-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2023-02-01 2023-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2022-02-01 2022-07-31 0001428336 2023-05-01 2023-07-31 0001428336 2022-05-01 2022-07-31 0001428336 2022-02-01 2022-07-31 0001428336 2023-04-30 0001428336 2022-04-30 0001428336 2022-01-31 0001428336 us-gaap:CommonStockMember 2023-04-30 0001428336 us-gaap:CommonStockMember 2022-04-30 0001428336 us-gaap:CommonStockMember 2023-01-31 0001428336 us-gaap:CommonStockMember 2022-01-31 0001428336 us-gaap:CommonStockMember 2023-02-01 2023-07-31 0001428336 us-gaap:CommonStockMember 2023-07-31 0001428336 us-gaap:CommonStockMember 2022-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2023-05-01 2023-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2022-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2023-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001428336 us-gaap:RetainedEarningsMember 2023-04-30 0001428336 us-gaap:RetainedEarningsMember 2022-04-30 0001428336 us-gaap:RetainedEarningsMember 2023-01-31 0001428336 us-gaap:RetainedEarningsMember 2022-01-31 0001428336 us-gaap:RetainedEarningsMember 2023-05-01 2023-07-31 0001428336 us-gaap:RetainedEarningsMember 2022-05-01 2022-07-31 0001428336 us-gaap:RetainedEarningsMember 2023-02-01 2023-07-31 0001428336 us-gaap:RetainedEarningsMember 2022-02-01 2022-07-31 0001428336 us-gaap:RetainedEarningsMember 2023-07-31 0001428336 us-gaap:RetainedEarningsMember 2022-07-31 0001428336 2022-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-02-01 2023-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-02-01 2022-07-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2023-02-01 2023-07-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2022-02-01 2022-07-31 0001428336 us-gaap:LeaseholdImprovementsMember 2023-07-31 0001428336 us-gaap:LeaseholdImprovementsMember 2023-01-31 0001428336 us-gaap:FurnitureAndFixturesMember 2023-07-31 0001428336 us-gaap:FurnitureAndFixturesMember 2023-01-31 0001428336 us-gaap:ComputerEquipmentMember 2023-07-31 0001428336 us-gaap:ComputerEquipmentMember 2023-01-31 0001428336 2023-08-01 2023-07-31 0001428336 2023-04-01 2023-04-30 0001428336 2024-08-01 2023-07-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-07-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2023-07-31 0001428336 us-gaap:CustomerRelationshipsMember 2023-07-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2023-07-31 0001428336 us-gaap:TradeNamesMember 2023-07-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-01-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2023-01-31 0001428336 us-gaap:CustomerRelationshipsMember 2023-01-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2023-01-31 0001428336 us-gaap:TradeNamesMember 2023-01-31 0001428336 hqy:TermLoanFacilityMember 2023-04-30 0001428336 hqy:WageWorksInc.Member 2021-04-30 0001428336 hqy:UnionMesaMember hqy:WageWorksInc.Member 2021-11-24 0001428336 hqy:A4500SeniorNotesDue2029Member 2023-07-31 0001428336 hqy:A4500SeniorNotesDue2029Member 2023-01-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember 2023-07-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember 2023-01-31 0001428336 us-gaap:RevolvingCreditFacilityMember 2023-07-31 0001428336 us-gaap:RevolvingCreditFacilityMember 2023-01-31 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2023-07-31 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:SeniorNotesMember 2023-01-31 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodFourMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:DebtInstrumentRedemptionPeriodFiveMember us-gaap:SeniorNotesMember 2021-10-08 2021-10-08 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2021-10-08 2021-10-08 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2021-10-08 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-10-08 2021-10-08 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-10-08 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LetterOfCreditMember 2021-10-08 0001428336 hqy:CreditAgreementMember 2021-10-08 0001428336 srt:MinimumMember hqy:CreditAgreementMember hqy:LondonInterbankOfferedRateMember 2023-05-31 2023-05-31 0001428336 srt:MaximumMember hqy:CreditAgreementMember hqy:LondonInterbankOfferedRateMember 2023-05-31 2023-05-31 0001428336 srt:MinimumMember hqy:CreditAgreementMember us-gaap:BaseRateMember 2023-05-31 2023-05-31 0001428336 srt:MaximumMember hqy:CreditAgreementMember us-gaap:BaseRateMember 2023-05-31 2023-05-31 0001428336 hqy:CreditAgreementMember hqy:SecuredOvernightFinancingRateSOFRMember 2023-06-01 2023-06-01 0001428336 srt:MinimumMember hqy:CreditAgreementMember hqy:SecuredOvernightFinancingRateSOFRMember 2023-06-01 2023-06-01 0001428336 srt:MaximumMember hqy:CreditAgreementMember hqy:SecuredOvernightFinancingRateSOFRMember 2023-06-01 2023-06-01 0001428336 srt:MinimumMember hqy:CreditAgreementMember us-gaap:BaseRateMember 2023-06-01 2023-06-01 0001428336 srt:MaximumMember hqy:CreditAgreementMember us-gaap:BaseRateMember 2023-06-01 2023-06-01 0001428336 hqy:CreditAgreementMember 2023-07-31 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-02-01 2023-07-31 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-02-01 2023-07-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtInstrumentAmortizationPeriodOneMember 2023-07-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtInstrumentAmortizationPeriodTwoAndThreePeriodMember 2023-07-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtInstrumentAmortizationPeriodFourMember 2023-07-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtInstrumentAmortizationPeriodFiveMember 2023-07-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2023-07-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2023-02-01 2023-07-31 0001428336 us-gaap:CostOfSalesMember 2023-05-01 2023-07-31 0001428336 us-gaap:CostOfSalesMember 2022-05-01 2022-07-31 0001428336 us-gaap:CostOfSalesMember 2023-02-01 2023-07-31 0001428336 us-gaap:CostOfSalesMember 2022-02-01 2022-07-31 0001428336 hqy:SalesandMarketingMember 2023-05-01 2023-07-31 0001428336 hqy:SalesandMarketingMember 2022-05-01 2022-07-31 0001428336 hqy:SalesandMarketingMember 2023-02-01 2023-07-31 0001428336 hqy:SalesandMarketingMember 2022-02-01 2022-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2023-05-01 2023-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2022-05-01 2022-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2023-02-01 2023-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2022-02-01 2022-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2023-05-01 2023-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2022-05-01 2022-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2023-02-01 2023-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2022-02-01 2022-07-31 0001428336 hqy:IncentivePlanMember 2023-07-31 0001428336 2022-02-01 2023-01-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2023-01-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2023-02-01 2023-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2023-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2023-02-01 2023-04-30 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2023-07-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2023-02-01 2023-07-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2023-02-01 2023-07-31 0001428336 hqy:A4500SeniorNotesDue2029Member us-gaap:FairValueInputsLevel2Member 2023-07-31 shares iso4217:USD iso4217:USD shares pure 0001428336 --01-31 2024 Q2 false 10-Q true 2023-07-31 false 001-36568 HEALTHEQUITY, INC. DE 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper, UT 84020 801 727-1000 Common stock, par value $0.0001 per share HQY NASDAQ Yes Yes Large Accelerated Filer false false false 85627521 290345000 254266000 4639000 4989000 92581000 96835000 39631000 31792000 422557000 382893000 9145000 12862000 51976000 56461000 881937000 936359000 1648145000 1648145000 52696000 52180000 3066456000 3088900000 12543000 13899000 31421000 45835000 49281000 43668000 0 17500000 10026000 10159000 103271000 131061000 873581000 907838000 52371000 58988000 13092000 12708000 74527000 82665000 1013571000 1062199000 1116842000 1193260000 0.0001 0.0001 100000000 100000000 0 0 0 0 0 0 0.0001 0.0001 900000000 900000000 85612000 85612000 84758000 84758000 9000 8000 1785014000 1745716000 164591000 149916000 1949614000 1895640000 3066456000 3088900000 105719000 103034000 210831000 207382000 98917000 65599000 193358000 124964000 38913000 37509000 83792000 79475000 243549000 206142000 487981000 411821000 76543000 74914000 157098000 155788000 9133000 7090000 18133000 13731000 6943000 6326000 13994000 13317000 92619000 88330000 189225000 182836000 150930000 117812000 298756000 228985000 19123000 15843000 39058000 32403000 54767000 46580000 107959000 91763000 27090000 25937000 51984000 49664000 23166000 24181000 46332000 47879000 2044000 7683000 5502000 16977000 126190000 120224000 250835000 238686000 24740000 -2412000 47921000 -9701000 13272000 11493000 28269000 21954000 2756000 32000 4584000 -269000 -10516000 -11461000 -23685000 -22223000 14224000 -13873000 24236000 -31924000 3643000 -3219000 9561000 -7631000 10581000 10581000 -10654000 -10654000 14675000 14675000 -24293000 -24293000 0.12 -0.13 0.17 -0.29 0.12 -0.13 0.17 -0.29 85533000 84443000 85286000 84236000 86341000 84443000 86356000 84236000 1918592000 1855263000 1895640000 1852575000 9000 8000 8000 8000 1000 9000 8000 9000 8000 1764573000 1692834000 1745716000 1676508000 368000 2134000 1021000 4474000 20073000 18154000 38277000 32140000 1785014000 1713122000 1785014000 1713122000 154010000 162420000 149916000 176059000 10581000 -10654000 14675000 -24293000 164591000 151766000 164591000 151766000 1949614000 1864896000 1949614000 1864896000 14675000 -24293000 77387000 80226000 38277000 32140000 1461000 1639000 -1157000 0 0 -269000 -8138000 -7558000 -4254000 3161000 8526000 1546000 -6594000 -4117000 -14675000 -4973000 3970000 -25586000 -8175000 -3594000 384000 -454000 108645000 47226000 18794000 24215000 590000 2384000 0 68725000 -19384000 -95324000 54375000 4375000 -161000 -991000 1354000 4936000 -53182000 -430000 36079000 -48528000 254266000 225414000 290345000 176886000 23504000 19450000 15113000 573000 3228000 5040000 300000 356000 0 1849000 50000 8000 0 163000 Summary of business and significant accounting policies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements as of July 31, 2023 and for the three and six months ended July 31, 2023 and 2022 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2023. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> The Company consolidates entities in which the Company has a controlling financial interest, which includes all of its wholly owned direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements as of July 31, 2023 and for the three and six months ended July 31, 2023 and 2022 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2023. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by GAAP. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> Net income (loss) per share<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per share: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Numerator (basic and diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (basic):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average dilutive effect of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,341 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,356 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended July 31, 2023 and 2022, approximately 1.6 million and 3.3 million shares, respectively, attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted net income (loss) per share as their inclusion would have been anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended July 31, 2023 and 2022, approximately 0.9 million and 2.6 million shares, respectively, attributable to outstanding stock options and restricted stock units were excluded from the calculation of diluted net income (loss) per share as their inclusion would have been anti-dilutive.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per share: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Numerator (basic and diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,675 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (basic):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average dilutive effect of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,341 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,356 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.12 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 10581000 -10654000 14675000 -24293000 85533000 84443000 85286000 84236000 85533000 84443000 85286000 84236000 808000 0 1070000 0 86341000 84443000 86356000 84236000 0.12 -0.13 0.17 -0.29 0.12 -0.13 0.17 -0.29 1600000 3300000 900000 2600000 Supplemental financial statement information<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,287 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,682 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,145 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,862 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended July 31, 2023 and 2022 was $2.0 million and $3.2 million, respectively, and $4.5 million and $6.4 million for the six months ended July 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of July 31, 2023 and January 31, 2023, the balance of deferred revenue was $6.7 million and $8.3 million, respectively. The balances are related to cash received in advance for interchange and custodial revenue arrangements, other up-front fees and other commuter deferred revenue. The Company expects to recognize approximately 63% of its balance of deferred revenue as revenue over the next 12 months and the remainder thereafter. During the three and six months ended July 31, 2023, approximately $1.4 million and $2.9 million, respectively, of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2023. The Company expects to satisfy its remaining obligations for these arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(981)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,046)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,303 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,985 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,667 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,756 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,584 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the application of Accounting Standards Codification ("ASC") 470-50, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Modifications and Extinguishments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded a $1.2 million loss on extinguishment of debt due to the prepayment of $50.0 million under the Company's Term Loan Facility (as defined in Note 6—Indebtedness) in April 2023, which is included within interest expense in the condensed consolidated statement of operations and comprehensive income for the six months ended July 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental cash flow information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company's operating leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,109 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,392 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,021 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,287 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,682 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,145 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,862 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 18199000 18269000 8392000 8392000 27696000 28021000 54287000 54682000 45142000 41820000 9145000 12862000 2000000 3200000 4500000 6400000 6700000 8300000 0.63 P12M 1400000 2900000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(981)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,046)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,303 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,985 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,667 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company's operating leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,109 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,092 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2365000 2854000 4966000 5713000 619000 551000 981000 1046000 1746000 2303000 3985000 4667000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,756 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,584 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2484000 89000 4082000 141000 0 47000 0 53000 272000 -10000 502000 -357000 2756000 32000 4584000 -269000 -1200000 50000000 5451000 6232000 2109000 1092000 Intangible assets and goodwill<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount and associated accumulated amortization of intangible assets were as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software and software development costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(173,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired HSA portfolios</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,413,484 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(531,547)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881,937 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software and software development costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152,178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired HSA portfolios</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">606,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,399,889 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(463,530)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">936,359 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended July 31, 2023 and 2022 was $36.3 million and $37.6 million, respectively, and $72.8 million and $73.8 million for the six months ended July 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the carrying value of goodwill during the six months ended July 31, 2023.</span></div> <div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount and associated accumulated amortization of intangible assets were as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software and software development costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(173,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired HSA portfolios</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,779)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,413,484 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(531,547)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881,937 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software and software development costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152,178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired HSA portfolios</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">606,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable intangible assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,399,889 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(463,530)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">936,359 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 246789000 173865000 72924000 261188000 72253000 188935000 759782000 179280000 580502000 132825000 93370000 39455000 12900000 12779000 121000 1413484000 531547000 881937000 233194000 152178000 81016000 261188000 63547000 197641000 759782000 153434000 606348000 132825000 81692000 51133000 12900000 12679000 221000 1399889000 463530000 936359000 36300000 37600000 72800000 73800000 0 Commitments and contingencies<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s principal commitments consist of long-term debt, operating lease obligations for office space and data storage facilities, processing services agreements, software subscriptions, telephony services, and other contractual commitments. In April 2023, the Company used $50.0 million of cash to prepay, in direct order of maturity, principal due under its Term Loan Facility. There were no other material changes during the six months ended July 31, 2023, outside of the ordinary course of business, in the Company's commitments from those disclosed in its Annual Report on Form 10-K for the fiscal year ended January 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, WageWorks, Inc. ("WageWorks"), a wholly owned subsidiary of the Company, exercised its right to terminate a lease for office space in Mesa, Arizona that had not yet commenced, with aggregate lease payments of $63.1 million and a term of approximately 11 years, following the landlord's failure to fulfill its obligations under the lease agreement. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease. WageWorks' right to terminate the lease agreement was disputed by the landlord, Union Mesa 1, LLC (“Union Mesa”). On November 5, 2021, Union Mesa notified WageWorks that it was in default of the lease for failure to pay rent, which Union Mesa claimed was due beginning in November 2021, and on November 24, 2021 drew $2.8 million, the full amount under the letter of credit that WageWorks had posted to secure its obligations under the lease. On December 1, 2021, WageWorks filed a lawsuit against Union Mesa in the Superior Court of the State of Arizona in and for the County of Maricopa. On January 4, 2022, WageWorks filed an amended complaint in the Superior Court. Pursuant to the lawsuit, WageWorks seeks declaratory judgment that the lease was properly terminated and recourse against Union Mesa for breach of contract, breach of the duty of good faith and fair dealing, and conversion, including return of the funds drawn under the letter of credit. On January 31, 2022, Union Mesa filed a motion to dismiss for the conversion cause of action, which the Superior Court denied on April 13, 2022. On May 18, 2022, Union Mesa filed an answer and counterclaim with the Superior Court, wherein Union Mesa denied WageWorks' claims, and separately seeks recourse against WageWorks for breach of contract and breach of the implied covenant of good faith and fair dealing. On May 19, 2022, Union Mesa filed an amended complaint and counterclaim seeking the same recourse. On June 29, 2022, Union Mesa filed a second amended answer and counterclaim, which names the Company as a counter-defendant. On July 21, 2022, WageWorks and the Company filed an answer to the counterclaims. On April 26, 2023, Union Mesa filed a motion for partial summary judgment, and the Company expects to file its response in due course. Through its claims, Union Mesa is seeking direct and consequential damages in an amount to be </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proven at trial and an award of its reasonable attorney fees, plus interest until any damages or fees that are awarded are paid. The parties are currently engaged in discovery.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.</span></div> 50000000 63100000 P11Y 2800000 Indebtedness<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">886,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">941,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: unamortized discount and issuance costs (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873,581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,500</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873,581 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">907,838 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">In addition to the $13.3 million and $15.9 million of unamortized discount and issuance costs related to long-term debt as of July 31, 2023 and January 31, 2023, respectively, $3.0 million and $3.4 million of unamortized issuance costs related to the Company's Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of July 31, 2023 and January 31, 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.50% Senior Notes due 2029</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Company completed its offering of $600 million aggregate principal amount of its 4.50% Senior Notes due 2029 (the “Notes”). The Notes were issued under an indenture (the “Indenture”), dated October 8, 2021, among the Company, the guarantors party thereto, and Wells Fargo Bank, National Association, as trustee. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are guaranteed by each of the Company’s existing, wholly owned domestic subsidiaries that guarantees its obligations under the Credit Agreement (as defined below) and are required to be guaranteed by any of the Company’s future subsidiaries that guarantee its obligations under the Credit Agreement or certain of its other indebtedness. The Notes will mature on October 1, 2029. Interest on the Notes is payable on April 1 and October 1 of each year. Accrued interest on the Notes was $9.0 million at each of July 31, 2023 and January 31, 2023, and is included within accrued liabilities on the Company's condensed consolidated balance sheets. The effective interest rate on the Notes is 4.72%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are unsecured senior obligations of the Company and rank equally in right of payment to all of its existing and future senior unsecured debt and senior in right of payment to all of its future subordinated debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are redeemable at the Company’s option, in whole or in part, at any time on or after October 1, 2024, at a redemption price if redeemed during the 12 months beginning (i) October 1, 2024 of 102.250%, (ii) October 1, 2025 of 101.125%, and (iii) October 1, 2026 and thereafter of 100.000%, in each case of the principal amount of the Notes being redeemed, and together with accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may also redeem some or all of the Notes before October 1, 2024 at a redemption price equal to 100% of the principal amount of the Notes, plus the applicable “make-whole” premium as of, and accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, at any time prior to October 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the Notes issued under the Indenture on one or more occasions in an aggregate amount equal to the net cash proceeds of one or more equity offerings at a redemption price equal to 104.500% of the principal amount of the Notes redeemed, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. Furthermore, the Company may be required to make an offer to purchase the Notes upon the sale of certain assets or upon specific kinds of changes of control.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture contains covenants that impose significant operational and financial restrictions on the Company; however, these covenants generally align with the covenants contained in the Credit Agreement. See "Credit Agreement" below for a description of these covenants. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Company entered into a credit agreement (the “Credit Agreement”) among the Company, as borrower, each lender from time to time party thereto (the “Lenders”), JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Agent”) and the Swing Line Lender (as defined in the Credit Agreement), and each L/C Issuer (as defined therein) party thereto, pursuant to which the Company established: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.12pt">a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $350 million; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.9pt">a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $1.0 billion (with a $25 million sub-limit for the issuance of letters of credit), the proceeds of which may be used for working capital and general corporate purposes of the Company and its subsidiaries, including the financing of acquisitions and other investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions set forth in the Credit Agreement (including obtaining additional commitments from one or more new or existing lenders), the Company may in the future incur additional loans or commitments under the Credit Agreement in an aggregate principal amount of up to $300 million, plus an additional amount so long as the Company’s pro forma First Lien Net Leverage Ratio (as defined in the Credit Agreement) would not exceed 3.85 to 1.00 as of the date such loans or commitments are incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to June 1, 2023, borrowings under the Credit Facilities bore interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2023, the Company entered into an amendment to the Credit Agreement (“Amendment No. 1”) which replaced interest rate provisions based on LIBOR with the forward-looking term rate based on the secured overnight financing rate published by the CME Group Benchmark Administration Limited (“Term SOFR”). As a result, borrowings under the Credit Agreement as so amended by Amendment No. 1 bear interest, as of July 31, 2023, at an annual rate equal to, at the option of the Company, either (i) Term SOFR, plus a 0.10% credit spread adjustment, plus a margin ranging from 1.25% to 2.25%, or (ii) an alternate base rate, plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined in either scenario by reference to a leverage-based pricing grid set forth in the Credit Agreement (as amended by Amendment No. 1). As of July 31, 2023, the stated interest rate was 6.92% and the effective interest rate was 7.68%. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to pay certain fees to the Lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of July 31, 2023, no amounts have been drawn under the Revolving Credit Facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans made under the Term Loan Facility amortize in equal quarterly installments in an aggregate annual amount equal to the following percentage of the original principal amount of the Term Loan Facility: (i) 2.5% for the first year after October 8, 2021; (ii) 5.0% for each of the second and third years after October 8, 2021; (iii) 7.5% for the fourth year after October 8, 2021; and (iv) 10.0% for the fifth year after October 8, 2021. In addition, the Term Loan Facility is required to be mandatorily prepaid with 100% of the net cash proceeds of all asset sales, insurance and condemnation recoveries, subject to customary exceptions and thresholds, including to the extent such proceeds are reinvested in assets useful in the business of the Company and its subsidiaries within 450 days following receipt (or committed to be reinvested within such 450-day period and reinvested within 180 days after the end of such 450-day period). The loans under the Credit Facilities may be prepaid, and the commitments thereunder may be reduced, by the Company without penalty or premium, subject to the reimbursement of customary “breakage costs.” In April 2023, the Company used $50.0 million of cash to prepay, in direct order of maturity, principal due under its Term Loan Facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains significant customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.00 to 1.00 and (ii) a minimum consolidated interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of July 31, 2023, and for the period then ended.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment obligation under the Credit Agreement may be accelerated upon the occurrence of an event of default thereunder, including, among other things, failure to pay principal, interest or fees on a timely basis, material inaccuracy of any representation or warranty, failure to comply with covenants, cross-default to other material debt, material judgments, change of control and certain insolvency or bankruptcy-related events, in each case, subject to any certain grace and/or cure periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of the Company under the Credit Agreement are required to be unconditionally guaranteed by each of the Company’s existing or subsequently acquired or organized domestic subsidiaries and are secured by security interests in substantially all assets of the Company and the guarantors, in each case, subject to certain customary exceptions.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2029</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">886,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">941,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: unamortized discount and issuance costs (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873,581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925,338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,500</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873,581 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">907,838 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">In addition to the $13.3 million and $15.9 million of unamortized discount and issuance costs related to long-term debt as of July 31, 2023 and January 31, 2023, respectively, $3.0 million and $3.4 million of unamortized issuance costs related to the Company's Revolving Credit Facility (as defined below) are included within other assets on the condensed consolidated balance sheets as of July 31, 2023 and January 31, 2023, respectively.</span></div> 0.0450 600000000 600000000 286875000 341250000 886875000 941250000 13294000 15912000 873581000 925338000 0 17500000 873581000 907838000 13300000 15900000 3000000 3400000 0.0450 600000000 0.0450 9000000 9000000 0.0472 1.02250 1.01125 1.00000 1 0.40 1.04500 P5Y 350000000 P5Y 1000000000 25000000 300000000 3.85 0.0125 0.0225 0.0025 0.0125 0.0010 0.0125 0.0225 0.0025 0.0125 0.0692 0.0768 0.0020 0.0040 0.025 0.050 0.075 0.100 1 P450D P450D P180D P450D 50000000 5.00 3.00 Income taxes<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company follows ASC 740-270, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes - Interim Reporting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to pre-tax income through the end of the latest fiscal quarter to determine the interim income tax provision. For the three and six months ended July 31, 2023, the Company recorded an income tax provision of $3.6 million and $9.6 million, respectively. This resulted in an effective income tax provision rate of 25.6% and 39.4% for the three and six months ended July 31, 2023, respectively, compared with an effective income tax benefit rate of 23.2% and 23.9% for the three and six months ended July 31, 2022, respectively. For the three and six months ended July 31, 2023 and 2022, discrete tax items impacting the effective tax rate were primarily due to differences in tax deductible stock-based compensation compared to GAAP stock-based compensation expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 31, 2023 and January 31, 2023, the Company’s total gross unrecognized tax benefit was $8.9 million and $8.7 million, respectively. If recognized, $5.6 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of July 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to the Company's taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2003.</span></div> 3600000 9600000 0.256 0.394 0.232 0.239 8900000 8700000 5600000 Stock-based compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technology and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,073 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,154 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,277 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,140 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock award plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Plan. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock options and restricted stock units ("RSUs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of July 31, 2023, 11.5 million shares were available for grant under the Incentive Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding stock options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for exercise prices and term)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$14.00 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.06 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$14.00 - 44.53</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$24.36 - 44.53</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of July 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$14.00 - 82.39</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest as of July 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable as of July 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.27 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,047 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs and PRSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except weighted-average grant date fair value)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of July 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,727 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.13 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance restricted stock units.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended April 30, 2023, the Company awarded 270,966 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2026. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $23.9 million. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technology and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,073 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,154 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,277 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,140 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4714000 3998000 8549000 7005000 3478000 2553000 6257000 4567000 4283000 2963000 9175000 6343000 7598000 8640000 14296000 14225000 20073000 18154000 38277000 32140000 2600000 0.03 11500000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding stock options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for exercise prices and term)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,021 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$14.00 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.06 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,293 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$14.00 - 44.53</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$24.36 - 44.53</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of July 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$14.00 - 82.39</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest as of July 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,047 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable as of July 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.27 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,047 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1021000 14.00 82.39 36.06 P3Y2M12D 27293000 34000 14.00 44.53 29.71 4000 24.36 44.53 38.41 983000 14.00 82.39 36.27 P2Y7M6D 32047000 983000 36.27 P2Y7M6D 32047000 983000 36.27 P2Y7M6D 32047000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs and PRSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except weighted-average grant date fair value)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of July 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,727 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.13 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3011000 70.40 1767000 64.46 801000 67.53 250000 71.53 3727000 68.13 270966 23900000 0 2 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are considered Level 1 instruments and are valued based on publicly available daily net asset values. The carrying values of cash and cash equivalents approximate fair values due to the short-term nature of these instruments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are valued based upon quoted market prices and are considered Level 2 instruments because the markets in which the Notes trade are not considered active markets. As of July 31, 2023, the fair value of the Notes was $536.7 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan Facility is considered a Level 2 instrument and recorded at book value in the Company's condensed consolidated financial statements. The Term Loan Facility reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, the fair value of the Term Loan Facility approximates carrying value.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div> 536700000 false false false false EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 140 235 1 false 48 0 false 4 false false R1.htm 0000001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed consolidated balance sheets Sheet http://healthequity.com/role/Condensedconsolidatedbalancesheets Condensed consolidated balance sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed consolidated balance sheets (Parenthetical) Sheet http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical Condensed consolidated balance sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited Condensed consolidated statements of stockholders' equity (unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed consolidated statements of cash flows (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited Condensed consolidated statements of cash flows (unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - Summary of business and significant accounting policies Sheet http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies Summary of business and significant accounting policies Notes 7 false false R8.htm 0000008 - Disclosure - Net income (loss) per share Sheet http://healthequity.com/role/Netincomelosspershare Net income (loss) per share Notes 8 false false R9.htm 0000009 - Disclosure - Supplemental financial statement information Sheet http://healthequity.com/role/Supplementalfinancialstatementinformation Supplemental financial statement information Notes 9 false false R10.htm 0000010 - Disclosure - Intangible assets and goodwill Sheet http://healthequity.com/role/Intangibleassetsandgoodwill Intangible assets and goodwill Notes 10 false false R11.htm 0000011 - Disclosure - Commitments and contingencies Sheet http://healthequity.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 11 false false R12.htm 0000012 - Disclosure - Indebtedness Sheet http://healthequity.com/role/Indebtedness Indebtedness Notes 12 false false R13.htm 0000013 - Disclosure - Income taxes Sheet http://healthequity.com/role/Incometaxes Income taxes Notes 13 false false R14.htm 0000014 - Disclosure - Stock-based compensation Sheet http://healthequity.com/role/Stockbasedcompensation Stock-based compensation Notes 14 false false R15.htm 0000015 - Disclosure - Fair value Sheet http://healthequity.com/role/Fairvalue Fair value Notes 15 false false R16.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 16 false false R17.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 17 false false R18.htm 9954701 - Disclosure - Summary of business and significant accounting policies (Policies) Sheet http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies Summary of business and significant accounting policies (Policies) Policies 18 false false R19.htm 9954702 - Disclosure - Net income (loss) per share (Tables) Sheet http://healthequity.com/role/NetincomelosspershareTables Net income (loss) per share (Tables) Tables http://healthequity.com/role/Netincomelosspershare 19 false false R20.htm 9954703 - Disclosure - Supplemental financial statement information (Tables) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationTables Supplemental financial statement information (Tables) Tables http://healthequity.com/role/Supplementalfinancialstatementinformation 20 false false R21.htm 9954704 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillTables Intangible assets and goodwill (Tables) Tables http://healthequity.com/role/Intangibleassetsandgoodwill 21 false false R22.htm 9954705 - Disclosure - Indebtedness (Tables) Sheet http://healthequity.com/role/IndebtednessTables Indebtedness (Tables) Tables http://healthequity.com/role/Indebtedness 22 false false R23.htm 9954706 - Disclosure - Stock-based compensation (Tables) Sheet http://healthequity.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://healthequity.com/role/Stockbasedcompensation 23 false false R24.htm 9954707 - Disclosure - Net income (loss) per share (Details) Sheet http://healthequity.com/role/NetincomelosspershareDetails Net income (loss) per share (Details) Details http://healthequity.com/role/NetincomelosspershareTables 24 false false R25.htm 9954708 - Disclosure - Supplemental financial statement information (Property and Equipment) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails Supplemental financial statement information (Property and Equipment) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 25 false false R26.htm 9954709 - Disclosure - Supplemental financial statement information (Narrative) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails Supplemental financial statement information (Narrative) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 26 false false R27.htm 9954710 - Disclosure - Supplemental financial statement information (Lease Cost) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails Supplemental financial statement information (Lease Cost) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 27 false false R28.htm 9954711 - Disclosure - Supplemental financial statement information (Other Income (Expense), Net) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails Supplemental financial statement information (Other Income (Expense), Net) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 28 false false R29.htm 9954712 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails Supplemental financial statement information (Supplemental Cash Flow Information) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 29 false false R30.htm 9954713 - Disclosure - Intangible assets and goodwill (Schedule of Intangible Assets) (Details) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails Intangible assets and goodwill (Schedule of Intangible Assets) (Details) Details http://healthequity.com/role/IntangibleassetsandgoodwillTables 30 false false R31.htm 9954714 - Disclosure - Intangible assets and goodwill (Narrative) (Details) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails Intangible assets and goodwill (Narrative) (Details) Details http://healthequity.com/role/IntangibleassetsandgoodwillTables 31 false false R32.htm 9954715 - Disclosure - Commitments and contingencies (Details) Sheet http://healthequity.com/role/CommitmentsandcontingenciesDetails Commitments and contingencies (Details) Details http://healthequity.com/role/Commitmentsandcontingencies 32 false false R33.htm 9954716 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details) Sheet http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails Indebtedness (Schedule of Long-term Debt) (Details) Details http://healthequity.com/role/IndebtednessTables 33 false false R34.htm 9954717 - Disclosure - Indebtedness (Narrative) (Details) Sheet http://healthequity.com/role/IndebtednessNarrativeDetails Indebtedness (Narrative) (Details) Details http://healthequity.com/role/IndebtednessTables 34 false false R35.htm 9954718 - Disclosure - Income taxes (Details) Sheet http://healthequity.com/role/IncometaxesDetails Income taxes (Details) Details http://healthequity.com/role/Incometaxes 35 false false R36.htm 9954719 - Disclosure - Stock-based compensation (Summary of Share Based Compensation Recognized) (Details) Sheet http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails Stock-based compensation (Summary of Share Based Compensation Recognized) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 36 false false R37.htm 9954720 - Disclosure - Stock-based Compensation (Narrative) (Details) Sheet http://healthequity.com/role/StockbasedCompensationNarrativeDetails Stock-based Compensation (Narrative) (Details) Details 37 false false R38.htm 9954721 - Disclosure - Stock-based compensation (Stock Option Activity) (Details) Sheet http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails Stock-based compensation (Stock Option Activity) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 38 false false R39.htm 9954722 - Disclosure - Stock-based compensation (Restricted Stock Unit Activity) (Details) Sheet http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails Stock-based compensation (Restricted Stock Unit Activity) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 39 false false R40.htm 9954723 - Disclosure - Fair value (Details) Sheet http://healthequity.com/role/FairvalueDetails Fair value (Details) Details http://healthequity.com/role/Fairvalue 40 false false All Reports Book All Reports hqy-20230731.htm exhibit311-ceo302xfy24q2.htm exhibit312-cfo302xfy24q2.htm exhibit321-ceo906xfy24q2.htm exhibit322-cfo906xfy24q2.htm hqy-20230731.xsd hqy-20230731_cal.xml hqy-20230731_def.xml hqy-20230731_lab.xml hqy-20230731_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-20230731.htm": { "axisCustom": 1, "axisStandard": 17, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 546, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 140, "dts": { "calculationLink": { "local": [ "hqy-20230731_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20230731_def.xml" ] }, "inline": { "local": [ "hqy-20230731.htm" ] }, "labelLink": { "local": [ "hqy-20230731_lab.xml" ] }, "presentationLink": { "local": [ "hqy-20230731_pre.xml" ] }, "schema": { "local": [ "hqy-20230731.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] } }, "elementCount": 461, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 1, "http://xbrl.sec.gov/dei/2023": 5, "total": 6 }, "keyCustom": 24, "keyStandard": 211, "memberCustom": 16, "memberStandard": 32, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20230731", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Intangible assets and goodwill", "menuCat": "Notes", "order": "10", "role": "http://healthequity.com/role/Intangibleassetsandgoodwill", "shortName": "Intangible assets and goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Commitments and contingencies", "menuCat": "Notes", "order": "11", "role": "http://healthequity.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Indebtedness", "menuCat": "Notes", "order": "12", "role": "http://healthequity.com/role/Indebtedness", "shortName": "Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Income taxes", "menuCat": "Notes", "order": "13", "role": "http://healthequity.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Stock-based compensation", "menuCat": "Notes", "order": "14", "role": "http://healthequity.com/role/Stockbasedcompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Fair value", "menuCat": "Notes", "order": "15", "role": "http://healthequity.com/role/Fairvalue", "shortName": "Fair value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "menuCat": "Notes", "order": "16", "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "shortName": "Pay vs Performance Disclosure", "subGroupType": "", "uniqueAnchor": null }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995445 - Disclosure - Insider Trading Arrangements", "menuCat": "Notes", "order": "17", "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "shortName": "Insider Trading Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - Summary of business and significant accounting policies (Policies)", "menuCat": "Policies", "order": "18", "role": "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies", "shortName": "Summary of business and significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - Net income (loss) per share (Tables)", "menuCat": "Tables", "order": "19", "role": "http://healthequity.com/role/NetincomelosspershareTables", "shortName": "Net income (loss) per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed consolidated balance sheets", "menuCat": "Statements", "order": "2", "role": "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "shortName": "Condensed consolidated balance sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Supplemental financial statement information (Tables)", "menuCat": "Tables", "order": "20", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationTables", "shortName": "Supplemental financial statement information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Intangible assets and goodwill (Tables)", "menuCat": "Tables", "order": "21", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillTables", "shortName": "Intangible assets and goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Indebtedness (Tables)", "menuCat": "Tables", "order": "22", "role": "http://healthequity.com/role/IndebtednessTables", "shortName": "Indebtedness (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - Stock-based compensation (Tables)", "menuCat": "Tables", "order": "23", "role": "http://healthequity.com/role/StockbasedcompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - Net income (loss) per share (Details)", "menuCat": "Details", "order": "24", "role": "http://healthequity.com/role/NetincomelosspershareDetails", "shortName": "Net income (loss) per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - Supplemental financial statement information (Property and Equipment) (Details)", "menuCat": "Details", "order": "25", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails", "shortName": "Supplemental financial statement information (Property and Equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Supplemental financial statement information (Narrative) (Details)", "menuCat": "Details", "order": "26", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails", "shortName": "Supplemental financial statement information (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Supplemental financial statement information (Lease Cost) (Details)", "menuCat": "Details", "order": "27", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails", "shortName": "Supplemental financial statement information (Lease Cost) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Supplemental financial statement information (Other Income (Expense), Net) (Details)", "menuCat": "Details", "order": "28", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails", "shortName": "Supplemental financial statement information (Other Income (Expense), Net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details)", "menuCat": "Details", "order": "29", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails", "shortName": "Supplemental financial statement information (Supplemental Cash Flow Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed consolidated balance sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical", "shortName": "Condensed consolidated balance sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Intangible assets and goodwill (Schedule of Intangible Assets) (Details)", "menuCat": "Details", "order": "30", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails", "shortName": "Intangible assets and goodwill (Schedule of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Intangible assets and goodwill (Narrative) (Details)", "menuCat": "Details", "order": "31", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "shortName": "Intangible assets and goodwill (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-75", "decimals": "-5", "first": true, "lang": "en-US", "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Commitments and contingencies (Details)", "menuCat": "Details", "order": "32", "role": "http://healthequity.com/role/CommitmentsandcontingenciesDetails", "shortName": "Commitments and contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-75", "decimals": "-5", "first": true, "lang": "en-US", "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details)", "menuCat": "Details", "order": "33", "role": "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails", "shortName": "Indebtedness (Schedule of Long-term Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-74", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Indebtedness (Narrative) (Details)", "menuCat": "Details", "order": "34", "role": "http://healthequity.com/role/IndebtednessNarrativeDetails", "shortName": "Indebtedness (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-107", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Income taxes (Details)", "menuCat": "Details", "order": "35", "role": "http://healthequity.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Stock-based compensation (Summary of Share Based Compensation Recognized) (Details)", "menuCat": "Details", "order": "36", "role": "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails", "shortName": "Stock-based compensation (Summary of Share Based Compensation Recognized) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-136", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Stock-based Compensation (Narrative) (Details)", "menuCat": "Details", "order": "37", "role": "http://healthequity.com/role/StockbasedCompensationNarrativeDetails", "shortName": "Stock-based Compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-136", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-4", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Stock-based compensation (Stock Option Activity) (Details)", "menuCat": "Details", "order": "38", "role": "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails", "shortName": "Stock-based compensation (Stock Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-133", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - Stock-based compensation (Restricted Stock Unit Activity) (Details)", "menuCat": "Details", "order": "39", "role": "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails", "shortName": "Stock-based compensation (Restricted Stock Unit Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-133", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)", "menuCat": "Statements", "order": "4", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "shortName": "Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-17", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-140", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954723 - Disclosure - Fair value (Details)", "menuCat": "Details", "order": "40", "role": "http://healthequity.com/role/FairvalueDetails", "shortName": "Fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-140", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-22", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited)", "menuCat": "Statements", "order": "5", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited", "shortName": "Condensed consolidated statements of stockholders' equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-22", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed consolidated statements of cash flows (unaudited)", "menuCat": "Statements", "order": "6", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "shortName": "Condensed consolidated statements of cash flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Summary of business and significant accounting policies", "menuCat": "Notes", "order": "7", "role": "http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies", "shortName": "Summary of business and significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Net income (loss) per share", "menuCat": "Notes", "order": "8", "role": "http://healthequity.com/role/Netincomelosspershare", "shortName": "Net income (loss) per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Supplemental financial statement information", "menuCat": "Notes", "order": "9", "role": "http://healthequity.com/role/Supplementalfinancialstatementinformation", "shortName": "Supplemental financial statement information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20230731.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ecd_Additional402vDisclosureTextBlock": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "localname": "Additional402vDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToCompAmt": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "localname": "AdjToCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AdjToCompAxis": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "localname": "AdjToCompAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "localname": "AdjToNonPeoNeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToPeoCompFnTextBlock": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "localname": "AdjToPeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AggtErrCompAmt": { "auth_ref": [ "r520", "r531", "r541", "r566" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "localname": "AggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "auth_ref": [ "r523", "r534", "r544", "r569" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "localname": "AggtErrCompNotYetDeterminedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AllAdjToCompMember": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "localname": "AllAdjToCompMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllExecutiveCategoriesMember": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "localname": "AllExecutiveCategoriesMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllIndividualsMember": { "auth_ref": [ "r527", "r535", "r545", "r562", "r570", "r574", "r582" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "localname": "AllIndividualsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllTradingArrangementsMember": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "localname": "AllTradingArrangementsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "ecd_AwardExrcPrice": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "localname": "AwardExrcPrice", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "perShareItemType" }, "ecd_AwardGrantDateFairValue": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "localname": "AwardGrantDateFairValue", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AwardTmgDiscLineItems": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "localname": "AwardTmgDiscLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMethodTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "localname": "AwardTmgMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "localname": "AwardTmgMnpiCnsdrdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardTmgMnpiDiscTextBlock": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "localname": "AwardTmgMnpiDiscTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgPredtrmndFlag": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "localname": "AwardTmgPredtrmndFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardUndrlygSecuritiesAmt": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "localname": "AwardUndrlygSecuritiesAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_AwardsCloseToMnpiDiscIndName": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "localname": "AwardsCloseToMnpiDiscIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTable": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "localname": "AwardsCloseToMnpiDiscTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "localname": "AwardsCloseToMnpiDiscTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ChangedPeerGroupFnTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "localname": "ChangedPeerGroupFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CoSelectedMeasureAmt": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "localname": "CoSelectedMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_CoSelectedMeasureName": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "localname": "CoSelectedMeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "localname": "CompActuallyPaidVsNetIncomeTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompAnalysisTextBlock": { "auth_ref": [ "r520", "r531", "r541", "r566" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "localname": "ErrCompAnalysisTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompRecoveryTable": { "auth_ref": [ "r517", "r528", "r538", "r563" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "localname": "ErrCompRecoveryTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ExecutiveCategoryAxis": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "localname": "ExecutiveCategoryAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "auth_ref": [ "r524", "r535", "r545", "r570" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "auth_ref": [ "r524", "r535", "r545", "r570" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "auth_ref": [ "r524", "r535", "r545", "r570" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "auth_ref": [ "r524", "r535", "r545", "r570" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ForgoneRecoveryIndName": { "auth_ref": [ "r524", "r535", "r545", "r570" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "ForgoneRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_IndividualAxis": { "auth_ref": [ "r527", "r535", "r545", "r562", "r570", "r574", "r582" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "localname": "IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_InsiderTradingArrLineItems": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "localname": "InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTradingPoliciesProcLineItems": { "auth_ref": [ "r516", "r586" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "localname": "InsiderTradingPoliciesProcLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "auth_ref": [ "r516", "r586" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "booleanItemType" }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "auth_ref": [ "r516", "r586" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "textBlockItemType" }, "ecd_MeasureAxis": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "localname": "MeasureAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_MeasureName": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "localname": "MeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_MnpiDiscTimedForCompValFlag": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "localname": "MnpiDiscTimedForCompValFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "localname": "MtrlTermsOfTrdArrTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "textBlockItemType" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "localname": "NamedExecutiveOfficersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "localname": "NonGaapMeasureDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonNeosMember": { "auth_ref": [ "r524", "r535", "r545", "r562", "r570" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "localname": "NonNeosMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "localname": "NonPeoNeoAvgTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoMember": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "localname": "NonPeoNeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonRule10b51ArrAdoptedFlag": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "localname": "NonRule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_NonRule10b51ArrTrmntdFlag": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "localname": "NonRule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_OtherPerfMeasureAmt": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "localname": "OtherPerfMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_OutstandingAggtErrCompAmt": { "auth_ref": [ "r522", "r533", "r543", "r568" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "localname": "OutstandingAggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryCompAmt": { "auth_ref": [ "r525", "r536", "r546", "r571" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "localname": "OutstandingRecoveryCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryIndName": { "auth_ref": [ "r525", "r536", "r546", "r571" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "OutstandingRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PayVsPerformanceDisclosureLineItems": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "localname": "PayVsPerformanceDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_PeerGroupIssuersFnTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "localname": "PeerGroupIssuersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_PeerGroupTotalShareholderRtnAmt": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "localname": "PeerGroupTotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoActuallyPaidCompAmt": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "localname": "PeoActuallyPaidCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoMember": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "localname": "PeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_PeoName": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "localname": "PeoName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_PeoTotalCompAmt": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "localname": "PeoTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PvpTable": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PvpTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PvpTableTextBlock": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "localname": "PvpTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "auth_ref": [ "r517", "r528", "r538", "r563" ], "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "localname": "RecoveryOfErrCompDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_RestatementDateAxis": { "auth_ref": [ "r518", "r529", "r539", "r564" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "localname": "RestatementDateAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_RestatementDeterminationDate": { "auth_ref": [ "r519", "r530", "r540", "r565" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "localname": "RestatementDeterminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "dateItemType" }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "auth_ref": [ "r526", "r537", "r547", "r572" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "localname": "RestatementDoesNotRequireRecoveryTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_Rule10b51ArrAdoptedFlag": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "localname": "Rule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_Rule10b51ArrTrmntdFlag": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "localname": "Rule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "auth_ref": [ "r521", "r532", "r542", "r567" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "localname": "StkPrcOrTsrEstimationMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TabularListTableTextBlock": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "localname": "TabularListTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TotalShareholderRtnAmt": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "localname": "TotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TradingArrAxis": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "localname": "TradingArrAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TradingArrByIndTable": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "localname": "TradingArrByIndTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrAdoptionDate": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "localname": "TrdArrAdoptionDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrDuration": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "localname": "TrdArrDuration", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "durationItemType" }, "ecd_TrdArrIndName": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "localname": "TrdArrIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrIndTitle": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "localname": "TrdArrIndTitle", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrSecuritiesAggAvailAmt": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "localname": "TrdArrSecuritiesAggAvailAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "sharesItemType" }, "ecd_TrdArrTerminationDate": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "localname": "TrdArrTerminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_UndrlygSecurityMktPriceChngPct": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "localname": "UndrlygSecurityMktPriceChngPct", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "pureItemType" }, "hqy_A4500SeniorNotesDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.500% Senior Notes due 2029", "label": "4.500% Senior Notes due 2029 [Member]", "terseLabel": "4.50% Senior Notes due 2029" } } }, "localname": "A4500SeniorNotesDue2029Member", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/FairvalueDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "hqy_AcquiredHSAIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired HSA Intangible Assets [Member]", "label": "Acquired HSA Intangible Assets [Member]", "terseLabel": "Acquired HSA portfolios" } } }, "localname": "AcquiredHSAIntangibleAssetsMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "hqy_AmortizationOfAcquiredIntangible": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Acquired Intangible", "label": "Amortization Of Acquired Intangible", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfAcquiredIntangible", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period", "label": "Debt Instrument, Amortization Period [Axis]", "terseLabel": "Debt Instrument, Amortization Period [Axis]" } } }, "localname": "DebtInstrumentAmortizationPeriodAxis", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "hqy_DebtInstrumentAmortizationPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period", "label": "Debt Instrument, Amortization Period [Domain]", "terseLabel": "Debt Instrument, Amortization Period [Domain]" } } }, "localname": "DebtInstrumentAmortizationPeriodDomain", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period Five [Member]", "label": "Debt Instrument, Amortization Period Five [Member]", "verboseLabel": "Fifth year after the Effective Date" } } }, "localname": "DebtInstrumentAmortizationPeriodFiveMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period Four [Member]", "label": "Debt Instrument, Amortization Period Four [Member]", "terseLabel": "Fourth year after the Effective Date" } } }, "localname": "DebtInstrumentAmortizationPeriodFourMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period One", "label": "Debt Instrument, Amortization Period One [Member]", "verboseLabel": "First year after the Effective Date" } } }, "localname": "DebtInstrumentAmortizationPeriodOneMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentAmortizationPeriodTwoAndThreePeriodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Period Two and Three Period", "label": "Debt Instrument, Amortization Period Two and Three Period [Member]", "terseLabel": "Second and third years after the Effective Date" } } }, "localname": "DebtInstrumentAmortizationPeriodTwoAndThreePeriodMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentCovenantMinimumInterestCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio", "label": "Debt Instrument, Covenant, Minimum Interest Coverage Ratio", "terseLabel": "Minimum interest coverage ratio" } } }, "localname": "DebtInstrumentCovenantMinimumInterestCoverageRatio", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentCovenantNetLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Net Leverage Ratio", "label": "Debt Instrument, Covenant, Net Leverage Ratio", "terseLabel": "Maximum leverage ratio" } } }, "localname": "DebtInstrumentCovenantNetLeverageRatio", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentCreditSpreadAdjustmentOnVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Credit Spread Adjustment On Variable Rate", "label": "Debt Instrument, Credit Spread Adjustment On Variable Rate", "terseLabel": "Credit spread adjustment on variable rate (as a percent)" } } }, "localname": "DebtInstrumentCreditSpreadAdjustmentOnVariableRate", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_DebtInstrumentPeriodicRepaymentsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Repayments, Percentage Of Principal Amount", "label": "Debt Instrument, Periodic Repayments, Percentage Of Principal Amount", "terseLabel": "Debt instrument, amortization of loans, percentage of principal amount (as a percent)" } } }, "localname": "DebtInstrumentPeriodicRepaymentsPercentageOfPrincipalAmount", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_DebtInstrumentPrepaymentCovenantPercentageOfProceedsFromSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales", "label": "Debt Instrument, Prepayment Covenant, Percentage Of Proceeds From Sales", "terseLabel": "Debt instrument, prepayment covenant, percentage of proceeds from sales to used to prepay (as a percent)" } } }, "localname": "DebtInstrumentPrepaymentCovenantPercentageOfProceedsFromSales", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_DebtInstrumentPrepaymentCovenantPeriodToCommitToReinvestAfterInitialPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period", "label": "Debt Instrument, Prepayment Covenant, Period To Commit To Reinvest After Initial Period", "terseLabel": "Debt instrument, number of days to commit to reinvesting proceeds from sales of assets after initial period (in days)" } } }, "localname": "DebtInstrumentPrepaymentCovenantPeriodToCommitToReinvestAfterInitialPeriod", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_DebtInstrumentPrepaymentCovenantPeriodToReinvestProceedsFromSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales", "label": "Debt Instrument, Prepayment Covenant, Period To Reinvest Proceeds From Sales", "terseLabel": "Debt instrument, number of days to reinvest proceeds from sales of assets (in days)" } } }, "localname": "DebtInstrumentPrepaymentCovenantPeriodToReinvestProceedsFromSales", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_ExerciseOfStockOptionsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exercise Of Stock Options Receivable", "label": "Exercise Of Stock Options Receivable", "terseLabel": "Exercise of common stock options receivable" } } }, "localname": "ExerciseOfStockOptionsReceivable", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_IncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Plan [Member]", "label": "Incentive Plan [Member]", "terseLabel": "Incentive Plan" } } }, "localname": "IncentivePlanMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "label": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "negatedTerseLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "terseLabel": "Operating lease not yet commenced undiscounted amount" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LineOfCreditFacilityMaximumBorrowingCapacityOfFutureCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments", "label": "Line Of Credit Facility, Maximum Borrowing Capacity Of Future Commitments", "terseLabel": "Maximum borrowing capacity of future commitments" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityOfFutureCommitments", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LondonInterbankOfferedRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "London Interbank Offered Rate", "label": "London Interbank Offered Rate [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_NoncashChangesInGoodwillMeasurementPeriodAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash Changes In Goodwill, Measurement Period Adjustments", "label": "Noncash Changes In Goodwill, Measurement Period Adjustments", "terseLabel": "Increase in goodwill due to measurement period adjustments, net" } } }, "localname": "NoncashChangesInGoodwillMeasurementPeriodAdjustments", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_OtherNonoperatingIncomeExpenseMiscellaneous": { "auth_ref": [], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Nonoperating Income (Expense), Miscellaneous", "label": "Other Nonoperating Income (Expense), Miscellaneous", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpenseMiscellaneous", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "hqy_PerformanceRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Restricted Stock Units [Member]", "label": "Performance Restricted Stock Units [Member]", "terseLabel": "Performance restricted stock units" } } }, "localname": "PerformanceRestrictedStockUnitsMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "hqy_ProceedsFromSettlementOfClientHeldFunds": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Settlement Of Client Held Funds", "label": "Proceeds From Settlement Of Client Held Funds", "terseLabel": "Settlement of client-held funds obligation, net" } } }, "localname": "ProceedsFromSettlementOfClientHeldFunds", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_SalesandMarketingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales and Marketing [Member]", "label": "Sales and Marketing [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SalesandMarketingMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_SecuredOvernightFinancingRateSOFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR)" } } }, "localname": "SecuredOvernightFinancingRateSOFRMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAvailableForGrantsPercentageOfCapitalStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Additional Shares Available For Grants, Percentage Of Capital Stock Outstanding, Percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Additional Shares Available For Grants, Percentage Of Capital Stock Outstanding, Percentage", "terseLabel": "Percentage of capital stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAvailableForGrantsPercentageOfCapitalStockOutstandingPercentage", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "terseLabel": "Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "terseLabel": "Exercised, minimum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "terseLabel": "Forfeited, minimum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "periodEndLabel": "Ending balance, minimum (in usd per share)", "periodStartLabel": "Beginning balance, minimum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "terseLabel": "Exercised, maximum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "terseLabel": "Forfeited, maximum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "periodEndLabel": "Ending balance, maximum (in usd per share)", "periodStartLabel": "Beginning balance, maximum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_TechnologyandDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology and Development [Member]", "label": "Technology and Development [Member]", "terseLabel": "Technology and development" } } }, "localname": "TechnologyandDevelopmentMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Facility [Member]", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "hqy_UnionMesaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Union Mesa", "label": "Union Mesa [Member]", "terseLabel": "Union Mesa" } } }, "localname": "UnionMesaMember", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "domainItemType" }, "hqy_WageWorksInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WageWorks Inc. [Member]", "label": "WageWorks Inc. [Member]", "terseLabel": "WageWorks, Inc" } } }, "localname": "WageWorksInc.Member", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "domainItemType" }, "hqy_WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "label": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in computing net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract", "nsuri": "http://healthequity.com/20230731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r150", "r151", "r234", "r262", "r367", "r476", "r478" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r216", "r217", "r218", "r219", "r274", "r372", "r401", "r413", "r414", "r465", "r466", "r467", "r468", "r469", "r471", "r472", "r483", "r490", "r495", "r501", "r612", "r649", "r650", "r651", "r652", "r653", "r654" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r216", "r217", "r218", "r219", "r274", "r372", "r401", "r413", "r414", "r465", "r466", "r467", "r468", "r469", "r471", "r472", "r483", "r490", "r495", "r501", "r612", "r649", "r650", "r651", "r652", "r653", "r654" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r196", "r373", "r395", "r396", "r397", "r398", "r399", "r400", "r473", "r491", "r500", "r589", "r608", "r609", "r614", "r657" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r196", "r373", "r395", "r396", "r397", "r398", "r399", "r400", "r473", "r491", "r500", "r589", "r608", "r609", "r614", "r657" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r216", "r217", "r218", "r219", "r267", "r274", "r303", "r304", "r305", "r371", "r372", "r401", "r413", "r414", "r465", "r466", "r467", "r468", "r469", "r471", "r472", "r483", "r490", "r495", "r501", "r504", "r604", "r612", "r650", "r651", "r652", "r653", "r654" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r216", "r217", "r218", "r219", "r267", "r274", "r303", "r304", "r305", "r371", "r372", "r401", "r413", "r414", "r465", "r466", "r467", "r468", "r469", "r471", "r472", "r483", "r490", "r495", "r501", "r504", "r604", "r612", "r650", "r651", "r652", "r653", "r654" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r150", "r151", "r234", "r262", "r367", "r477", "r478" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r14", "r499" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r199", "r200" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $4,639 and $4,989 as of July 31, 2023 and January 31, 2023, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r122", "r388" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental financial statement information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Supplementalfinancialstatementinformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r74", "r499", "r659" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r311", "r312", "r313", "r411", "r594", "r595", "r596", "r642", "r661" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital:" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r52", "r53", "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r307", "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r129", "r201", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r252", "r357", "r488", "r489", "r590" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r5", "r32", "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r105", "r126", "r148", "r182", "r190", "r194", "r202", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r334", "r336", "r349", "r381", "r435", "r499", "r511", "r610", "r611", "r647" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r118", "r131", "r148", "r202", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r334", "r336", "r349", "r499", "r610", "r611", "r647" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Customary Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r54" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Merger integration" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r28", "r29", "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable or accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r26", "r120", "r475" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r26", "r88", "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Ending cash and cash equivalents", "periodStartLabel": "Beginning cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r88" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r62", "r383", "r422" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 5)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r97", "r213", "r214", "r470", "r605" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r502", "r503", "r504", "r506", "r507", "r508", "r509", "r594", "r595", "r642", "r658", "r661" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock:" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r73", "r423" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r73", "r423", "r441", "r661", "r662" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r73", "r385", "r499" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 900,000 shares authorized, 85,612 and 84,758 shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r24", "r133", "r135", "r140", "r377", "r392" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r474", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer software intangible asset" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r57", "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenue recognition" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r83", "r373" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditAndDebitCardMember": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Card issued to user to facilitate payment for purchase of product and service paid directly to merchant by issuer, or from user's checking account.", "label": "Credit and Debit Card [Member]", "terseLabel": "Interchange" } } }, "localname": "CreditAndDebitCardMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "verboseLabel": "Acquired customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r98", "r147", "r230", "r236", "r237", "r238", "r239", "r240", "r241", "r246", "r253", "r254", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Indebtedness" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Indebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r69", "r70", "r106", "r107", "r152", "r231", "r232", "r233", "r234", "r235", "r237", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r358", "r485", "r486", "r487", "r488", "r489", "r591" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/FairvalueDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate borrowing spread (as a percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r13", "r107", "r257" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r59", "r61", "r231", "r358", "r486", "r487" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r19", "r59", "r260", "r358" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r19", "r232" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r152", "r231", "r232", "r233", "r234", "r235", "r237", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r358", "r485", "r486", "r487", "r488", "r489", "r591" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r20", "r152", "r231", "r232", "r233", "r234", "r235", "r237", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r358", "r485", "r486", "r487", "r488", "r489", "r591" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/FairvalueDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Five [Member]", "terseLabel": "Prior to October 1, 2024, 40% of Principal" } } }, "localname": "DebtInstrumentRedemptionPeriodFiveMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodFourMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Four [Member]", "terseLabel": "Prior to October 1, 2024" } } }, "localname": "DebtInstrumentRedemptionPeriodFourMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "October 1, 2024" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "October 1, 2026 and thereafter" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "October 1, 2025" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price (as a percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Percentage of principal amount redeemed (as a percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r20", "r42", "r43", "r58", "r59", "r61", "r63", "r99", "r100", "r152", "r231", "r232", "r233", "r234", "r235", "r237", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r358", "r485", "r486", "r487", "r488", "r489", "r591" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Facility term (in years)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r60", "r242", "r258", "r486", "r487" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Less: unamortized discount and issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r60", "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r318", "r319", "r382" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r90" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r5", "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r5", "r186" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r275", "r280", "r308", "r309", "r310", "r496" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Stockbasedcompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r141", "r158", "r159", "r160", "r161", "r162", "r167", "r169", "r174", "r175", "r176", "r180", "r345", "r346", "r378", "r393", "r480" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net income (loss) per share:", "verboseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r141", "r158", "r159", "r160", "r161", "r162", "r169", "r174", "r175", "r176", "r180", "r345", "r346", "r378", "r393", "r480" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r166", "r177", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Netincomelosspershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r116", "r136", "r137", "r138", "r153", "r154", "r155", "r157", "r163", "r165", "r181", "r203", "r204", "r263", "r311", "r312", "r313", "r327", "r328", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r350", "r351", "r352", "r353", "r354", "r355", "r366", "r402", "r403", "r404", "r411", "r462" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r244", "r268", "r269", "r270", "r271", "r272", "r273", "r348", "r368", "r369", "r370", "r486", "r487", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Fairvalue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r244", "r268", "r273", "r348", "r369", "r486", "r487", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r244", "r268", "r269", "r270", "r271", "r272", "r273", "r368", "r369", "r370", "r486", "r487", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialServiceOtherMember": { "auth_ref": [ "r615" ], "lang": { "en-us": { "role": { "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other.", "label": "Financial Service, Other [Member]", "terseLabel": "Custodial" } } }, "localname": "FinancialServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r124", "r209" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r207", "r208", "r209", "r210", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r95", "r375" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r33", "r35" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r95", "r374" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r5", "r40", "r41" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r84", "r445" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r123", "r206", "r376", "r484", "r499", "r600", "r601" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Intangibleassetsandgoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Change in goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r82", "r148", "r182", "r189", "r193", "r195", "r202", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r349", "r482", "r610" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r79", "r109", "r182", "r189", "r193", "r195", "r379", "r390", "r482" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r211", "r212", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r212", "r446" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r149", "r316", "r322", "r325", "r326", "r329", "r331", "r332", "r333", "r410" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r112", "r115", "r164", "r165", "r187", "r320", "r330", "r394" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax payments, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r4" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities, and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r4" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r4" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r170", "r171", "r172", "r176", "r279" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Weighted-average dilutive effect of stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r31", "r34" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r60", "r111", "r139", "r185", "r356", "r447", "r510", "r660" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r142", "r144", "r145" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest expense paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r85" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r362", "r498" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net operating lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating lease not yet commenced term of contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r148", "r202", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r335", "r336", "r337", "r349", "r421", "r481", "r511", "r610", "r647", "r648" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r78", "r108", "r387", "r499", "r592", "r598", "r643" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r119", "r148", "r202", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r335", "r336", "r337", "r349", "r499", "r610", "r647", "r648" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r13", "r66", "r67", "r68", "r71", "r148", "r202", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r335", "r336", "r337", "r349", "r610", "r647", "r648" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee (as a percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r107", "r243", "r259", "r486", "r487", "r656" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total debt, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r127" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt", "verboseLabel": "Less: current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Fair value of the notes" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails", "http://healthequity.com/role/FairvalueDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r128" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of issuance costs", "verboseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r20", "r39" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [ "r215", "r216", "r217", "r220", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r215", "r216", "r217", "r220", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r143" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r143" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r88", "r89", "r90" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r80", "r90", "r110", "r117", "r132", "r134", "r138", "r148", "r156", "r158", "r159", "r160", "r161", "r164", "r165", "r173", "r182", "r189", "r193", "r195", "r202", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r346", "r349", "r391", "r443", "r460", "r461", "r482", "r510", "r610" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited", "http://healthequity.com/role/NetincomelosspershareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator (basic and diluted):" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r28", "r29", "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Purchases of intangible assets" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r182", "r189", "r193", "r195", "r482" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r644" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r360" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r360" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r361", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r359" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r65", "r91", "r92", "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of business and significant accounting policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r130", "r499" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r125" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r21" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r87" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Purchases of software and capitalized software development costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "terseLabel": "Prepayment of debt" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r87" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Acquisitions of HSA portfolios" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r72", "r261" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r72", "r423" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r72", "r261" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r72", "r423", "r441", "r661", "r662" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r72", "r384", "r499" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2023 and January 31, 2023, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r2", "r11" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r96", "r121", "r389" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r380", "r389", "r499" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r25", "r408" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Principal payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r64", "r315", "r655" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Technology and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r75", "r101", "r386", "r405", "r406", "r409", "r424", "r499" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r116", "r153", "r154", "r155", "r157", "r163", "r165", "r203", "r204", "r311", "r312", "r313", "r327", "r328", "r338", "r340", "r341", "r343", "r344", "r402", "r404", "r411", "r661" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r183", "r184", "r188", "r191", "r192", "r196", "r197", "r198", "r264", "r265", "r373" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "verboseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Remaining performance obligation, percentage" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "verboseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r365", "r498" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r20", "r42", "r43", "r58", "r59", "r61", "r63", "r99", "r100", "r486", "r488", "r593" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r7", "r44", "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Income (Loss) Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/NetincomelosspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Share Based Compensation Recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r33", "r35", "r374" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r33", "r35" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of Other Income (Expense), Net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r276", "r278", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r9", "r10", "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r4" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Performance units awards (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r292", "r293" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, ending balance (in usd per share)", "periodStartLabel": "Outstanding, beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r276", "r278", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant under incentive plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable, weighted-average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number\u00a0of options (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in usd per share)", "periodStartLabel": "Opening balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest, aggregate intrinsic value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest, weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedStockUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]", "terseLabel": "Range of exercise prices" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, weighted-average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding stock options, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and software development costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r23", "r116", "r136", "r137", "r138", "r153", "r154", "r155", "r157", "r163", "r165", "r181", "r203", "r204", "r263", "r311", "r312", "r313", "r327", "r328", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r350", "r351", "r352", "r353", "r354", "r355", "r366", "r402", "r403", "r404", "r411", "r462" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r153", "r154", "r155", "r181", "r373", "r407", "r412", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r442", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r505" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r153", "r154", "r155", "r181", "r373", "r407", "r412", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r436", "r437", "r438", "r439", "r440", "r442", "r444", "r445", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r505" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r72", "r73", "r101", "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r50", "r72", "r73", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock upon exercise of stock options, and for restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r73", "r76", "r77", "r93", "r425", "r441", "r463", "r464", "r499", "r511", "r592", "r598", "r643", "r661" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r363", "r498" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow data:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Acquired trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r317", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Gross unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r324" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r168", "r176" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator (diluted):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r167", "r176" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Weighted-average common shares outstanding (in shares)", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator (basic):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r513": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r514": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r515": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r516": { "Name": "Form 20-F", "Paragraph": "a", "Publisher": "SEC", "Section": "16", "Subsection": "J", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r517": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r518": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r519": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "A", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "B", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r521": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "C", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r522": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "D", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r523": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "E", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r524": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r525": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "iii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r526": { "Name": "Form 20-F", "Paragraph": "2", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r527": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r528": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r529": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r532": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r533": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r534": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r535": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r536": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r537": { "Name": "Form 40-F", "Paragraph": "b", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r538": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r539": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r541": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r542": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r543": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r544": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r545": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r546": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r547": { "Name": "Form N-CSR", "Paragraph": "b", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r548": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r549": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r551": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r552": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r553": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r554": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "vi", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r555": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "3", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r556": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "4", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r557": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r558": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r559": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r561": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r562": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r563": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r564": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r565": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r566": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "B", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r567": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r568": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r569": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r571": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r572": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r573": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r574": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r575": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r576": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r577": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r578": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r579": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "F", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r581": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r582": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "A", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r583": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "B", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r584": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "C", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r585": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "D", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r586": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r587": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org//350/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 59 0001428336-23-000033-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-23-000033-xbrl.zip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

  •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�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Ð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end